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Abstract 
The non-receptor tyrosine kinase SRC plays an important and context-dependent role 
in a variety of cell signalling pathways that regulate cell motility, survival, division and 
growth factor signalling. SRC activity has been closely linked to several hallmarks of 
cancer (cell proliferation, metastasis, angiogenesis) and treatment resistance. 
Multiple studies found SRC to be aberrantly activated and/or overexpressed in solid 
tumours, such as breast, colorectal and ovarian cancer, which often correlated with 
malignancy and poor prognosis.  
 
Dual SRC/ABL kinase inhibitors (e.g. dasatinib, bosutinib) are already in clinical use 
for the treatment of chronic myeloid leukaemia. However, attempts to repurpose them 
for their SRC inhibition alone have so far failed in clinical trials. Several studies 
suggest that ABL kinase can act as a tumour suppressor in solid cancers and its 
inhibition has been linked to cardiotoxic events in patients. This complicates the use 
of SRC/ABL inhibitors in combination with other anti-cancer agents with cardiac side 
effects, such as chemotherapeutics, certain monoclonal antibodies and other kinase 
inhibitors; yet resistance to several of these drugs was found to involve the activation 
of SRC signalling pathways. Consequently, there is a clear need for more selective 
SRC inhibitors which have the potential to exhibit greater efficacy and fewer side 
effects than the ones currently available. 
 
The novel small molecule SRC inhibitor eCF506 has recently been discovered by the 
Innovative Therapeutics Lab at the University of Edinburgh 1. It exhibits nanomolar 
potency, thousand-fold selectivity for SRC over ABL kinase and superior drug-like 
properties compared to the current gold-standard SRC inhibitor dasatinib. This thesis 
continues the preclinical development of eCF506 by (i) investigating its potency 
against different cancers in in vitro and in vivo models, (ii) assessing its safety and 
pharmacokinetic properties and (iii) identifying a unique binding mode to SRC kinase. 
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Lay summary 
Kinases are proteins that add phosphate groups to other molecules in the cell. This 
often activates the target molecule and can cause it to phosphorylate others, leading 
to the activation of complex signalling pathways in the cell. SRC is a type of kinase 
that phosphorylates the amino acid tyrosine on its target proteins. SRC and its family 
members are found in many cell types of the human body and their activity plays an 
important role in the growth, division and movement of cells. However, abnormal SRC 
activity has been linked to the growth and spread of cancer and to treatment 
resistance. Higher levels of active SRC have been found in many different cancers 
(e.g. breast, ovarian and colorectal) and this has been associated with worse 
outcomes for patients.  
There are currently no drugs available that inhibit only SRC kinase, but there are 
several that inhibit both SRC and another kinase called ABL (e.g. dasatinib, 
bosutinib). These dual SRC/ABL inhibitors are used in the clinic to treat patients with 
a type of blood cancer called chronic myeloid leukaemia (CML), which is caused by a 
mutation in ABL kinase. Several clinical trials have tested these drugs in other cancers 
for their SRC inhibition but so far they have not shown enough benefit for the patients 
to gain regulatory approval. A possible reason for this is that ABL may not be a good 
target in certain cancers, as some studies found ABL inhibition can contribute to 
cancer growth. Additionally, ABL inhibitors can cause heart problems that may limit 
the maximum dose patients can take and prohibit the combination with other anti-
cancer drugs with similar side effects. This is a major drawback, as resistance to some 
of these drugs is thought to involve SRC activation. Based on these findings, there is 
a clear need for a selective SRC kinase inhibitor which has the potential to be more 
potent and safer than the current dual SRC/ABL inhibitors available. 
 
The first potent and selective SRC kinase inhibitor eCF506 has recently been 
discovered by the Innovative Therapeutics Lab at the University of Edinburgh 1. It can 
inhibit SRC kinase at very low concentrations, has high selectivity over ABL kinase 
and has better properties to be made into a drug than the current gold-standard 
SRC/ABL inhibitor dasatinib. This PhD thesis continues the preclinical development 
of eCF506 by (i) testing its effects in different models of cancer in isolated cancer cells 
and in animals, (ii) investigating its safety and fate in the body and (iii) finding out more 
about how it binds and inhibits its target SRC kinase.  
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R Recruiting 
R2 Coefficient of determination  
RFI Relative fluorescence intensity  
RIPA Radioimmunoprecipitation assay 
RNA Ribonucleic acid 
RPPA Reverse phase protein array 
RSV Rous sarcoma virus 
RTK Receptor tyrosine kinase 
S Suspended 
SCB Santa Cruz Biotechnology 
SCLC Small-cell lung cancer  
SD Stable disease 
SDS Sodium dodecyl sulfate 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SFK SRC family kinase 
SH SRC homology domain 
siRNA Small interfering RNA 
STR Short tandem repeat 
T Terminated 
t1/2 Half-life  
TBS Tris-buffered saline 
TBST Tris-buffered saline tween 
TCEP Tris(2-carboxyethyl)phosphine 
TCR T-cell receptor 
TFA Trifluoroacetic acid 
TGI Total growth inhibition 
TGS Tris glycine saline 
THF Tetrahydrofuran 
TLR Toll-like receptor 
Tmax  Time to reach maximum concentration 
TNBC Triple negative breast cancer 
Tris Tris(hydroxymethyl)aminomethane 
UPLC-MS/MS Ultra performance liquid chromatography with tandem mass spectrometry 
UV Ultraviolet 




















































1.1. Cancer and kinases 
Cancer 
Cancer is a group of diseases characterised by aberrant cell proliferation and invasion 
of other tissues that can lead to the disruption of normal body functions. More than 18 
million patients were diagnosed with cancer in 2018 and it is the second-leading cause 
of mortality in the world after heart disease 2. Cancer is caused by the accumulation 
of genetic mutations in the cell that lead to the activation of oncogenes or inactivation 
of tumour suppressor or DNA repair genes 3. Despite their genetic complexity, most 
cancers share common traits defined as the hallmarks of cancer by Hanahan and 
Weinberg (see Table 1.1) 3,4.  
 
Table 1.1. Hallmarks of cancer 3,4.
 1 Self-sufficiency in growth signals 
2 Insensitivity to anti-growth signals 
3 Evading apoptosis 
4 Limitless replicative potential 
5 Sustained angiogenesis 
6 Tissue invasion and metastases 
7 Abnormal metabolic pathways 
8 Evading the immune system 
 
Risk factors for cancer include genetic predisposition, certain infections and/or 
lifestyle factors, including obesity, lack of exercise, malnutrition, smoking and alcohol 
use 5. Extensive research into cancer has led to the development of many different 
classes of anti-cancer agents, including chemo-, hormone, targeted and immune 
therapies 6. The success of these differs between the type of cancer, stage of the 
disease and individual patients, and personalised medicine aims to match the unique 
tumour biology of each patient to tailored treatment regimens 7. This process has 
accelerated the development of targeted therapies, which inhibit specific molecular 
targets that are involved in the development or spread of the cancer. These targets 
include modulators of cell signalling, gene expression, apoptosis or angiogenesis 3. 
One important group of proteins involved in cell signalling are kinases, which connect 





Role of kinases in cancer 
Kinases are proteins which phosphorylate other biomolecules in the cell by catalysing 
the following reaction: MgATP1- + substrate-OH → MgADP + substrate-OPO3
2- + H+. 
This transfer of the γ-phosphate of ATP onto the hydroxyl group of a substrate is one 
of the most common post-translational modifications and plays a critical part in many 
cellular and extracellular processes 9. Eukaryotic protein kinases phosphorylate 
specific amino acid residues, either tyrosine, serine/threonine or both tyrosine and 
threonine residues of a wide range of proteins, and separate groups of kinases can 
phosphorylate other molecules such as sugars and lipids. There are 538 protein 
kinases encoded in the human genome and their actions are countered by protein 
phosphatases, which catalyse the dephosphorylation of their substrates 8. Most 
proteins are activated by phosphorylation, with some exceptions, which makes 
kinases the key activators of signalling pathways in the cell. 
 
Aberrant phosphorylation has been linked to many pathologies, including cancer, 
immunodeficiencies, endocrine and cardiovascular diseases 8–10. It can be caused by 
increased kinase activity, decreased phosphatase activity or a combination of both. 
Several malignancies have been directly linked to chromosomal rearrangements or 
activating mutations in kinases; examples are the BCR-ABL fusion protein in chronic 
myeloid and lymphoblastic leukaemia, ALK rearrangements in a subset of non-small-
cell lung cancers, the BRAF V600E mutation in melanoma, and mutations in FLT3, 
EGFR and KIT in acute leukaemia, lung and gastrointestinal tumours 8,10. 
Furthermore, amplification of kinase genes or their overexpression can lead to tumour 
development, as can hyperactivation of these kinases through phosphorylation (e.g. 
EGFR or MET in non-small-cell lung cancer; HER2 in breast, ovarian, oesophageal 
and gastric cancer; AKT2 in pancreatic, ovarian and breast cancers; ERK in breast 
cancer). Kinase mutations, expression levels and activation status are already being 
used as biomarkers in diagnosis and prognosis and to stratify treatment options 11. 
More than 240 kinase inhibitors have been evaluated in the clinic and many have 
received regulatory approval for use in cancer and other diseases, comprising both 
small molecule drugs (currently 55 compounds FDA approved) and biologicals such 
as antibodies 12. Intensive research into the development of novel kinase inhibitors 
continues, as the current collection targets less than half of the human kinome and 
many small molecule inhibitors are highly promiscuous or liable to the development 
of resistance mechanisms in patients.   
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1.2. SRC kinase 
1.2.1. Discovery of SRC kinase  
SRC kinase has been closely linked to cancer since its discovery more than a century 
ago 13,14. In 1911, Peyton Rous showed that injecting a healthy chicken with the cell-
free filtrate of a chicken sarcoma led to the development of the same tumour 15. His 
hypothesis, that these sarcomas are caused by a tumour-secreted “ultramicroscopic 
organism”, went largely unacknowledged due to the prevalent assumption that 
cancers are non-infectious and of endogenous origin. It was not until 1955 that the 
Rous sarcoma virus (RSV) was identified in pock assays as the cancer-causing agent 
and studies in the following years confirmed it could trigger cancer in mammals 16–18. 
Rous received the Nobel prize for his original discovery in 1966 19. Three years later 
Huebner and Todaro first proposed the existence of a transforming “oncogene” in 
RSV, which led to the identification of the v-Src gene 20. Hybridisation studies with a 
DNA probe complementary to v-Src revealed that it was also present in the cellular 
genome and had probably been captured and repurposed by viruses 21. Since the 
cellular homologue, called c-Src, did not have the same transforming ability as v-Src, 
it was classified as a “proto-oncogene” and a second Nobel Prize linked to SRC was 
awarded for this discovery in 1989 22,23.  
 
Further studies of SRC largely focussed on the protein, which was first isolated in 
1977 24. Two independent groups revealed the kinase activity of SRC a year later, 
with much higher activity observed for v-Src than c-Src 25,26. The serendipitous use of 
an aged buffer in 1980 then revealed that SRC can phosphorylate tyrosine residues 
on other proteins as well as on itself; the phosphorylated residue of v-Src was 
identified to be tyrosine 416 27. c-Src was phosphorylated at the same residue in vitro 
but a different one in vivo, later identified as tyrosine 527 in the C-terminus, which is 
missing in v-Src 28,29. An important study showed that c-Src can be activated by 
dephosphorylation of tyrosine 527, which led to the understanding that 
phosphorylation of tyrosine 416 or 527 results in SRC activation or inhibition, 
respectively 30. It emerged that SRC is predominantly inactive in non-transformed cells 
due to phosphorylation of its C-terminus but can be activated by phosphatases as 




1.2.2. Structure and regulation of SRC kinase  
SRC is a non-receptor tyrosine kinase and the prototype of an eleven-member family 
of kinases named SRC family kinases (SFKs) 31. SFKs are further divided into 
subfamilies based on their sequence similarity, forming the SRC-like subfamily (SRC, 
YES, FYN, FGR), the LYN-like subfamily (LYN, HCK, LCK, BLK) and a third more 
distantly related subfamily containing FRK, BRK and SRM.  
Not all SFKs are expressed ubiquitously in all cell types and their specific roles are 
summarised in Table 1.2. While SRC is expressed in all tissues, its levels are 
especially high in osteoclasts, platelets and neurons 32.  
 
 
Table 1.2. Main tissues of expression of SRC family kinases 31. 
 






FGR Haematopoietic (Myeloid cells, B-cells) 
LYN 
LYN-related 
Haematopoietic (Myeloid cells, B-cells) 
HCK Haematopoietic (Myeloid cells) 
LCK Haematopoietic (T-cells) 
BLK Haematopoietic (B-cells) 
FRK 
SFK-related 
Bladder, brain, breast, colon, lymphoid 




SRC-like and LYN-like SFKs share a conserved structure which consists of (from N- 
to C-terminus): a myristoylated membrane-targeting region in the N-terminus, a 
unique domain, a SH3 domain, a SH2 domain, a linker domain, the SH1 protein-
tyrosine kinase domain, and a short regulatory C-terminus (see Figure 1.1a) 33. The 
SH2 and SH3 domains are important for protein-protein interactions, while the SH1 
domain contains the active site of the kinase. The SFK-like kinases of the third 
subfamily differ from the other two as they lack the myristoyl group and C-terminus 
but they still contain all three SH domains. The human SRC, chicken c-Src and viral 
v-Src proteins have different lengths of 536, 533 and 527 amino acids, respectively, 
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and this thesis will use the established chicken c-Src numbering throughout for 
consistency 31. Figure 1.1a shows the species-dependent numbering of important 
residues. While chicken Src and human SRC are nearly identical, v-Src lacks seven 
residues in its C-terminus, including the important autoinhibition residue tyrosine 527. 
 
SRC kinase activity is regulated by phosphorylation of two important residues: the 
autoinhibition site at tyrosine 527 in the C-terminus and the autophosphorylation site 
at tyrosine 416 in the activation loop of the kinase domain 33. The carboxyterminal 
tyrosine can be phosphorylated by C-terminal SRC kinase (CSK) or CHK (CSK 
homologous kinase). This inactivates SRC by promoting its assembly into a closed, 
autoinhibited conformation in which the phosphorylated C-terminus binds the SH2 
domain (see Figure 1.1b). Further interactions between the SH3 domain, linker region 
and kinase domain help maintain this state. SRC can be activated by 
dephosphorylation of tyrosine 527 by phosphatases such as SHP-1, PTP-α and 
PTP1B or by interactions with high-affinity proteins that bind the SH2 or SH3 domain, 
such as growth factor receptors 34. While phosphorylation of tyrosine 416 by another 
SRC molecule has been thought to activate SRC as well, is has recently been shown 
that SRC can exist in a double phosphorylated state, suggesting that tyrosine 416 
phosphorylation on its own is not enough to induce an open conformation 35. The lack 
of the regulatory C-terminus is the reason for v-Src’s oncogenic activity 34. 
In its open and active state, intramolecular phosphorylation of tyrosine 416 is required 
for full kinase activity, as it stabilises the activation loop in a conformation that 
facilitates substrate binding 31. In its activated state, SRC can phosphorylate tyrosine 
residues on many different substrates and it is involved in signalling via growth factor 
receptors, integrins, G-protein coupled receptors, T-cell and B-cell receptors, steroid 
hormone receptors, cytokine receptors and NMDA receptors 36. Some of these 
interactions, such as SRC’s role in cell migration due to its activation of focal adhesion 
kinase (FAK), have been characterised extensively and are explained in more detail 
















Figure 1.1. Structure and activation of SRC kinase. a) Structure of human, chicken and 
viral SRC showing the conserved SRC homology domains (SH1, SH2, SH3), the linker 
domain, the unique domain (U), the myristoyl group and key tyrosine phosphorylation sites. b) 
Conformation of inhibited and active SRC kinase: SRC is inactivated by phosphorylation of 
tyrosine 527, which results in binding of the C-terminus to the SH2 domain. Dephosphorylation 




1.2.3. Functions of SRC kinase  
SRC family kinases interact with and phosphorylate many different substrates in the 
cell 37. Their role is often context-dependent and can differ between cell types and 
extracellular stimuli. The most prominent roles of SRC are its involvement in the 
transduction of growth factor signalling via receptor tyrosine kinases as well as cell 
migration and invasion. However, may other functions of SRC have been discovered 
and the following will give an overview of the key areas.  
 
1.2.3.1. Cell adhesion, migration and invasion 
SRC plays an important role in the adhesion of cells to the extracellular matrix (ECM) 
as well as other cells, thus controlling cell polarity, tissue integrity and cell migration.  
 
Cell-ECM contacts through focal adhesions 
Cells adhere to the extracellular matrix through dynamic macromolecular assemblies 
called focal adhesions. The central component of focal adhesions are heterodimeric 
transmembrane proteins called integrins, which connect the actin cytoskeleton to the 
substratum, thereby allowing the transmission of mechanical force and biochemical 
signals 37. Integrins do not possess intrinsic catalytic activity but aggregate upon 
ligand binding, which allows intracellular proteins to bind. Focal adhesion kinase 
(FAK) plays a key role in integrin-mediated signal transduction and localises to 
integrin clusters via interactions between its C-terminal domain and the β1 integrin 
cytoplasmic domain 38. This triggers its autophosphorylation on tyrosine 397, which 
enables transient binding of SRC kinase via its SH2 domain or interaction with other 
proteins such as phosphatidylinositol 3-kinase (PI3K) or phospholipase Cγ 39. SRC, 
in turn, phosphorylates FAK on several tyrosine residues (576, 577, 861, 925) which 
form binding sites for other focal adhesion proteins, such as GRB2, leading to the 
formation of a multiprotein complex tethered to the actin cytoskeleton (see Figure 1.2 
and Figure 1.3) 40.  
The exact dynamics of focal adhesions as still not fully understood due to their 
complexity and the involvement of over 50 proteins 37. The dynamic formation and 
turnover of focal adhesions is essential for cell migration, as new protrusions form at 
the leading edge while the trailing edge detaches from the substratum 41. 
Phosphorylation of p130Cas by the active SRC-FAK complex can stimulate Rac1 
activity, leading to actin polymerisation at the cell periphery and the formation of 
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membrane protrusions 42. SRC also appears to be essential for the disassembly of 
focal adhesions, for example through its phosphorylation of integrin cytoplasmic 
domains, enhancement of the proteolytic cleavage of FAK by calpains and activation 
of the RhoA antagonist p190 RhoGAP, which disrupts the actin cytoskeleton 39,41–43. 
Cell migration beyond matrix barriers (e.g. the basement membrane) leads to invasion 
of other tissues, which is often seen in cancer, and SRC contributes to this phenotype 
by promoting the expression of matrix degrading proteins, such as matrix 
metalloproteinases 44,45. Taken together, SRC kinase plays a central role in the 
dynamic regulation of focal adhesions, actin remodelling and ECM degradation, which 
is necessary for cell migration and invasion.  
 
Cell-cell contacts through adherens junctions 
SRC kinase is also involved in the assembly and disassembly of cell-cell interactions 
called adherens junctions (AJs). These contacts are important in the integration of 
individual cells into tissues, epithelial cell polarity and the suppression of tumour 
invasion 39. 
AJs are organised similar to focal adhesions and connect the actin cytoskeleton of 
neighbouring cells. The transmembrane proteins of AJs are calcium-dependent 
cadherin receptors; E-cadherin is the prototype cadherin that is ubiquitously 
expressed in epithelial cells, while VE-cadherin is commonly found in endothelial 
tissues. Cadherins form homodimers which bind other cadherin molecules on 
neighbouring cells via their extracellular domains, while their intracellular tails connect 
to actin filaments through adaptor proteins such as α-, β-, and p120-catenin, 
plakoglobin, actinin and vinculin 37. SRC kinase can associate with this complex and 
phosphorylate p120-catenin, β-catenin or its homologue plakoglobin, and to a lesser 
degree E-cadherin; this has been linked to AJ turnover and E-cadherin internalisation 
via endocytosis and hyperactive SRC was found to decrease cell-cell adhesion 39,46,47. 
In contrast, lower levels of SRC activity have been shown to support cadherin function 
and SRC deletion or inactivation is associated with the lack of AJ formation and 
turnover 39,48. SRC therefore appears to be important in both the assembly and 
disassembly of AJs, with differing roles depending on its level of activation.  
 
Due to the role of SRC in the turnover of both cell-cell and cell-ECM adhesions, as 
well as matrix degradation, its activity has been linked to a biological process called 
epithelial-to-mesenchymal transition (EMT) 49–51. EMT is associated with normal 
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development and wound healing but also cancer invasion; it causes epithelial cells to 
lose their polarity and adhesion to neighbouring cells, as they acquire an invasive 




Figure 1.2. FAK structure and phosphorylation sites. Focal adhesion kinase protein 
contains a FERM (protein 4.1, ezrin, radixin and moesin homology), kinase and FAT (focal 
adhesion targeting) domain. There are three proline-rich domains (Pro1-3) which can bind 
SH3 sites. The FERM and kinase domains contain two NES (nuclear export sequence) and 
one NLS (nuclear localisation sequence). Integrin clusters trigger autophosphorylation of 
tyrosine 397 which forms a binding site for SH2 domain containing proteins, such as SRC, p85 
subunit of PI3K, PLCγ and others. SRC phosphorylates other tyrosine residues on FAK (576, 





Figure 1.3. SRC signalling pathways. SRC kinase is located downstream of adherens 
junctions, focal adhesions, receptor tyrosine kinases, steroid receptors and other signalling 
pathways. Context-dependent SRC activation leads to substrate phosphorylation and 
promotes cell motility, invasion, angiogenesis, cell survival and proliferation.  
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1.2.3.2. Cell proliferation and survival 
SRC kinase plays a key role in the transduction of pro-survival and proliferation 
signals across the cell membrane through its interactions with receptor tyrosine 
kinases, G-protein coupled receptors, and steroid hormone receptors 36. Some of 
these interactions lead to the activation of downstream signalling pathways that 
facilitate cell cycle progression from G1 to S phase 52. 
 
Receptor tyrosine kinases 
SRC kinase is involved in the mitogenic signalling of several receptor tyrosine kinases 
(RTKs); these include the platelet-derived growth factor receptor (PDGFR), epidermal 
growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), 
fibroblast growth factor receptor (FGFR), insulin-like growth factor receptor (IGFR), 
hepatocyte growth factor receptor (HGFR/c-Met), colony-stimulating factor receptor 
(CSFR) and several others 53,54. 
RTKs contain an extracellular N-terminal ligand-binding domain, a hydrophobic 
transmembrane domain and a highly conserved intracellular C-terminal domain with 
catalytic kinase activity. Binding of a ligand (e.g. growth factors, cytokines or 
hormones) usually triggers receptor dimerization, which leads to trans-
phosphorylation of residues within their carboxyterminal domain by the other receptor 
and results in receptor activation 55. This creates binding sites for other substrates, 
such as SRC, which binds RTKs via its SH2 domain and subsequently becomes 
activated by phosphorylation 53. SRC can then signal via different pathways, 
depending on the RTK, resulting in specific gene expression changes. For example, 
activation of the MAPK pathway (SHC-GRB2-RAS-RAF-MEK1/2-ERK1/2) increases 
cell proliferation, while signalling via the PI3K-AKT-IKK-NFkB pathway promotes cell 
survival (see Figure 1.3) 56. Other molecules involved in SRC downstream signalling 
are STAT3 and protein kinase C (PKC) 45,53,57. SRC is also involved in the RTK-
induced remodelling of the actin cytoskeleton, for example in the EGF-stimulated 
phosphorylation of p190 RhoGAP. In addition to relaying RTK signalling, studies have 
found that SRC activity can also modulate RTK turnover by affecting endocytosis and 







G-protein coupled receptors 
G-protein coupled receptors (GPCRs) are transmembrane proteins which, upon 
ligand-binding, exchange GDP for GTP in their associated G proteins; this triggers 
the dissociation of G proteins into GTP-Gα and Gβγ subunits, which then regulate 
enzymes or ion channels that generate second messengers 58. These enzymes and 
second messengers can be involved in cell proliferation and differentiation but do not 
traditionally signal through tyrosine kinases. However, studies found that SRC family 
kinases can bind some GPCRs, either directly (e.g. β2 and β3-adrenergic receptor) 
or via β-arrestins 59. Further, GPCRs can activate SFKs directly via the Gα subunit or 
via crosstalk with RTKs or focal adhesions, and SFKs in turn were shown to regulate 
Gα activity by phosphorylation 58,59. SFKs can also mediate the internalisation of some 
GPCRs (e.g. M1 muscarinic receptors) 58. In general, GPCR signalling has been 
shown to include the activation of SFKs, either directly or indirectly, expanding the 
role of SFKs as transductors of extracellular signalling beyond RTKs.  
 
Steroid hormone receptors 
Nuclear steroid hormone receptors are typically characterised as ligand-activated 
transcription factors that directly bind the DNA. While they are not traditionally 
associated with kinases, studies found that these receptors can also trigger rapid 
signalling outside the nucleus, some of it mediated via tyrosine kinases, and that SRC 
can affect receptor function 60–62.  
One study showed that SRC can phosphorylate oestrogen receptor alpha (ERα) on 
tyrosine 537, which increased binding affinity for the ligand estradiol and triggers 
cytoplasmic localisation that promotes cell cycle progression; another one discovered 
that SRC promotes oestrogen-induced ERα proteolysis 63,64. Estradiol treatment also 
induced rapid phosphorylation events in MCF-7 cells that could be blocked by a SRC 
inhibitor 61. SRC was further found to mediate ligand-independent transcriptional 
activation of the androgen receptor (AR) and potentiate its activation 65–67.  
ERα can be palmitoylated and localised to the plasma membrane where it can signal 
through multiple proteins including SRC (see Figure 1.3) 68. Similarly, the AR and 
progesterone receptor (PrR) were also found at the cell membrane where their 
signalling via SRC kinase regulates cell proliferation 60. It is thought that nuclear 
steroid receptors located at the membrane interact with caveolin-1, which facilitates 




Cell Cycle Progression 
One of the effects of oncogenic SRC is anchorage- and growth factor-independent 
cell proliferation, which is mediated through its effects on the cyclin-dependent kinase 
(CDK) inhibitor p27 in the cell cycle 69,70.  
The cell cycle consists of four distinct stages that lead to cell division (gap 1, 
synthesis, gap 2, mitosis) and a fifth resting phase (gap 0). During gap 1 (G1), the cell 
increases in size and activates control mechanisms (G1 checkpoint) that ensure it is 
ready for DNA synthesis. This is followed by the synthesis (S) phase, during which 
the cell duplicates its genome. The gap 2 (G2) phase allows further growth and 
contains the G2 checkpoint that determines whether the cell is ready for division. 
During the final mitosis (M) phase, the cell divides into two under control of the 
metaphase checkpoint, after which the daughter cells may either re-enter the cell 
cycle to divide again or enter the gap 0 (G0) resting phase. 
Transition of cells from G1 to S phase involves the binding of cyclin D to CDK4 or 
CDK6, which leads to hyperphosphorylation of the Rb protein and causes it to 
dissociate from the transcription factor E2F (Figure 1.4) 52. Unbound E2F can then 
activate gene expression, including that of cyclin E and cyclin A, and ensuing binding 
of CDK2 to cyclin E triggers S phase entry. SRC can directly phosphorylate p27, an 
inhibitor of cyclin E-CDK2, at tyrosine 74 and 88 71. SRC overexpression reduced 
p27’s binding and inhibition of cyclin E-CDK2 and lead to its proteolysis, which 
facilitates G1 to S transition. The use of pharmacological SRC inhibitors was able to 
stabilise p27, inhibit cyclin E-CDK2, downregulate cyclin D1 and induce G1 cell cycle 
arrest 52,71. Both SRC siRNA and ERK1/2 or AKT inhibition reduced the expression of 
cyclin D and cyclin E and increased p27, which shows that SRC downstream 
signalling also promotes cell cycle progression. Overexpression of EGFR or HER2 
amplification in breast cancer is known to induce p27 proteolysis, which highlights the 













Figure 1.4. Role of SRC kinase in the cell cycle. p27 inhibits transition from G1 to S phase 
by interacting with CDK2 and Cyclin E in the nucleus. Phosphorylation of p27 by SRC triggers 
its cytoplasmic translocation and degradation, allowing the cell to enter S phase.  
 
 
1.2.3.3. Cell metabolism 
A less well-known role of SFKs in the cell is their involvement in the mitochondrial 
energy production by oxidative phosphorylation and the Warburg effect in cancer. 
Several mitochondrial proteins are phosphorylated by SRC which results in positive 
modulation of the oxidative phosphorylation machinery (e.g. mitochondrial 
cytochrome C oxidase, adenine nucleotide translocase 1) and evasion of hypoxia-
induced apoptosis via Hif1α-SRC-NFkB signalling 72–74. SRC-mediated 
phosphorylation also appears to play a role in the switch of malignant cells from 
oxidative phosphorylation to anaerobic glycolysis, as it attenuates pyruvate 
dehydrogenase activity while activating the rate-limiting glycolysis enzymes HK1 and 
HK2 75,76. SRC-stimulated ATP production also facilitates activation of mTORC1 and 





Angiogenesis, the formation of new blood vessels from existing ones, is an important 
physiological process in development and wound healing but also involved in cancer 
3. Multiple steps are involved in angiogenesis, including the local breakdown of the 
basement membrane followed by the migration and proliferation of endothelial cells 
78. Several molecules are known to stimulate angiogenesis, in particular growth 
factors (e.g. FGF, VEGF), their receptors (e.g. VEGFR) and proteases (e.g. matrix 
metalloproteinases) 3,78. Particular attention has been paid to the role of VEGF, and 
several inhibitors of this growth factor or its receptors (VEGFR1-3) have been 
approved for use in cancer and degenerative eye diseases (antibodies: bevacizumab, 
aflibercept, ramucirumab; small molecule inhibitors: axitinib, cabozantinib, lenvatinib, 
pazopanib, regorafenib, sunitinib, sorafenib, vandetanib) 79,80. SFKs are involved in 
the downstream signalling of growth factor receptors such as VEGFR and required 
for VEGF-induced endothelial cell proliferation, migration, tube formation and vascular 
permeability 81,82. Reduced migration of SRC-inhibited endothelial and vascular 
smooth muscle cells has been linked to its role in the organisation of the actin 
cytoskeleton 83. Moreover, SRC activation can increase VEGF expression through 
activation of STAT3 signalling 57,84. Other studies have shown that targeting FAK can 
also inhibit angiogenesis by disrupting the SRC-FAK-Rho GTPase signalling pathway 
85–88. Taken together, SFKs play an important role in angiogenesis by mediating 
growth factor signalling in endothelial cells and enabling cell migration.  
 
1.2.3.5. Bone resorption 
The remodelling and integrity of bones is governed by a carefully controlled balance 
between bone formation by osteoblasts and resorption by osteoclasts. The major 
phenotype of SRC knockout mice is osteopetrosis, an accumulation of excess bone 
due to impaired osteoclast function 32. Indeed, SRC is highly expressed in osteoclasts 
and essential for their ability to resorb bone; specifically, it is involved in their ability to 
form ruffled borders and maintain high levels of ATP through phosphorylation of 
mitochondrial cytochrome C oxidase 72,89,90. SRC activity has also been linked to the 
formation of bone metastases, which is a primary metastatic site for breast and 
prostate cancer but also a frequent site for thyroid, lung and bladder cancer 91–94. 
Inhibitors of SRC kinase are therefore being investigated both for their ability to reduce 
the occurrence of metastatic bone disease and associated pain 95–98. 
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1.2.3.6. Immune system and platelets 
SFKs are involved in the functioning of the immune system through their roles in T-
cells, B-cells, platelets and cytokine signalling 36.  
 
T-cells 
LCK is expressed and active in T-cells where it is involved in the signal transduction 
of T cell receptors (TCRs) that is necessary for effector T-cell activation 99. TCRs 
respond to pathogen or tumour-derived antigenic peptides presented by antigen 
presenting cells (e.g. macrophages, dendritic cells, B-cells) via the major 
histocompatibility complex (MHC). Upon binding of TCR to MHC, CD4 or CD8 are 
recruited and trigger TCR phosphorylation by LCK 99. LCK then recruits and 
phosphorylates ZAP70 via its SH2 domain and binds the ZAP70 substrate LAP via its 
SH3 domain, allowing LAP activation and signalling via multiple downstream 
pathways (e.g. GRB2, PI3K, PLC) 100,101. Some activated LCK also translocates inside 
lipid rafts where it activates FYN and further downstream signalling leading to 
changes in gene transcription 102. Taken together, LCK and FYN activity is necessary 
for the formation of both helper and cytotoxic T-cells by inducing cell differentiation, 
proliferation and cytokine secretion 103.  
The SFK target FAK was found to negatively regulate TCR-mediated signalling in 
CD4 T-cells, as FAK knockdown resulted in lower levels of LCK inhibition 104. The 
paper suggests that FAK expression is necessary to recruit CSK to the membrane, 
which phosphorylates the autoinhibition site on LCK and thus hinders its activation. 
However, a second study that utilised the FAK inhibitor PF562271 found that 
pharmacological inhibition impairs CD4 T-cell activation; while these results may be 
due to off-target effects, it shows the challenges of defining FAK’s role in T-cells 105. 
 
B-cells 
SFKs can have both activating and inhibitory effects on B-cells which are involved in 
antibody-mediated immune responses 106. Multiple SFKs (LYN, BLK, FYN, FGR, 
YES) are expressed in B-cells and LYN in particular is involved in signalling via the 
B-cell receptor and downstream activation of SYK. LYN-deficient mice exhibited fewer 
mature B-cells but also a lower threshold for B-cell activation and autoreactive 
antibodies 107, while continuously active LYN similarly reduced the number of 
peripheral B-cells and induced autoimmunity 108. This suggests that LYN is important 




SFKs in macrophages appear to act as rheostats that modulate the activity of 
signalling pathways, rather than having a specific function 110. They can affect signal 
transduction by phosphorylating two motifs that are found in several receptors or their 
associated signalling molecules: the immunoreceptor tyrosine-based activation motif 
(ITAM) and the immunoreceptor tyrosine-based inhibitory motif (ITIM). ITAMs can be 
found for example in DAP12 and FcRγ, which associate with integrins, and their 
phosphorylation by SFKs leads to the recruitment of SYK kinase and downstream 
phosphorylation events 111. ITIMs are often contained in the receptors themselves, 
such as in the IL-4 alpha chain, and their phosphorylation leads to the recruitment of 
phosphatases that inhibit downstream signalling 110.  
Another role of SFKs in macrophages may be in Toll-like receptor (TLR) signalling, 
as HCK and LYN were found to be activated by the TLR4 ligand lipopolysaccharide 
(LPS); TLR4 was in turn phosphorylated in an SFK-dependent manner, which 
attenuates the inflammatory response to LPS 112,113. However, SFK knockout 
macrophages showed no significant defects in the LPS response and the importance 
of SFKs in TLR signalling in macrophages currently remains unclear 110.  
 
Neutrophils 
Several studies found that SFKs play a role in the ability of neutrophils to generate an 
inflammatory environment. The inhibition of SFKs or SYK was found to hinder 
inflammatory cytokine production by neutrophils by reducing the phosphorylation of 
proteins involved in the control of translation 114. Further, Hck-/-, Fgr-/-, Lyn-/- knockout 
mice were protected from inflammatory responses, not because of changes in 
neutrophil migratory ability, but due to their failure to release pro-inflammatory 
mediators in response to immune complexes 115. Neutrophils have several receptors 
containing ITAMs and ITIMs, like macrophages, and SFKs were found to 
phosphorylate the ITAM-containing FcRγ chain of the activating Fc receptor, with 
FcRγ-/- mice showing a similar immune phenotype as the Hck-/-, Fgr-/-, Lyn-/- mice 115.  
 
Dendritic cells 
Dendritic cells process antigens and subsequently present them on their cell surface 
to the immune system. Two studies found that SRC may play a role in TIM-3 mediated 
dendritic cell suppression and that its inhibition can improve the anti-tumour effects of 




Cytokine receptors have no intrinsic enzymatic activity and rely on kinases for the 
signal transduction of extracellular cytokine signals. Type I and II receptors (e.g. 
interleukin, growth hormone, prolactin and interferon receptors) signal via the JAK-
STAT pathway to change gene expression 118. However, some studies have found 
that the growth hormone receptor can also signal via LYN kinase, independent of JAK, 
and that SRC can regulate JAK signalling in the prolactin receptor in a kinase-
independent manner 119,120. SFKs are activated by pro-inflammatory cytokines in both 
inflammation and cancer and have been proposed as a mechanistic link between both 
diseases 121. Furthermore, SFKs can activate STAT signalling independent of JAK, 
for example through growth factor receptors, although this only includes a subset of 
the STAT molecules that can be activated by cytokines 122. 
 
Platelets 
SFKs are highly expressed in platelets and play a pivotal role in platelet activation in 
response to injury 123. They are involved in the signal transduction of various tyrosine 
kinase-linked receptors (e.g. α2β1 integrin, collagen receptor, von Willebrand factor 
receptor) and GPCRs (e.g. PAR-4 thrombin receptor) which enable platelet adhesion 
and thrombus formation. SFK inhibitors have been shown to induce bleeding and 
thrombocytopenia in patients and reduce platelet count and reactivity in vivo, 
suggesting an important role for SRC in platelet-producing megakaryocytes 124–127.  
 
 
1.2.3.7. Central nervous system 
Several SFKs (SRC, FYN, YES, LCK, LYN) are highly expressed in neurons, which 
was a surprising finding as these are differentiated cells that no longer proliferate 128. 
It was discovered that the role of SFKs in the CNS is to upregulate the activity of ion 
channels, including ionotropic glutamate receptors (e.g. N-methyl-D-aspartate 
receptor, NMDAR), voltage-gated ion channels (e.g. potassium, calcium) and 
ionotropic neurotransmitter receptors (e.g. GABAA, nicotinic acetylcholine receptor). 
Studies of the NMDAR revealed that SRC phosphorylates the carboxyterminal of NR2 
subunits which potentiates NMDAR currents by increasing channel gating and might 
reduce internalisation of the receptor 129. Its actions are opposed by STEP 
phosphatase 128. SFKs signalling has been implicated in neurodegenerative diseases 
such as Alzheimer’s, which is discussed in more detail in chapter 1.2.4.4.  
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1.2.3.8. Kinase-independent scaffolding roles 
Most actions of SFKs are mediated via their kinase activity, which allows them to 
phosphorylate other proteins and activate cell signalling pathways. However, their 
SH2 and SH3 domains also enable them to bind other proteins and act as an adapter 
protein 33. Several studies have tried to distinguish between SRC’s kinase and 
scaffolding activity by using kinase-defective SRC K295M, which is mutated in the 
ATP binding site 130. They found that the osteopetrosis phenotype observed in SRC 
knockout mice (see chapter 1.2.3.5) was partially rescued by re-expression of kinase-
defective SRC by improving cytoskeletal organisation in osteoclasts 131. Further 
evidence for its scaffolding role in the cytoskeleton comes from the observation that 
reduced cell spreading of SRC -/- fibroblasts on fibronectin could be rescued by SRC 
K295M, which exhibited similar distribution to focal adhesions during attachment as 
wild-type SRC 132. Kinase-defective SRC was found to mediate FAK-dependent 
phosphorylation of p130Cas and downstream ERK activation in fibroblasts by binding 
FAK and p130Cas via its SH2 and SH3 domains, respectively 133. Activation of 
p130Cas through SRC’s adapter function alone also occurs in cardiomyocytes during 
pressure overload 134. The phosphorylation of several SRC-linked tyrosine residues 
on FAK in colorectal cancer cells was also found to be independent of SRC kinase 
activity but dependent on its SH2 domain, although other papers reported opposite 
findings 135,136. In the same cells, kinase-defective SRC was able to induce the 
formation of cell-matrix adhesions but not the disruption of adherens junctions 47.  
Moreover, the SH2 and SH3 domains are necessary to mediate signalling of the 
prolactin receptor via JAK2-STAT5 in kinase-defective SRC, and kinase-defective 
LYN was able to reverse the increase of B-cell receptor-dependent PLC activation 
observed with LYN knockout back to wild-type levels 119,137. LCK-mediated TCR 
activity was reduced by mutations in either the kinase and SH2 domain, but only fully 
ablated when both were mutated, although another study found that Y394 
phosphorylation is essential for TCR function 138,139. These examples highlight 






1.2.4. The role of SRC kinase in cancer and disease 
1.2.4.1. SRC and the hallmarks of cancer 
SRC is a critical component of various signalling pathways, cellular processes and 
physiological functions and was the first proto-oncogene to be discovered. It is closely 
linked to several of the eight hallmarks of cancer (see Table 1.1), as its activity can 
stimulate cell proliferation and survival (chapter 1.2.3.2), angiogenesis (chapter 
1.2.3.4), cell migration, invasion and metastasis (chapter 1.2.3.1 and 1.2.3.5), and 
mitochondrial ATP production and glycolysis (chapter 1.2.3.3). 
 
Due to its role as a central signalling node for many receptors and cell types, SRC 
activation can have multiple interconnected outcomes that promote cancer 
progression. For example, signalling through growth factor receptors traditionally 
involved in mitogenic signalling can also induce EMT and promote an invasive 
phenotype 49–51. Furthermore, SRC activity in endothelial cells plays a dual-role in 
tumour progression; it stimulates angiogenesis in the absence of nutrients and 
oxygen, allowing tumours to grow beyond 1-2 mm2 in size, and increases vascular 
permeability that enables the dissemination of cancer cells across the body 81,140,141. 
SRC activity is also at the centre of a vicious cycle in the development of latent bone 
metastasis. Cancer cells release osteolytic factors and disrupt the RANK-RANKL loop 
between osteoclasts and osteoblasts, while the metastatic bone microenvironment 
releases factors (e.g. CXCL12, TRAIL) that lead to SRC-mediated activation of 
survival pathways and evasion of apoptosis 92,142,143.  
 
1.2.4.2. SRC expression and activity in cancer 
Increased SRC expression or activity has been found in several different solid 
tumours. Early studies showed SRC activity and/or expression was upregulated in a 
subset of sarcomas, breast and colorectal cancers compared to normal tissues 144–
148. Aberrant SRC activity or overexpression was later also identified in several other 
tumours, including prostate, lung, pancreatic, head and neck and ovarian cancer 149–
153. It was also increased in hepatocellular carcinoma, which correlated with reduced 
expression of the SRC inactivator CSK 154,155. HER2 amplification in breast cancer 
was found to increase SRC levels by enhancing both its translation and stability 156. 
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Increased SRC activation or expression in cancer is generally associated with later 
stages of the disease, metastatic potential and poor clinical prognosis 157–161.  
 
A recent study found that aberrant SRC signalling is a key hallmark of Group 4 
medulloblastoma, which is the most common malignant brain tumour in children 162. 
It showed that genomic, epigenetic and transcriptomic data does not necessarily 
correlate with protein abundance and post-translational pathway activation and can 
miss the activation of kinase signalling pathways. An integrated multi-omics approach 
was able to identify the distinct activation of ErbB4 and SRC signalling in a defined 
subgroup of medulloblastoma, which could lead to future applications for SRC and 
RTK inhibitors in this disease.  
 
1.2.4.3. SRC in treatment resistance  
SRC activity is frequently upregulated in cancers after treatment with chemo-, 
hormone or targeted therapies and can contribute to resistance by activating 
alternative signalling or survival pathways 54. It has been proposed to combine these 
drugs with SRC kinase inhibitors to delay or overcome resistance and many studies 
reported positive results in in vitro and in vivo resistance and combination studies.  
Examples of resistance to chemotherapy include the SRC-mediated activation of 
EGFR signalling by cisplatin and 5-fluorouracil in breast and pancreatic cancer cell 
lines, respectively 163,164. Cisplatin resistance was also linked to SRC-mediated 
downregulation of cell-cell communication via gap junctions 165. SRC is known to be 
overexpressed and activated with HER2 amplification and this contributes to breast 
cancer resistance to paclitaxel 156,166. Inhibition of SRC kinase, either by siRNA or 
small molecule inhibitors, was further found to re-sensitise paclitaxel-resistant breast 
and ovarian cancer cells and gemcitabine-resistant pancreatic cancer models 167–171. 
Moreover, the SRC inhibitor dasatinib combined with doxorubicin or oxaliplatin 
produced synergistic effects in breast and colon carcinoma cells, respectively 172,173.  
SRC activation has also been linked to hormone therapy resistance in breast and 
prostate cancers, which is associated with the role of SRC in hormone receptor 
signalling (see chapter 1.2.3.2) 54. Resistance of breast cancer cells to the selective 
oestrogen modulator tamoxifen is modulated by SRC-induced signalling through 
EGFR-STAT5b and SRC inhibition can prevent tamoxifen-resistance in vitro 71,174,175. 
Moreover, only hormone-refractory prostate cancer cells stopped proliferation in 
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response to SRC inhibition and downregulation of the SRC inhibitor CSK was found 
to promote resistance to anti-androgen therapy 176,177.  
 
Aberrant activation of EGFR involving SRC has been identified in multiple resistance 
pathways; conversely, SRC also becomes activated in response to EGFR inhibitors 
(e.g. cetuximab, afatinib, gefinitib, erlotinib, osimertinib) or ALK inhibition (e.g. 
alectinib) and contributes to treatment resistance in NSCLC models 178–180. It is also 
involved in acquired sorafenib resistance in KRAS mutant NSCLC xenografts 181. SRC 
activation by HER2 in some breast cancers was also found to contribute to de novo 
and acquired resistance to the HER2 inhibitors trastuzumab and lapatinib and their 
combination with the SRC inhibitor saracatinib re-sensitised resistant tumours in vitro 
and in vivo 182,183.  
 
There are many examples in which SRC has been involved in resistance in preclinical 
studies, which re-emphasises its role as a central signalling node in the cell. However, 
clinical trials of drug combinations with SRC inhibitors have so far failed to 
demonstrate sufficient additional benefit to warrant their regulatory approval in solid 
tumours (see chapter 1.3.2). Further studies are needed to determine whether this is 
due to insufficient patient stratification, lack of efficacy of current SRC inhibitors or 
inadequacy of SRC kinase as a drug target.  
 
1.2.4.4. SRC family kinases in other diseases  
SRC kinase activity has been linked to cancer since its discovery (see chapter 1.2.1). 
However, the central role of SRC in cellular signalling pathways means it has also 
been implicated in other diseases associated with diabetes, fibrosis, neuronal 
excitation and viral infections. 
 
Diabetes-associated morbidities  
SRC kinase signalling has been implicated in multiple pathways of diabetes 
associated morbidities. It plays an important role in the glucose-induced secretion of 
insulin by pancreatic β-cells and is involved in the diabetes-induced disruption of the 
endothelial barrier and vascular hyperpermeability184,185. The SRC inhibitor dasatinib 
was able to reduce VEGF-induced retinal vascular leakage in a mouse model and 
SRC might be a promising target in diabetic retinopathies 186,187. Moreover, SRC is 
involved in diabetic nephropathy as it activates EGFR signalling in the presence of 
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high glucose leading to collagen IV accumulation; this pathway was disrupted when 
streptozotocin-induced diabetic mice were treated with a SRC inhibitor 188.  
 
Fibrosis-associated diseases  
SFKs have been implicated in multiple fibrosis-associated diseases, such as 
idiopathic pulmonary fibrosis (IPF), chronic kidney disease, pancreatic fibrosis and 
liver fibrosis 189. Myofibroblasts play an important role in wound healing and fibrosis 
and TGFβ1 stimulation leads to SFK-mediated differentiation of lung fibroblasts into 
myofibroblasts which was blocked by the SFK inhibitor saracatinib 190. Indeed, this 
inhibitor has recently been granted orphan drug status by the FDA after a phase I 
clinical trial in IPF 191. Multiple roles for SFKs have also been identified in chronic 
kidney diseases, including renal fibrosis, glomerulonephritis and nephropathies 189. 
The SFK LYN plays an important role in the migration, proliferation and collagen 
production of chronic pancreatitis myofibroblasts and its inhibition prevented 
pancreatic fibrosis in a mouse model 192. LYN is also involved in hepatic fibrosis by 
modulating hepatic stellate cell activation 193. The JAK1/2 and SRC inhibitor ruxolitinib 
has already been approved for use in myelofibrosis and its efficacy may in part be 
due to its potent SFK inhibition (see Table 1.3 in chapter 1.3.1) 194.  
 
Alzheimer’s disease and other neuronal disorders 
SFKs kinase upregulate the activity of the excitatory ionotropic glutamate receptor 
NMDAR by phosphorylation (see chapter 1.2.3.7). Excessive NMDAR activity can 
cause excitotoxicity which has been linked to neurodegeneration and Alzheimer’s 
disease (AD) 195–197. FYN is known to bind Tau, a protein closely linked to AD, and 
this interaction is necessary to target FYN to NMDARs and enable their 
phosphorylation 198. The binding of cellular prion protein to amyloid beta oligomers is 
also associated with AD phenotypes; this interaction leads to the activation of FYN 
which then phosphorylates the NR2 subunit of NMDARs 199. Further studies also 
suggest a role for SFKs in AD through their involvement in amyloid beta plaque-
induced microglial activation in microgliosis 200,201. Indeed, inhibition of FYN by 
saracatinib was able to reverse spatial memory deficits and synapse density loss in 
AD mice and reduced microglial activation 202. However, a phase IIa clinical trial of the 
SFK inhibitor saracatinib in patients with mild Alzheimer’s dementia has recently 
reported no significant changes in its primary outcome (cerebral metabolic rate for 




Dysregulated NDMAR signalling also plays a critical role in the genetic 
neurodegenerative disorder Huntington’s disease; SFK inhibition or mutation of its 
target tyrosine residues on NR2B subunit was found to significantly attenuate mutant 
huntingtin-induced neuronal death 204. Upregulated NMDAR signalling by SFKs has 
also been linked to pain hypersensitivity in neuropathic or inflammatory pain, while an 
NRG1-ErbB4-mediated inhibition of SRC may play a role in schizophrenia 205. 
 
Viral infections 
SFK activity can facilitate the infection, replication, assembly and release of different 
viruses. FYN is necessary for the assembly of dengue virus particles in the 
endoplasmic reticulum and FYN inhibition by dasatinib or saracatinib lead to reduced 
dengue virus replication, assembly and secretion 206,207. However, prolonged 
treatment of dengue virus-infected cells led to viral mutations that rendered it resistant 
to SFK-mediated replication inhibition, although the other processes remained 
unaffected 207. Similarly, SFK activity is involved in the replication of Herpes simplex 
virus 1, while an SFK inhibitor prevented secretion of the West Nile Virus from infected 
cells 208,209. Inhibition of HCK also prevented reactivation of the cytomegalovirus in 
vitro 210. SRC has further been implicated in the transfer of HIV-1 from dendritic cells 
to CD4+ T-cells and SRC inhibitors reduced infection in vitro; however, another study 
suggests SRC protects CD4+ T-cells from infection 211–213.  
SFKs may be involved in virus-associated morbidities, for example in Epstein-Barr 
induced EMT of human corneal epithelial cells 214. On top of that, HCK/LCK/FGR were 
found to downregulate the antiviral response of zebrafish and mice in a negative 
feedback loop 215. This highlights the opportunity to repurpose selective SFK inhibitors 
in viral diseases, some of which (e.g. dengue virus) only have limited treatment 




1.3. SRC kinase inhibitors 
The role of SRC family kinases as central nodes for cell signalling pathways and their 
involvement in several diseases make them attractive targets for pharmaceutical 
manipulation. Several dual SRC/ABL kinase inhibitors are already in use clinically for 
the treatment of chronic myeloid leukaemia (CML). However attempts to repurpose 
these drugs for their SRC inhibition alone have so far failed (see chapter 1.3.2) 54. 
Several studies found that ABL kinase may act as a tumour suppressor in a subset of 
solid tumours, and its inhibition has been linked to cardiotoxic events in CML patients 
(see chapter 1.3.3). Recently, the first selective small molecule SRC kinase inhibitor 
eCF506 has been discovered 1. It has equally high potency as the current best-in-
class SRC inhibitors and approximately 1000-fold selectivity over ABL. This thesis will 
investigate eCF506 further in different preclinical models of cancer.  
 
1.3.1. Current competitive landscape 
The linkage between SRC activation, disease progression and treatment resistance, 
as well as promising results in pre-clinical studies, all support the premise that SRC 
represents an important therapeutic target in cancer. Consequently, efforts have been 
made to develop potent and selective SRC inhibitors since the approval of the first 
targeted therapies in the 1990s 54,216,217. The ABL kinase inhibitor imatinib (Gleevec®) 
was the first targeted tyrosine kinase inhibitor that gained FDA approval in 2001 217. It 
is used in Philadelphia chromosome-positive cancers (e.g. chronic myeloid 
leukaemia), which are caused by a chromosomal translocation that gives rise to the 
constitutively active oncogenic BCR-ABL fusion protein. The emergence of imatinib 
resistance in patients led to the development of second-generation ABL inhibitors with 
higher potency and delayed resistance; these include dasatinib and bosutinib, 
promiscuous inhibitors which also potently inhibit SFKs at nanomolar concentrations 
218,219. Further ABL and other kinase inhibitors were developed and gained regulatory 
approval over the years, with several of them also inhibiting SRC and other SFKs (see 
Table 1.3).  
 
Most small molecule kinase inhibitors target the highly conserved ATP-binding pocket 
of kinases; this is the reason why many of them exhibit high promiscuity across the 
kinome and should therefore be regarded as multi-kinase inhibitors (e.g. 
staurosporine, ponatinib) 12,220,221. Most discovered SFK inhibitors exhibit similar 
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potency against SRC and ABL kinase, which is in part due to their targeted 
development in CML but also due to the high sequence similarity between these two 
kinases 222. This lack in selectivity is important, as ABL kinase may not be a desirable 
target in some solid tumours (see chapter 1.3.3).  
Table 1.3 compares the reported potency of all SFK inhibitors for SRC and ABL. Only 
three compounds exhibit both high potency (IC50 <5 nM in cell-free assays) against 
SRC kinase and selectivity over ABL: ruxolitinib, eCF506 and saracatinib. Ruxolitinib 
gained FDA-approval for its potent JAK1/2 inhibition (3.3 and 2.8 nM, respectively) 
and is therefore not SFK-selective 223. While it does not inhibit proliferation of a BCR-
ABL-expressing cell line, no confirmation is provided from cell-free ABL kinase 
assays. Saracatinib has similar potency for SRC as ruxolitinib and exhibits 
approximately 10-fold selectivity over ABL kinase 224. However, the recently 
discovered eCF506 (see chapter 1.3.4) is over 5-times more potent than saracatinib 
for SRC (<0.5 nM and 2.7 nM, respectively), and exhibits approximately 1000-fold 
selectivity over ABL kinase 1. The only other inhibitors with similar potency against 
SRC are dasatinib (<0.5 nM), bosutinib (1.2 nM) and AP23464 (0.45 nM), all of which 
are equipotent against ABL kinase. This comparison highlights the superior potency 
and selectivity profile of eCF506 in comparison to currently available SRC inhibitors, 












Table 1.3. Approved and experimental SFK inhibitors. Listed in order of IC50 for SRC kinase. IC50 describes the concentration (in nM) needed for 50% 
inhibition of maximal kinase activity in a cell-free assay, except: + binding constant (Kd); * in cells (EC50); ° inhibitory constant (Ki). Indications: Ph+ CML 
= Philadelphia chromosome positive chronic myeloid leukaemia; Ph+ ALL = Philadelphia chromosome positive acute lymphoblastic leukaemia; MF = 
myelofibrosis; PCV = polycythemia vera; IPF = idiopathic pulmonary fibrosis; NSCLC = non-small-cell lung cancer; MTC = medullary thyroid cancer.  
 
 
 Table continued on next page 
  
Inhibitor CAS No. IC50 SRC IC50 ABL Other main targets 
Indication 







302962-49-8 <0.5 <0.5 EphB2, CSF1R, c-KIT, 
PDGFR, RET 
Ph+ CML,  
Ph+ ALL 
Sprycel 




380843-75-4 1.2 1 MAP4K, MINK, ERBB4, SIK2, 
EGFR 










943319-70-8 5.4 0.37 PDGFRα, VEGFR2, FGFR1, c-
KIT 














443913-73-3 Yes  
(same as ABL) 
Yes 
(same as SRC) 
VEGFR, EGFR, KDR MTC Caprelsa  
(Genzyme) 
221 
Clinical development or experimental 
AP23464 845895-51-4 0.45 0.67 EGFR, HER2, PDGFR, FGFR   228 
eCF506 (06, 52, 11a) 1914078-41-3 <0.5 479 ARAF, BMX, BTK, ERBB4   1 
PP20  <1 <1 VEGFR2, EGFR, PDGFR   229 
Saracatinib (AZD0530) 379231-04-6 2.7 30 EGFR, c-KIT, EphA2 Y (III) (AstraZeneca) 224 
UM-164 903564-48-7 2.7+ 2.9+ p38β   230,231 
XL-228 898280-07-4 5 5 IGF1R Y (I) (Exelixis) 232 
Repotrectinib  
(TPX-0005) 
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Inhibitor CAS No. IC50 SRC IC50 ABL Other main targets 
Indication 




Staurosporine 62996-74-1 5.3 75 PKC, S6 kinase, Cdc2    234 
WH-4-023 837422-57-8 6 (LCK 2) Unknown SIK   235 
KX01 (KX2-391) 897016-82-9 9-60* 100-200* Tubulin polymerisation Y (II) (Kinex) 236 
PP121 1092788-83-4 14 (HCK 8) 18 PDGFR, VEGFR, mTOR   229 
PP1 172889-26-8 17 (LCK 5, FYN 6) 147 KIT, EGFR   1,237 
CCT196969 1163719-56-9 30 (LCK 20) Unknown c-RAF, V600E BRAF   238 
SAB298  31 (YES <10) 87 (ABL2) HER2   239 
PP2 172889-27-9 33° (LCK 4, FYN 5) Yes PDGFRβ, BRK   237,240 
Rebastinib (DCC2036) 1020172-07-9 34 0.8 FLT3, KDR, TIE2, PDGFRα Y (II) (Deciphera Pharm.) 241 
SKI-1 179248-59-0 44 Unknown VEGFR2   242 
Compound 4   44°, 86+ >125,000° BRAF, c-RAF   240 
LCK Inhibitor 213743-31-8 70 (LCK <1) Unknown    221,243 
SU6656 330161-87-0 280 (YES 20) 1,740    244 
Bafetinib (INNO-406) 859212-16-1 1,700 (LYN 19) 5.8  Y (II) (CytRx) 245 




1.3.2. SRC inhibitors in clinical trials 
Several potent, albeit not very selective, SRC inhibitors are already approved for use 
in the clinic (e.g. dasatinib, bosutinib). Attempts have been made to repurpose these 
or approve novel SFK inhibitors (e.g. saracatinib) for use in different types of cancer. 
Multiple clinical trials have been conducted based on the promising preclinical activity 
of these compounds in breast, prostate, ovarian, NSCLC and pancreatic cancer 
patients, among many others 246. While phase I studies of SRC inhibitors generally 
confirmed the safety of these compounds in humans, phase II trials mostly did not 
show sufficient additional benefit to proceed to phase III 54,217,247. For example in 
breast cancer patients, dasatinib, bosutinib or saracatinib monotherapy only resulted 
in an objective response rate (ORR, combines complete and partial response) of 4-
5%, 5% and 0%, respectively; the clinical benefit rate (CBR), which combines ORR 
and stable disease, was only marginally better at 10-13%, 27% and 0%, respectively 
(see Table 1.4) 248,249. Similar results of CBR <25% were obtained with dasatinib in 
prostate cancer and melanoma; no clinical benefit was observed for dasatinib in 
NSCLC and colorectal cancer or for saracatinib in head and neck squamous cell 
carcinoma or prostate, pancreatic, gastric and breast cancer 54. 
 
In most cancers, aberrant SRC kinase activity is not thought to be a primary driver of 
carcinogenesis, unlike BCR-ABL in CML, which is likely a reason for the poor results 
of SRC inhibitor monotherapy. However, SRC was found to play important roles in 
preventing and overcoming treatment resistance and showed synergistic effects with 
other anti-cancer agents in preclinical models, which provides a case for rational drug 
combinations (see chapter 1.2.4.3). In the case of breast cancer, several clinical trials 
investigated the combination of dasatinib, bosutinib or saracatinib with chemo-, 
hormone or targeted therapies (see Table 1.5). While two phase II trials reported 
improved progression-free survival (PFS) or CBR with dasatinib compared to 
hormone treatment alone, and two cases of complete response have been reported 
in others, the results of these trials have not yet led to phase III trials with dasatinib or 
other SFK inhibitors in breast cancer 250–253. Two trials with bosutinib were terminated 
early due to too poor risk-to-benefit ratios 254,255. 
Two phase III clinical trials with dasatinib combination therapy have been conducted 
in metastatic hormone resistant prostate cancer (NCT00744497) and gastrointestinal 
stromal tumours (GIST, NCT00688766); overall survival of prostate cancer patients 




terminated early 246,256. A phase II trial of saracatinib with paclitaxel in platinum-
resistant ovarian cancer (NCT01196741) showed no significant effects but a tendency 
towards worse outcomes with saracatinib; AstraZeneca has reportedly stopped its 
development in cancer, although it continues testing in other indications 257.  
 
Overall, these results show that only a subset of patients respond moderately to 
current SRC inhibitors. It remains to be seen whether this can be improved with better 
biomarker-based patient stratification methods or more selective, potent inhibitors that 
can be used at higher doses. 
 
 
Table 1.4. Phase II clinical trials of dasatinib, bosutinib or saracatinib as single agents 
in breast cancer. Status: C = completed, T = terminated, NR = not recruiting, S = suspended, 
W = withdrawn. Outcome: CR = complete response, PR = partial response, SD = stable 
disease, PFS = median progression-free survival, OS = overall survival. 
 
  
Trial ID Phase Type Status Outcome Ref 
Dasatinib 
NCT00371254 II TNBC  C 
PR 5%, SD>16 wks 5%, PFS 8.3 
wks 
248 
NCT00371345 II HER2+, ER+, PrR+ C PR 4%, SD>16 wks 9% 249 
NCT00817531 II untreated TNBC T Futility 246 
NCT00780676 II advanced T Futility 258 
NCT00546104 II advanced C Early closure due to low PFS 259 
NCT00410813 II bone mets C PFS 12.6 weeks 260 
NCT01471106 II no mets, ER- NR - 246 
NCT02720185 II TNBC S - 246 






PR 6%, SD>24 wks 21%, PFS 15 
wks, OS>2 yrs 26.4% 
261 
Saracatinib 
NCT00559507 II advanced, ER-, PR- C CR 0%, PR 0%, SD>6 mts 0% 262 




Table 1.5. Phase I/II clinical trials of dasatinib, bosutinib or saracatinib in combination 
therapies in breast cancer. Status: C = completed, T = terminated, NR = not recruiting, R = 
recruiting. Outcome: CR = complete response, PR = partial response, SD = stable disease, 
PFS = median progression-free survival, OS = overall survival, CBR = clinical benefit rate (CR 
+ PR + SD). 
Combination Trial ID Phase Type Status Outcome Ref 
Dasatinib 




CBR higher with dasatinib 
(PR 6% vs 0%; SD>6 mts 
43% vs 29%), 
PFS no difference (18.1 
wks D+E vs 16.1 wks E) 
246,250 





Higher PFS with dasatinib 
(20.1 mts vs 9.9 mts),  
CBR no difference (71% 
D+L vs 66% L)  
251  




PFS, CBR, OS not 
improved with dasatinib 
263 
Fulvestrant NCT00903006 I/II 
mets, ER+, 
PrR+, HER2- 







PR 79%, SD 4%, PFS 24 
mts 
264 
Capecitabine NCT00452673 I advanced C 
PR 24%, SD 32%, PFS 
14.4 wks 
265 





PR 31%, SD 29% 
Phase 2: 
CR 2.8%, PR 20%, SD>6 
mts 20%, OS 20.6 mts, PFS 






Ixabepilone NCT00924352 I 
advanced,  
HER2- 
















PR 2.4%, SD>24 wks 7.1%,  
PFS 12.3 wks; 
risk:benefit ratio too high 
254 





PR 6.7%, SD>24 wks 6.7%; 
risk:benefit ratio too high 
255 






R  246 
Saracatinib 




CBR no difference (PR 70% 







1.3.3. The unclear role of ABL in solid tumours 
Many attempts have been made to repurpose or approve dual SRC/ABL inhibitors for 
their SRC inhibition, but all showed insufficient efficacy to date to warrant regulatory 
approval (see previous chapter 1.3.2). One contributing factor may be the promiscuity 
and associated off-target effects of current inhibitors. ABL kinase appears to have a 
complex role in solid tumours, as different studies link its activity either to cancer 
invasiveness and treatment resistance or to p53-mediated tumour suppression 270,271.  
 
ABL kinase was found to be highly activated in aggressive breast cancer cells, where 
it promotes invasion, proliferation and anchorage-independent growth in vitro that was 
reduced by the ABL inhibitor imatinib 272,273. Aromatase-resistant patients were found 
to have higher levels of PDGFR and ABL kinase expression and ABL inhibition was 
able to re-sensitise lapatinib- or tamoxifen-resistant cells to treatment 274–276. 
Moreover, ABL activity is necessary for the oncogenic transformation of fibroblasts 
and human breast cancer cells by SRC kinase, highlighting an interaction between 
both kinases 277.  
Contradicting roles were found in an in vivo breast cancer model, in which knockdown 
of the ABL2 protein ARG increased tumour size and proliferation but simultaneously 
reduced tumour invasiveness 278. Indeed, nuclear ABL kinase activity has long been 
linked to inhibition of cell growth, which was found to be mediated by its interaction 
with the tumour suppressor p53 and activation of p53-mediated transcription 279,280. 
ABL activation was found to induce senescence in TNBC by upregulating p21 
expression in a p53-dependent manner and wild-type p53 and ABL expression were 
identified as a prognostic factor for patient survival 281. Recently, it was shown that the 
dual role of ABL in TNBCs can be linked to p53 status and subcellular localisation of 
the p53:ABL complex; mutant p53 triggers cytoplasmic accumulation of p53:ABL that 
inhibits ABL-mediated anti-tumour activity 282.  
Another pathway distinct from ABL’s nuclear function links signalling via the EphB4 
receptor, ABL kinase and the CRK adapter protein to cytoskeletal changes that inhibit 
cell migration and tumour invasion 283–285. Moreover, α3β1 integrin-mediated signalling 
through ABL was found to activate the Hippo pathway and suppress metastases in a 
prostate cancer model 286.  
 
In addition to the role of ABL as a potential tumour suppressor, it also plays a key role 




mutant mice exhibit cardiac hyperplasia and the same phenotype was found by Fraser 
et al. after treatment of Zebrafish embryos with the dual SRC/ABL inhibitor dasatinib 
but not with the SRC-selective inhibitor eCF506, even at a 50-fold higher 
concentration 1,287. The ABL inhibitor imatinib was found to cause severe cardiotoxicity 
in some CML patients, although it should be noted that cardiac side effects of ABL 
inhibitors only occur in a small subset of patients 288,289.  
 
The risk of ABL inhibition combined with the role of ABL in p53-mediated tumour 
suppression cautions against the long-term use of dual SRC/ABL inhibitors in 
indications of solid carcinomas and non-malignant diseases. Consequently, there is 
a clear case for the development and preclinical assessment of SRC selective, non-
ABL inhibitors, which have the potential to exhibit greater potency and fewer side 
effects in the clinic. 
 
 
1.3.4. The discovery of eCF506 
The Innovative Therapeutics Lab at the University of Edinburgh has recently 
developed the first potent and highly selective small molecule SRC inhibitor eCF506 
(see Figure 1.5) 1. Its IC50 in isolated kinase screens of SRC was found to be <0.5 
nM, which is on par with the current best-in-class inhibitor dasatinib. Notably, it is the 
only known SRC inhibitor to exhibit approx. one thousand-fold selectivity over ABL 
kinase (IC50 479 nM) and does not inhibit c-KIT, PDGFR or RET, which are known 
targets of dasatinib (see Table 1.3).  
 
Further testing by Fraser et al. confirmed that eCF506 can potently inhibit SRC 
activation in cells and in an in vivo xenograft model, as well as reduce the proliferation 
and migration of two breast cancer cell lines and neuromasts in Zebrafish 1. 
Preliminary safety and pharmacokinetic studies show that it does not inhibit the hERG 
channel or cytochrome P450 enzymes and shows favourable plasma protein binding 
and metabolic stability. eCF506 is highly water soluble, unlike dasatinib, and its oral 
bioavailability and half-life in mice were also found to be superior. The high potency 
and selectivity of eCF506 combined with its excellent pharmacodynamic and 






Figure 1.5. Structure of eCF506. 
 
 
1.4. Aims and hypothesis 
The non-receptor tyrosine kinase SRC is a central node in cell signalling pathways 
and has repeatedly been associated with cancer progression, treatment resistance, 
angiogenesis and other diseases. While multiple dual SRC/ABL inhibitors are already 
used in the clinic to treat CML, efforts to repurpose these for their SRC inhibition have 
so far failed. Indeed, ABL may not be a desirable target in solid tumours such as 
breast cancer and the promiscuity of current inhibitors may lead to undesirable off-
target effects. The recently discovered selective SRC/non-ABL inhibitor eCF506 has 
the potential to overcome these limitations. It exhibits nanomolar potency, excellent 
drug-like properties and has achieved target inhibition in vivo.  
 
Hypothesis 
Based on its potency, selectivity and drug-like properties, eCF506 has the potential 
be better than current dual SRC/ABL inhibitors in preclinical models of cancer. 
 
Aims 
The aim of this thesis is to continue the preclinical investigation of eCF506, with a 
particular focus on: 
• eCF506’s potency in vitro in comparison to other SRC inhibitors and in 
different types of cancer. 
• Unique properties distinguishing eCF506 from the current best-in-class 
inhibitor dasatinib. 
• eCF506’s pharmacokinetic and pharmacodynamic properties and ability to 





















2.1.1. Common buffers and reagents 
The compositions of commonly used buffers are listed below in Table 2.1. Buffers 
were prepared using Milli-Q® water, unless stated otherwise. 
 
Table 2.1. Composition of common buffers and reagents. 
Buffer Composition 
Blocking Buffer 5% (w/v) bovine serum albumin (BSA) (Sigma, A9647) 
added to TBST 0.1%. 
Buffer A 20 mM Tris pH 7.5, 1 mM MgCl2, 1 mM EGTA; sterile 
filtered and stored at 4°C. 
Add PI directly before use. 
With detergent: add 0.03% (v/v) NP-40. 
Buffer B 10 mM Tris-HCl pH 7.4, 2.5 mM MgCl2, 1.5 mM KCl, 0.2 M 
LiCl; sterile filtered and stored at 4°C.  
Add PI, 0.1% (v/v) Triton X100 and 0.1% (w/v) sodium 
deoxycholate directly before use. 
DAPI solution 20 µg/mL DAPI (Sigma, D9542) in PBS; prepare directly 
before use. 
Citrate Buffer 18 mL of 0.1 M citric acid (21 g in 1L water), 82 mL of 0.1 
sodium citrate (29.4 g in 1 L water), make up to 1 L with 
water. 
Mammosphere medium 500 mL DMEM/F12 (Gibco, 21041), 10 mL B27 
supplement without vitamin A (Invitrogen, 12587), 20 
ng/mL rEGF (Gibco, PHG0314). 
Lysis Buffer (2X) 40 mM Tris pH 7.5, 300 mM NaCl, 1% (v/v) Triton X100. 
Pepsin solution 1 mg / mL pepsin (Sigma, P6887) in 30 mM hydrochloric 
acid (pH 1.5); freshly prepared. 
pHEMA coating 12 g of poly-(2-hydroxyethyl methacrylate) were dissolved 
in 1 L of 98% ethanol by constant mixing on a heated plate.  
Phosphate Buffered Saline 
(PBS) 
137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM 












1.25 mM PMSF (Sigma, 93482), 0.1% (v/v) aprotinin 
(Sigma, A6278), 100 µM Na3VO4 (Sigma, S6508), 500 µM 
NaF (Sigma, S7920). 
Added to RIPA buffer, Buffer A and Buffer B. 
Radioimmunoprecipitation 
assay (RIPA) buffer 
50 mM Tris pH 8.0, 150 mM NaCl, 1% (v/v) NP-40, 0.5% 
(w/v) sodium deoxycholate, 0.1% (v/v) SDS. Sterile filtered, 
stored at 4°C. 
RIPA lysis buffer PI are added to RIPA buffer directly before use. 
Scott’s Tap Water 3.5 g sodium bicarbonate, 20 g magnesium sulphate, make 
up to 1 L with water. 
Tris Buffered Saline (TBS) 24.23 g Trizma HCl and 80.06 g NaCl in 1 L water, pH 7.6. 
Tris Buffered Saline Tween 
(TBST 0.1%) 
Add 0.1% (v/v) Tween® 20 (Sigma, P1379) to TBS. 
Tris Glycine SDS (TGS) 25 mM Tris HCl, 192 mM glycine, 0.1% (w/v) SDS, pH 8.3.  
Trypsin 10X Trypsin-EDTA (Sigma, T4174) diluted to 1X in PE 







Antibodies for Western blots were diluted in blocking buffer to which sodium azide 
(0.02% w/v) was added and prepared antibody dilutions were stored at 4°C. 
Antibodies for co-immunoprecipitation were added directly to samples in RIPA lysis 
buffer. Antibodies for immunohistochemistry were diluted in Dako antibody diluent. 
 
Table 2.2. Antibody list. SCB = Santa Cruz Biotechnology, CST = Cell Signalling Technology. 
Table continued on next page 
Target Host Company ID Dilution 
Western blots 
ABL Mouse SCB SC-23 1 / 1000 
ABL (Y245) Rabbit CST 2861 1 / 1000 
α-tubulin Mouse CST 3873 1 / 1000 
β-actin Mouse CST 3700 1 / 1000 
β-catenin Rabbit CST 9582 1 / 1000 
BRCA1 Rabbit CST 9010 1 / 1000 
cdc25A Mouse Neomarker MS-640-P0 1 / 1000 
CDK2 Rabbit CST 2546 1 / 1000 
CDK4 Mouse Neomarker MS-299-P0 1 / 1000 
CDK6 Mouse Neomarker MS-451-P0 1 / 1000 
c-Myc Mouse SCB SC-40 1 / 1000 
CRKL Mouse CST 3182 1 / 1000 
CRKL (Y207) Rabbit CST 3181 1 / 1000 
ERα Rabbit Abcam 16660 1 / 1000 
FAK Rabbit CST 3285 1 / 1000 
FAK  Mouse Millipore 05-537 1 / 1000 
FAK (Y397) Rabbit CST 3283 1 / 1000 
FAK (Y861) Rabbit Invitrogen 44626 1 / 1000 
FAK (Y407) Rabbit Invitrogen 44-650 1 / 1000 
GAPDH Rabbit CST 5174 1 / 1000 
GM130 Mouse BD 610822 1 / 1000 
HER3 / ErbB3 Rabbit CST 4754 1 / 1000 
Histone H4 Mouse CST 2935 1 / 1000 
JNK/SAPK1 Rabbit Upstate 06-748 1 / 1000 
mTOR (S2448) Rabbit CST 2971 1 / 1000 




















Target Host Company ID Dilution 
Rb Mouse CST 9309 1 / 1000 
SRC Rabbit CST 2109 1 / 1000 
SRC Mouse SCB SC-8056 1 / 1000 
SRC (Y416) Rabbit CST 2101 1 / 1000 
SRC (Y527) Rabbit CST 2105 1 / 1000 
Anti-Mouse Horse CST 7076 1 / 5000 
Anti-Rabbit Goat CST 7074 1 / 5000 
Co-immunoprecipitation  
SRC Rabbit CST 2109 2 µg / sample 
SRC Mouse SCB SC-8056 2 µg / sample 
FAK Mouse Millipore 05-537 2 µg / sample 
Rabbit IgG Rabbit CST 2729 2 µg / sample 
Mouse IgG1  Mouse CST 5415 2 µg / sample 
Immunohistochemistry  
Ki67 (Mouse-preferred) Rabbit CST 12202 1 / 4000 
CD8α (Mouse-specific) Rabbit CST 98941 1 / 400 





Primers sequences are based on previously published papers and all primers were 
made by Integrated DNA Technologies as ready-formulated solutions (100 µM in 
IDTE buffer which contains 10 mM Tris and 0.1 mM EDTA, pH 8.0). 
 
Table 2.3. Primer sequences. 
Gene Species Sequence (5’-3’) Ref 
CCL5 Mouse F - CCCTCACCATCATCCTCACT 
R - CCTTCGAGTGACAAACACGA 
290 
CXCL10 Mouse F - GGATGGCTGTCCTAGCTCTG 
R - TGAGCTAGGGAGGACAAGGA 
291 
TGFB2 Mouse F - GAACCCAAAGGGTACAATGC 
R - TGGTGTTGTACAGGCTGAGG 
292 
IGFBP3 Mouse F - AATGCTGGGAGTGTGGAAAG 
R - TTCTGGGTGTCTGTGCTTTG 
293 
B2M Mouse F - GGGAAGCCGAACATACTGAA 
R - TGCTTAACTCTGCAGGCGTAT 
290 
VEGFR2 Human  F - GAGAGTTGCCCACACCTGTT 
R - CAACTGCCTCTGCACAATGA 
294 
GAPDH Human F - CAGCCTCAAGATCATCAGCA 





Dasatinib was acquired from Cell Guidance Systems (SM45). Bosutinib (S1014), 
imatinib (S2475), saracatinib (S1006), sunitinib (S7781) and VS-4718 (S7653) were 
acquired from Selleck Chemicals. 
 
eCF506 was synthesised in five steps from commercially available starting materials. 
The method has previously been described by Fraser et al. 1 and minor changes made 
for scale up purposes are highlighted in the following (see also Figure 2.1):  
- Step 1 (A to B) and step 2 (B to C): No changes. 
- Step 3 (C to D): No changes in synthesis. The solvent mix used for purification 





- Step 4 (D to E): Reactant amounts and volumes of solvents were tripled during 
synthesis. The aldehyde intermediate was suspended in THF instead of DCM 
to improve solubility. Four batches were combined for purification.  The solvent 
mix used for purification of E was changed to DCM : methanol : triethylamine 
(89 : 10 : 1) to reduce costs.   
- Step 5 (E to eCF506): Reactant amounts and volumes of solvents were tripled 
during synthesis. Five batches were combined for purification. The solvent mix 
used for purification of eCF506 was changed to DCM : methanol : 4 M 
ammonia in methanol (85 : 10 : 5). Scaling up of the last step improved the 
yield from 38% to 65%.  
A total of 3.4 g of eCF506 was synthesised by me and an additional 4 g was 









Figure 2.1. Synthetic route of eCF506. Modifications from the method published by Fraser 
et al. are highlighted in blue 1. DCM - dichloromethane, DMF - dimethylformamide, Et2N - 
triethylamine, EtOAc - ethyl acetate, MeOH - methanol, NH3 - ammonia, NIS - N-





2.2. Cellular assays 
2.2.1. Cell culture methods 
The cell lines used were either purchased directly from the European Collection of 
Authenticated Cell Cultures (MCF-7) or were a kind donation from several research 
groups at the Institute of Genetics and Molecular Medicine, Edinburgh, UK (all others).  
Cells are grown in the medium specified in Table 2.4 and maintained in a Heracell 
240i tissue culture incubator (37°C, humidified air, 5% CO2). Cell lines in culture were 
mycoplasma tested every 2 months.  
 
Table 2.4. Cell culture conditions. DMEM = Dulbecco’s Modified Eagle’s Medium (Gibco, 
21969035); RPMI = RPMI 1640 Medium (Gibco, 31870025); FBS = foetal bovine serum 
(Gibco, 10270-106); L-glutamine (Gibco, 25030081). Seeding density shown is for 96-well 
plates (see chapter 2.2.2.1 for protocol). 
Cell line Medium Supplements Cells / well 
BT-474 RPMI 10% FBS, 2 mM L-glutamine 5,000 
BT-549 RPMI 10% FBS, 2 mM L-glutamine 1,000 
CAMA-1 DMEM 10% FBS, 2 mM L-glutamine 1,000 
ES-2 DMEM 10% FBS, 2 mM L-glutamine 1,000 
HCC-1569 DMEM 10% FBS, 2 mM L-glutamine 3,000 
HCC-1954 DMEM 10% FBS, 2 mM L-glutamine 2,000 
HUVEC Ham’s F-12K 10% FBS, 100 µg/mL heparin (Sigma, 
H3149-10KU), 30 µg/mL endothelial cell 
growth supplement (Sigma, E2759) 
1,000 
IGROV-1 RPMI 10% FBS, 2 mM L-glutamine 1,000 
JIMT-1 DMEM 10% FBS, 2 mM L-glutamine 1,000 
K-562 RPMI 10% FBS, 2 mM L-glutamine 4,000 
KCL-22 RPMI 10% FBS, 2 mM L-glutamine 4,000 
KPL-4 DMEM 10% FBS, 2 mM L-glutamine 1,000 
LAMA-84 RPMI 10% FBS, 2 mM L-glutamine 4,000 
MCF-7 DMEM 10% FBS, 2 mM L-glutamine 1,000 
MDA-MB-134VI RPMI 10% FBS, 2 mM L-glutamine 10,000 
MDA-MB-157 DMEM 10% FBS, 2 mM L-glutamine 5,000 
MDA-MB-231 DMEM  10% FBS, 2 mM L-glutamine 1,000 
MDA-MB-436 DMEM 10% FBS, 2 mM L-glutamine 3,000 
Met1 DMEM 10% FBS, 2 mM L-glutamine 1,000 




Table continued from previous page 
Cell line Medium Supplements Cells / well 
MetBo2 DMEM 10% FBS, 2 mM L-glutamine 1,000 
OVCAR-3 RPMI 20% FBS, 2 mM L-glutamine, 0.01 mg/mL 
bovine insulin 
3,000 
OVMANA RPMI 10% FBS, 2 mM L-glutamine 3,000 
OVTOKO RPMI 10% FBS, 2 mM L-glutamine 1,000 




SCC cell lines MEM 10% FBS, 2 mM L-glutamine, 1X MEM 
non-essential amino acids, 1X MEM 
vitamins, 1 mM sodium pyruvate; SCC 
FAK WT and SCC FAK NLS are 
maintained in 1% Hygromycin 
1,000 
SKBR3 DMEM 10% FBS, 2 mM L-glutamine 4,000 
SKOV-3 McCoy’s 5a 10% FBS, 2 mM L-glutamine 1,000 
SUM44PE Ham’s F-12 1 g/L BSA, 5 mM ethanolamine, 10 mM 
HEPES, 1 µg/mL hydrocortisone, 5 µg/mL 
insulin, 50 nM sodium selenite, 5 µg/mL 
apo-transferrin, 10 nM triiodo thyronine; 
2% FBS was added when thawing and 
splitting cells. 
5,000 
SYF DMEM 10% FBS, 2 mM L-glutamine 1,000 
T47-D RPMI 10% FBS, 2 mM L-glutamine 2,000 
TOV112D RPMI 10% FBS, 2 mM L-glutamine 1,000 
TOV-21G RPMI 10% FBS, 2 mM L-glutamine, 1X non-
essential amino acids, 1 mM sodium 
pyruvate, 0.01 mg/mL bovine insulin 
1,000 
ZR75.1 RPMI 10% FBS, 2 mM L-glutamine 4,000 
 
 
2.2.2. Cell proliferation assays 
2.2.2.1. Cell viability assays 
On day 0, cells were seeded in 96-well plates at the seeding density specified in Table 
2.4. Edge wells are not used due to evaporation effects that can affect cell growth. 




except for suspension cell lines which were seeded and treated on the same day. 
Dilution plates of the test compounds were prepared in DMSO and diluted 1:50 into 
medium, of which 5 µL were added to the cell plates (final DMSO concentration 0.1% 
v/v). Cells were treated for 5 days before cell viability was measured using the 
resazurin-based PrestoBlue solution (Invitrogen, A13262), which is converted into 
fluorescent red resorufin in the reducing environment of viable cells. PrestoBlue was 
added to an untreated plate on day 2 and treated plates on day 7 (1 in 10 dilution) 
and fluorescence (550 nm excitation, 580 nm emission) was measured after the same 
incubation time on both days (0.25-6 hours after addition, depending on cell line) using 
the Perkin Elmer Envision 2101 plate reader. The average fluorescence on day 2 was 
subtracted from the values on day 7 to distinguish between cytotoxic and cytostatic 
treatment effects and the data was normalised to DMSO controls. GraphPad Prism 7 
was used to fit non-linear regression curves (four-parameter logistic fit or biphasic fit, 
depending on shape of data points) to determine growth inhibition 50% (GI50), 75% 
(GI75), 90% (GI90) and total growth inhibition (TGI) concentrations. 
 
2.2.2.2. Oesophageal cancer screen 
This work was done by Dr Richard Elliott and Becka Hughes from the Drug Discovery 
group of Prof Neil Carragher at the University of Edinburgh, UK. 
 
eCF506, dasatinib and imatinib were tested in six oesophageal adenocarcinoma cell 
lines (FLO-1, OE33, MFD1, SKGT4, OAC-P4C, JHesoAD1) and two non-malignant, 
tissue matched controls immortalised by hTERT (EPC2 is a human oesophageal 
squamous epithelial cell line; CP-A is a Barrett’s oesophagus epithelial cell line with 
non-dysplastic metaplasia; both are p53 wild-type). 
Cells were seeded in 384-well plates (1000 cells/well, 45 µL/well) and left to attach 
for 24 hours. Compounds were added (10X dose, 5 µL/well) in a 10-point dose 
response with half-log serial dilutions from 10 µM to 0.5 nM final concentration with 
DMSO controls (final DMSO concentration 0.1% v/v). Cells were then incubated for 
48 hours prior to fixation with 4% formaldehyde. Fixed cells were stained with Hoechst 
33342 (2 µg/mL) for 20 minutes. Total Nuclei per well was quantified automatically 
using an ImageXpress MicroXl platform (10X objective, DAPI channel, 4 sites per 
well, average Total Nuclei/site calculated via a built-in ‘Count Nuclei’ analysis 





2.2.2.3. GDSC cell line screen  
This work was done by the group of Dr Mathew Garnet, Wellcome Sanger Institute, 
UK.  
 
eCF506 was screened in the Genomics of Drug Sensitivity in Cancer (GDSC) cell line 
collection. This collection comprises of 750 cell lines, most of which are commercially 
available, across a variety of cancer types. All cell lines have been authenticated by 
STR analysis and are kept in either DMEM/F12 (supplemented with 10% FBS, 1% 
Pen-Strep) or RPMI (supplemented with 10% FBS, 1% Pen-Strep, 4.5 mg/mL 
glucose, 1 mM sodium pyruvate). The cell lines were split into two sets and the screen 
was performed in two stages lasting ca. 4 months each. Cells are seeded at optimal 
density in 1536-well plates in 7.5 µL medium by automated fluid dispensers and 
incubated (37°C, 5% CO2, humidified atmosphere) for 24 hours. Compounds are 
added (final DMSO concentration 0.1% v/v) using the Echo555 Acoustic Dispenser 
(Labcyte) and plates were incubated for 72 hours. Cell viability is measured after 
addition of 2.5 µL Cell Titer Glo 2.0 (Promega) per well and a 10-minute incubation at 
room temperature. Luminescence is measured on a Paradigm (Molecular Devices) 
plate reader. An additional untreated plate is read 24 hours after seeding as above to 
determine cell viability at the time of treatment. Negative controls (untreated, DMSO) 
and positive controls (MG-132, staurosporine, media only) are included in the screen 
for quality control and seven cell lines are tested at multiple stages of the screening 
process to identify inconsistencies and systematic errors. eCF506 dissolved in DMSO 
was stored in 1536-well source plates at room temperature (low humidity <12%, low 
oxygen <2.5%, UV protected) for the duration of the screening period. Data analysis 
was done after normalisation of each plate to negative and positive controls using the 
R package gdscIC50 (see https://github.com/CancerRxGene/gdscIC50). Dose-
response curves were fitted using a non-linear mixed effects model which assumes a 
classical sigmoidal S-shape dose-response from which IC50 and AUC values were 
calculated.  
 
2.2.2.4. Spheroid assay 
Cells were seeded on day 0 in ultra-low adhesion round bottom 96-well plates (Costar, 
7007) at the seeding densities shown in Table 2.5 in 200 µL of medium. Plates were 




incubated for 2-3 days as specified in Table 2.5 to allow spheroids to form. 
Compounds were added to the wells without changing the medium (final DMSO 
concentration 0.1% v/v) and the plates were incubated for 7 days. Spheroids were 
imaged on the day of treatment, 4 days post treatment and 7 days post treatment 
using the ImageXpress MicroXI platform. Eight Z-stack images (40X, brightfield) were 
taken with 50 µM size step and collapsed into a single image from which the size of 
the spheroid was measured using CellProlifer. On the final day of treatment, calcein-
AM (3.5 µM) and propidium iodide (4 µM) were added to the plates, which were 
incubated for 1 hour and fluorescence was measured on the ImageXpress to visualise 
viable and dead cells, respectively. The size of each spheroid was calculated for all 
time points and expressed as percentage of spheroid size on day of treatment start. 
 
Table 2.5. Seeding densities of 3D spheroid models. 
Cell Line Seeding Density  
(cells / well) 
Treatment start / end  
(days post seeding) 
MDA-MB-231 4,000 3 / 10 
MCF-7 2,000 2 / 9 
T-47D 2,000 2 / 9 
MetBo2 2,000 2 / 9 
 
2.2.2.5. Mammosphere assay 
This protocol was adapted from Shaw et al. 295. The mammosphere forming ability in 
the first generation was assessed as follows: 6-well plates were coated with warm 
pHEMA solution (1 mL/well) and left to dry at 40°C for 72 hours under sterile 
conditions. MetBo2 cells were trypsinised, collected in normal medium, centrifuged 
(580 x g, 2 min) and the cell pellet was resuspended in 2 mL of ice-cold PBS. A single 
cell suspension was created by syringing the cells with a 25 G needle six times. The 
cell concentration was determined using a haemocytometer and 4,000 cells were 
added to each well in 2 mL of mammosphere medium (see Common buffers for 
composition). Compounds were added to the wells (final DMSO concentration 0.1% 
v/v) and the plates were incubated for 5 days without any disturbance. Plates were 
then imaged on the ImageXpress MicroXI platform (40X, brightfield) and the number 
of mammospheres with a diameter over 50 µM counted using CellProfiler. 





MFE (%) =  
number of mammospheres per well
4,000 cell seeded per well
∗ 100 
 
To assess their self-renewal capacity, mammospheres were then passaged and 
assessed again in a secondary generation as follows: All mammospheres for each 
condition were collected, centrifuged (115 x g, 5 min), resuspended in 300 µL of 
trypsin and incubated at 37°C for 3 minutes. A single cell suspension was created by 
syringing the mammospheres with a 25 G needle six times, after which the trypsin 
was neutralised with 1 mL of normal medium. The cell suspension was centrifuged 
(580 x g, 5 min) and the cell pellet was resuspended in 100 µL of ice-cold PBS. The 
cell concentration was determined using a haemocytometer and for each condition 
the entire cell suspension was plated out in mammosphere medium in new pHEMA 
coated 6-well plates as close to the original seeding density as possible. Compounds 
were added to the wells (final DMSO concentration 0.1% v/v) and the plates were 
incubated for 5 days without any disturbance. The number of mammospheres in the 
secondary generation were counted as described for the first generation and the 
mammosphere self-renewal rate was calculated as follows:  
 
Self − renewal rate =  
total number of second generation mammospheres
total number of first generation mammospheres
 
 
2.2.2.6. Cell migration assay 
HUVEC cells (20,000 cells / well) were seeded on 96-well ImageLock plates (Essen 
Bioscience, 4379) and left to attach for 3 hours. Compounds were added to the wells 
(final DMSO concentration 0.1% v/v) and plates were incubated for 2 hours before 
homogenous scratch wounds (700-800 µm) were created in all wells using the 
WoundMaker tool (Essen BioScience, 4563). Wells were washed twice with medium 
to remove detached cells before plates were incubated in the IncuCyte ZOOM 
incubator (37°C, humidified air, 5% CO2). Photos were taken every hour for 24 hours 
and the relative wound density was determined using the IncuCyte wound cell 





2.2.2.7. Cell cycle assay 
Cells were seeded (1 million cells / 15 cm plate) and left to attach for 24 hours. 
Compounds were added (final DMSO concentration 0.1% v/v) and the treated plates 
were incubated for 48 hours. Cells were trypsinised, resuspended in medium and 
centrifuged (1,000 rpm, 5 minutes). The cell pellet was resuspended in 50 µL PBS 
with 2% FBS and cell aggregates were broken up through gentle pipetting. Cells were 
fixed by adding 1 mL ice-cold 70% ethanol dropwise while vortexing gently and 
samples were stored at 4°C for up to two weeks. The cell concentration was 
determined using a haemocytometer and 1.5 million cells were used per sample. Cells 
were centrifuged (1,000 rpm, 5 minutes) and the cell pellet was resuspended in 2 mL 
pre-warmed pepsin solution and incubated for 30 minutes in a 37°C water bath with 
frequent vortexing. The digested samples were centrifuged (4,000 rpm, 4 minutes) 
and the pellet was resuspended in 0.25 mL HCl and incubated for 15 minutes at room 
temperature. 12 mL PBS was added and samples were centrifuged (4,000 rpm, 4 
minutes), after which the pellet was washed a second time in 5 mL PBS. The pellet 
was resuspended in 0.5 mL DAPI solution and incubated in the dark for 30 minutes 
at room temperature. Samples were analysed by flow cytometry using the LSR 






2.3. Nucleic acid methods 
2.3.1. RNA extraction 
Cells were seeded (500,000 cells / 10 cm dish) and left to attach for 48 hours. 
Compounds were added (final DMSO concentration 0.1% v/v) and cells incubated for 
24 hours. Cells were lysed and ribonucleic acid (RNA) was extracted using the 
RNeasy Mini Kit (Qiagen, 74106) according to the manufacturer’s instructions.  
 
2.3.2. cDNA synthesis 
The RNA concentration was determined and 1 µg of each sample was used to 
synthesise complementary deoxyribonucleic acid (cDNA) using the qScript cDNA 
SuperMix (Quanta Biosciences, 95048) according to the manufacturer’s instructions.  
 
2.3.3. Real time PCR 
100 ng of cDNA was used for each reaction and each sample was assessed in 
triplicate. Primers were used at a final concentration of 200 nM.  
Real Time PCR was performed using SYBR Select Master Mix (Applied Biosystems) 
according to the manufacturer’s instructions and PCR-grade H2O was used as a 
control for primer specificity. The cycling conditions used on the StepOnePlusTM Real-
Time PCR System (Applied Biosystems) were as follows: 
 
- Pre-incubation: 95°C (10 minutes) 
- 40 cycles: 
o Denaturation: 95°C (15 sec) 
o Annealing/Extension: 60°C (1 min) 
- Dissociation/Melt Curve analysis:  
o Denaturation: 95°C (15 sec) 
o Annealing: 60°C (1 min) 
o Increasing temperature by 0.3°C every 15 seconds until 95°C 
 
The cycle threshold (CT) was determined by StepOne Real-Time PCR Systems 




housekeeping gene (B2M for mouse cells, GAPDH for human cells) and compound-
treated samples were normalised to DMSO-treated controls.  
 
2.3.4. siRNA 
Master mixes were prepared as shows in Table 2.6. On a 12-well plate, 200 µL master 
mix was added per well and complexes were allowed to form for 20 minutes at room 
temperature. Cells were trypsinised, counted, centrifuged and resuspended in 
OptiMEM (80,000 cells / mL) and 1 mL of cell suspension was added to each well. 
Plates were left at room temperature for 1 hour and then incubated at 37°C. After 24 
hours, medium as replaced with standard medium, compounds were added (final 
DMSO concentration 0.1% v/v) and cells incubated for 4 days. Cells were lysed with 
RIPA lysis buffer (80 µL / well) and Western blotting was performed as described in 
methods 2.4. 
 
Table 2.6. siRNA mastermix composition.  
Sample Master mix 
Untreated 200 µL OptiMEM 
Mock 200 µL OptiMEM, 2 µL Lipofectamine RNAiMAX (Invitrogen, 13778100) 
Non-silencing 
RNA 
200 µL OptiMEM, 2 µL Lipofectamine RNAiMAX, 40 nM Non-targeting 
control siRNA (Dharmacon, D-001206-14) 
SRC siRNA 200 µL OptiMEM, 2 µL Lipofectamine RNAiMAX, 40 nM Human SRC 






2.4. Protein methods 
2.4.1. Cell lysates 
Cells were seeded in 6-well plates or 10 cm dishes, depending on the experiment, 
and incubated for 48 hours until 70% confluence was reached. Compounds were 
added (final DMSO concentration 0.1% v/v) and cells incubated for the time specified 
(3, 6 or 24 hours). Plates were put on ice, the medium was removed and cells were 
washed twice with ice-cold PBS. RIPA lysis buffer with protease and phosphatase 
inhibitors was added (100 µL / well or 200 µL / 10cm dish) and the cells were scraped, 
collected and incubated on ice for 10 minutes with occasional vortexing. Lysates were 
centrifuged at 4°C (17,000 x g, 10 minutes) and the supernatant was transferred into 
a new microcentrifuge tube. Lysates were stored at -20°C (short-term) or -70°C (long-
term).  
 
The protein concentration of lysates was determined in a bicinchoninic acid (BCA) 
assay. The Pierce BCA Protein Assay Kit (Thermo Scientific, 23225) was used 
according to the manufacturer’s instructions, with samples being diluted 1 in 4 and set 
up in duplicate on 96-well plates. Plates were read on a Spark 20M microplate reader 
(Tecan) and absorbance was measured at 562 nm. 
 
2.4.2. Western blotting 
Samples for SDS-PAGE were prepared as follows: 20 µg cell lysate was diluted with 
RIPA buffer to a final volume of 15 µL, to which 5 µL of 4X Laemmli Sample Buffer 
(Bio-Rad, 1610747) were added. Samples were heated to 95°C for 5 minutes and 
then loaded onto Mini-PROTEAN TGX precast gels (12-well or 15 well, 4-15% or 12%, 
depending on experiment; Bio-Rad). Precision Plus Protein Dual Color Standards 
(Bio-Rad, 1610374) were loaded alongside the lysates. Gels were run in Mini-
PROTEAN Tetra Cell tanks in TGS buffer (pH 8.3) at 150 V for 45 minutes. Proteins 
were transferred onto Trans-Blot Turbo Nitrocellulose membranes (Bio-Rad, 
1704159) using the Trans-Blot Turbo Transfer System (Bio-Rad) for semi-dry blotting 
at 2.5 A (midi) or 1.3 A (mini) and up to 25 V for 10 minutes. Membranes were cut and 
blocked with blocking buffer for 1 hour at room temperature before incubation with 
primary antibodies at 4°C over night. Membranes were washed twice with TBST 




hours at room temperature, before washing another 3 times with TBST (0.1%) for 5 
minutes. Antibodies were detected by chemiluminescence by incubating membranes 
for 2 minutes with the Clarity ECL Western Blotting Substrates (Bio-Rad, 102031309) 
before imaging in the ChemiDoc XRS+ Imaging System (Bio-Rad). Protein bands 
were quantified using the ImageLab software v5.2 (Bio-Rad) with automated band 
detection and background subtraction (disk size 70 mm).  
 
2.4.3. Thermal shift assay 
This protocol is adapted from the Nature Protocols publication by Jafari et al. 296. Cells 
were seeded (3 million cells per 10 cm dish) and left to attach for 24 hours. 
Compounds were added (final DMSO concentration 0.1% v/v) and cells incubated for 
1 hour before being washed with PBS, trypsinised, collected in PBS and centrifuged 
(300 x g, 3 min). The cell pellet was gently resuspended in 10 mL PBS, centrifuged 
again (300 x g, 3 min) and resuspended in 1 mL PBS with protease inhibitors 
(aprotinin and leupeptin, both 1/1,000 dilution). Compounds were added back to 
samples at the previously used concentrations. Each sample was split into 10 PCR 
tubes (100 µL) which were heated at different temperatures (40.0°C to 65.0°C) for 3 
minutes. Samples were cooled at room temperature for 3 minutes before being put 
on ice, lysed in 100 µL of a mild detergent lysis buffer prepared at 2X (40 mM Tris 
HCl pH 7.5, 300 mM NaCl, 1% v/v Triton X100), briefly vortexed and centrifuged at 
4°C (17,000 x g, 20 minutes). The supernatant was transferred into a new 
microcentrifuge tube and stored at -20°C.  
Western blots were performed and quantified as described in methods 2.4.2 to assess 
heat degradation of the compounds’ protein targets compared to DMSO controls.  
 
2.4.4. Subcellular fractionation 
Cells were seeded in 10 cm or 15 cm dishes and left to attach for 48 hours until 70% 
confluence was reached. Compounds were added (final DMSO concentration 0.1% 
v/v) and cells incubated for 6 or 24 hours. Cells were washed twice with ice-cold PBS 
and 300 µL (10 cm) or 500 µL (15 cm) Buffer A with detergent was added before cells 
were gently scraped, collected in microcentrifuge tubes and rotated at 4°C for 5 
minutes. Samples were centrifuged at 4°C (800 x g, 4 minutes) and both the 




The supernatant was transferred into a new tube to which NP-40 was added to a final 
concentration of 1% v/v, samples vortexed rigorously and centrifuged at 4°C (17,000 
x g, 10 minutes). The supernatant was transferred into a new microcentrifuge tube 
and labelled as ‘cytoplasmic fraction’.  
The pellet from the previous step was washed once with Buffer A with detergent and 
once with Buffer A without detergent by flicking the tubes until the pellet is suspended, 
centrifuging at 4°C (800 x g, 3 minutes) and removing the supernatant. The pellet was 
resuspended in two volumes of Buffer B (related to pellet size), samples rotated at 
4°C for 15 minutes, centrifuged at 4°C (2,000 x g, 5 minutes) and both the supernatant 
and pellet were kept. The supernatant was transferred into a new tube and centrifuged 
at 4°C (17,000 x g, 10 minutes). The supernatant was transferred into a new 
microcentrifuge tube and labelled as ‘perinuclear fraction’. 
The pellet from the previous step was washed twice with Buffer B by flicking the tubes 
until the pellet is suspended, centrifuging at 4°C (2,000 x g, 3 minutes) and removing 
the supernatant. The pellet was resuspended in two volumes of RIPA lysis buffer 
(related to pellet size), sonicated for five cycles (30 seconds on, 30 seconds off) and 
centrifuged at 4°C (17,000 x g, 10 minutes). The supernatant was transferred into a 
new microcentrifuge tube and labelled as ‘nuclear fraction’.  
All fractions were stored at -20°C (short-term) or -70°C (long-term) and Western blots 
were performed as described in methods 2.4.2. The following controls were used for 




Cell lysates were prepared from 10 cm dishes and the protein concentration 
determined as described in methods 2.4.1. 1 mg of lysate was diluted with RIPA lysis 
buffer to 1 mL in a microcentrifuge tube. 20 µL Dynabeads Magnetic Beads 
(Invitrogen) per sample were washed once in 1 mL RIPA lysis buffer using the 
DynaMag-2 Magnet (Invitrogen), resuspended in 20 µL RIPA lysis buffer and added 
to the cell lysate. 2 µg primary antibody or appropriate IgG control was added and 
samples rotated at 4°C over night. Dynabeads were washed twice with RIPA lysis 
buffer and three times with PBS before being resuspended in 20 µL of 1X Laemmli 
sample buffer (4X Laemmli sample buffer diluted to 1X with PBS). Samples were 
heated to 95°C for 5 minutes and beads were separated using the magnetic rack 




Dynabeads were matched to the source of the antibody used for co-
immunoprecipitation, and primary antibodies used during Western blotting were 
chosen from a different species to avoid visualisation of the co-immunoprecipitation 
antibody’s heavy (50 kDa) and light (25 kDa) chains (unless otherwise stated), as 
shown in Table 2.7. 
 
Table 2.7. Co-IP Dynabead and antibody host combination. 
Host of co-IP Abs  Dynabeads Host of primary Abs  
(Western Blot) 
Rabbit Protein A (10002D) All mouse 
Mouse Protein G (10004D) All rabbit 
 
 
2.4.6. Zeptosens reverse phase protein array 
This work was done together with Kenneth Macleod from the Drug Discovery group 
of Prof Neil Carragher at the University of Edinburgh, UK. 
 
The general procedure for the reverse phase protein array has previously been 
published by Macleod, Serrels and Carragher 297. The following section describes the 
specific method used in this thesis. 
 
Cells were seeded in 6-well plates (MDA-MB-231 400,000 cells/well, MCF-7 600,000 
cells/well) and left to attach for 24 hours. Compounds were added (final DMSO 
concentration 0.1% v/v) and plates incubated for 3 or 24 hours. Cells were washed 
twice with 3 mL PBS and lysed with 80 µL CLB1 (Bayer Technology Services), 
scraped and collected in microcentrifuge tubes and incubated at room temperature 
for 30 minutes with occasional vortexing. Lysates are centrifuged (17,000 x g, 10 
minutes) and the supernatant transferred to new microcentrifuge tubes. The protein 
concentration was determined in a Bradford Assay using the Coomassie Plus Protein 
Assay (Thermo Scientific) according to the manufacturer’s instructions and all 
samples were adjusted to 2 mg/mL. Samples were stored at -70°C. 
20 µL of the samples were diluted 1:10 with spotting buffer CSBL1 (Bayer Technology 
Services) and a dilution series (0.2, 0.15, 0.1, 0.05 mg/mL) was created with CSBL1 
and 10% CLB1. The diluted samples were transferred onto a 384-well plate and 




controlled environment (70% humidity, 14°C). Fluorescently labelled BSA standards 
were also printed onto the slides. ZeptoChips were blocked for 1.5 hours in blocking 
buffer BB1 (Bayer Technology Services), washed three times for 2 minutes in distilled 
water, dried by centrifugation and washed 3 times with 90 µL CAB1 buffer (Bayer 
Technology Services). Primary antibodies diluted in CAB1 or CAB2 buffer were added 
and incubated at room temperature overnight, before ZeptoChips were washed three 
times with CAB1 and 90 µL of appropriate Alexa Fluor conjugated secondary 
antibodies were added and incubated for 2.5 hours in the dark at room temperature. 
ZeptoChips were washed three times with CAB1, with the last wash left on, and slides 
scanned using the ZeptoReader (Zeptosens-Bayer). Exposure times just below 
saturation of the fluorescent signal were automatically selected for analysis by the 
ZeptoView 3.1 software and a weighted linear fit through the fourfold dilution series 
was used to calculate the relative fluorescence intensity (RFI) of each sample. 
Normalisation to the reference BSA signal was used to compensate for intra- and 
inter-chip variation. Proteins with very low signal (RFI <0.05) were excluded from 
analysis. The local normalised RFI values were then normalised to DMSO controls 
for each cell lines, relative protein abundance plotted and hierarchical clustering 
performed (Euclidian distance, complete linkage) using the free online Morpheus 
software (Broad Institute). 
 
2.4.7. Cytokine array  
This work was done together with Kenneth Macleod from the Drug Discovery group 
of Prof Neil Carragher at the University of Edinburgh, UK. 
 
MetBo2 cells were seeded (1.5 million cells / 10 cm dish) and left to attach for 24 
hours. Compounds were added (final DMSO concentration 0.1% v/v) and cells pre-
treated for 24 hours. Medium was changed and any floating cells were spun down 
and returned to the dishes. Compounds were added again to 4 mL fresh medium per 
dish and cells treated for 48 hours. A control sample of medium without cells was 
incubated for 48 hours. Medium was collected and spun down at 1,000 rpm for 5 
minutes, supernatant was transferred into a fresh tube and frozen at -80°C. Cells were 
washed with PBS, lysed and protein concentration determined as described in 
methods 2.4.1 for later normalisation. 
Oncyte supernova slides (one slide per sample) with 64 sub-arrays are prepared with 




(at 0.2 mg/mL in PBS with 0.05% v/v Tween20) using the Aushon 2470 Arrayer 
Platform. Slides are blocked with Superblock T20 (Thermo Scientific, 37536) for one 
hour prior to incubation with sample at 4°C overnight. Slides were washed three times 
for five minutes in PBST (PBS supplemented with 0.05% v/v Tween20), incubated in 
Super G blocking buffer (Grace Biolabs, 105101) for 10 minutes and washed again 
three times in PBST. Slides were incubated with detection antibodies (1:500 in PBST 
with 5% w/v BSA and 10% v/v Super G blocking buffer) for one hour after which they 
were washed three times in PBST, incubated for 10 minutes in Super G blocking 
buffer, washed again three times in PBST and incubated with streptavidin 800 (Li-
Cor, 926-32230) diluted 1:500 in PBST with 5% w/v BSA and 10% v/v Super G 
blocking buffer. Slides were washed three times in PBST, three times in PBS, once 
with water, centrifuged at 200 x g to dry for five minutes and then air dried in the dark.  
Slides were imaged and microarray images analysed using Mapix software 
(Innopsys) by determining the average signal intensity for each spot and subtracting 
the median background from the adjacent area. The net signal per spot is expressed 
as relative fluorescence intensity (RFI) and averaged across all four spots per 
antibody. Proteins with similar RFI as the media only control sample were excluded. 
RFI value per protein is normalised to the amount of protein present in the respective 





2.5. Other assays 
 
2.5.1. Kinase screening assays  
This work was done by Reaction Biology Corporation, USA and the method has 
previously been described for the same data set by Fraser et al. 1. 
 
 
2.5.2. Hepatocyte stability / Metabolite study 
This work was performed by Cyprotex Discovery Limited.  
 
A suspension of cryopreserved human hepatocytes (0.5 x 106 viable cells/mL) was 
incubated with Williams E media (supplemented with 2 mM L-glutamine, 25 mM 
HEPES) and eCF506 (3 µM, final DMSO concentration 0.25% v/v) at 37°C for 120 
minutes. Two control compounds and vehicle controls were included. At six different 
time points, 50 µL of incubate was transferred to 100 µL acetonitrile and centrifuged 
at 2500 rpm at 4°C for 30 minutes to remove protein. Supernatants were analysed by 
LC-MS/MS using Cyprotex generic conditions. 
The data was plotted as ln peak area ratio (compound peak area / internal standard 
peak area) over time, from which the gradient of the line was determined. Half-life 
(t1/2) and intrinsic clearance (CLint) were calculated as follows: 
 
Elimination rate constant (k) = (- gradient) 
Half-life (t1/2) (min) = 0.693 / k 
Intrinsic clearance (CLint) (µL / min / million cells) = V x 0.693 / t1/2 
with V = incubation volume (µL) / number of cells 
 
Further metabolite profiling of the 60-minute and 120-minute samples was performed 
using a Q-Tof UPLC-MS/MS platform. This uses a 15-minute gradient where the test 
compound eludes after 70-80% of the gradient. Samples are compared to a time zero 
control sample. Analysis is done using the instrument manufacturer’s proprietary 
functions (MSe) which reports the mass and abundance as percentage of total 
compound related material of the parent and any metabolites found. Metabolites are 




metabolites are searched for by comparison to time zero control samples. Area 
percentage will be calculated and may be related to the amount of metabolite based 
on the assumption that each metabolite is equally as responsive as parent. The 
combination of fragmentation patterns and internal biotransformation expertise was 
applied to the data to propose structures for the identified metabolites.  
 
 
2.5.3. X-ray crystallography 
This work was done by Dr Daniel Lietha at the Centro de Investigaciones Biológicas 
(CIB) in Madrid, Spain.  
 
Expression and purification: 
The hSRC kinase domain (residues 254-536) was expressed with an N-terminal 
6xHis tag in E.coli (BL21) co-expressed with the YopH phosphatase, as described 
previously 298. Pure protein was obtained by Ni-chelate affinity chromatography 
(HisTrap, GE Healthcare), ion exchange chromatography (Source 15Q column, GE 
Healthcare) and size exclusion chromatography (Superdex200, GE Healthcare). After 
the Ni-chelating column, the 6xHis tag was removed by incubation with TEV protease. 
 
Crystallisation: 
Purified SRC kinase was concentrated to 6.3 mg/ml (193uM) and incubated with 10 
mM eCF506 for 30 min on ice. Crystallisation was performed using the hanging drop, 
vapor diffusion method. Crystallisation conditions were optimised from 299 with final 
crystals grown by mixing the protein with equal volume of 6% PEG3350, 300mM 
ammonium acetate, 0.1M HEPES pH7.5, 10mM TCEP. Crystals were flash frozen in 
liquid nitrogen after soaking in growth condition with 25% ethylene glycol. 
 
Data collection and structure solution: 
Diffraction data collection was carried out at the XALOC beamline of the ALBA 
synchrotron facility (Barcelona, Spain). Data was integrated to 1.5 Å using XDS 300, 
scaled with AIMLESS 301 and an initial structure obtained by molecular replacement 
with PHASER 302 using the SRC kinase domain (pdb:4MXO) as search probe. The 
structure was refined using Refmac5 303 and manual rebuilding with Coot 304. Final R-





2.5.4. Ames test 
This work was done by Sequani Limited, UK. 
 
The mutagenic potential of eCF506 was assessed in four 4 Salmonella typhimurium 
strains (TA1535, TA1537, TA98, TA100) and 1 Escherichia coli strain (WP2 uvrA), in 
the presence and absence of a metabolic activation system (S-9 mix). A range of six 
concentrations of eCF506 up to 5,000 µg / plate were tested in triplicate alongside 
negative and positive controls (see Table 2.8). 
The following components were mixed in an Eppendorf tube: 
- 2 mL of L-histidine: D-biotin solution (Salmonella) or tryptophan (Escherichia) 
supplemented top agar 
- 0.1 mL bacterial culture 
- 0.5 mL of S-9 mix or 0.2 M phosphate buffer 
- 0.1 mL solvent (negative control) or eCF506 dilution or positive control 
The mixtures were added to a Petri dish containing minimal agar, which were inverted 
when set and incubated at 37±3°C. The integrity of the background lawns was 
assessed and revertant colonies were scored after approx. 66±1 hours using an 
image analyser. Statistical analysis was carried out using Dunnett’s t-test.  
 
Table 2.8. Ames test positive controls. 
Strain Without S-9 mix With S-9 mix 
Salmonella typhimurium 
TA1535 Sodium azide (1 µg / plate) 2-aminoanthracene (2 µg / plate) 
TA1537 9-aminoacridine (50 µg / plate) 2-aminoanthracene (4 µg / plate) 
TA98 2-nitrofluorence (1 µg / plate) 2-aminoanthracene (2 µg / plate) 
TA100 Sodium azide (1 µg / plate) 2-aminoanthracene (4 µg / plate) 
Escherichia coli 






2.5.5. Ex vivo murine choroidal angiogenesis model 
This work was done by Oxurion (formerly Thrombogenics), Belgium. 
 
This method was adapted from Shao et al. 305. Briefly, the choroid attached to the 
sclera is dissected from mice and embedded in MatrigelTM. Compounds were added 
to the explant culture media and explants treated for 4 days. Explants were imaged, 
the vessel outgrowth area annotated and calculated and treated samples normalised 
to vehicle treated control.  
 
 
2.5.6. Human retinal microvascular endothelial cell cytotoxicity assay 
This work was done by Oxurion (formerly Thrombogenics), Belgium. 
 
Primary human retinal microvascular endothelial cells (hRMVEC) were seeded in 96-
well plates and left to attach. Compounds were added at different concentrations and 
cells treated for 24 hours. Cytotoxicity was determined using CellToxTM Green 
Cytotoxicity assay (Promega) according to the manufacturer’s instructions, with 
higher fluorescence indicating the presence of nonviable cells with permeable cell 
membranes. Background fluorescence was measured in cell-free wells and 
subtracted from the final results. Hydrogen peroxide was used as a positive control. 











2.6. Animal models 
 
2.6.1. Efficacy models 
Experiments involving animals were carried out in accordance with the UK 
Coordinating Committee on Cancer Research guidelines by approved protocol. 
Animal models assessing the efficacy of eCF506 were done at the Institute of 
Genetics and Molecular Medicine by Morwenna Muir and Dr John Dawson (MDA-MB-
231 xenograft, MetBo2 mammary fat pad) or at the Queen’s Medical Research 
Institute by Dr Xue-Feng Li (MetBo2 bone metastasis), both of which are part of the 
University of Edinburgh, UK.  
 
2.6.1.1. MDA-MB-231 xenograft model  
This work was done by Dr John Dawson and Morwenna Muir of the groups of Prof 
Valerie Brunton and Prof Margaret Frame at the University of Edinburgh, UK. 
 
MDA-MB-231 tumour fragments were created by injecting MDA-MB-231 cells into 
each flank of CD1 nude mice (50 million cells / flank). Tumours were allowed to 
develop up to 8 mm in diameter and were collected before ulceration or necrosis had 
occurred. Tumours were dissected into 1 mm3 pieces for transplantation into recipient 
mice.  
Fifteen CD1 nude mice were implanted subcutaneously with MDA-MB-231 fragments 
bilaterally on both flanks using a 12G trochar with local anaesthesia (ethyl chloride). 
Tumour growth was monitored by calliper measurements and treatment started after 
24 days when average tumour volume reached 20 mm3. Mice were randomised into 
three groups and received daily treatment by oral gavage (100 µL per 10 g mouse 
weight) with vehicle (saline), eCF506 (25 mg/kg) or dasatinib (25 mg/kg). Mice were 
weighed and tumours measured twice a week for 25 days. Mice were dosed 2 hours 
prior to culling by cervical dislocation after which tumours were removed and fixed in 





2.6.1.2. MetBo2 bone metastasis model  
This work was done by Dr Xue-Feng Li in the group of Dr Bin-Zhi Qian at the University 
of Edinburgh, UK. 
 
FVB mice were anesthetised by isoflurane and injected with 100,000 MetBo2 cells 
into the left ventricle. Tumour growth was monitored by bioluminescence imaging on 
the Optima imager (Biospace). Bone metastasis tumours were allowed to grow for 7 
days until the signals of bone metastasis were clearly detected by Optima imager. 11 
mice that developed tumours in the hind legs or jaw were included in the study. Mice 
were randomized and put into control (5 mice) or treatment (6 mice) groups. Treated 
mice received daily eCF506 by oral gavage (40 mg/kg in ultrapure water, dissolved at 
8 mg/mL) and control group mice received vehicle only. Mice were imaged twice a 
week and the bioluminescence intensity of tumours in the hind legs or jaw was 
quantified by M3 software. Mice were culled when the tumour burden became too 
great.  
 
2.6.1.3. MetBo2 mammary fat pad model 
This work was done by Dr John Dawson and Morwenna Muir of the groups of Prof 
Valerie Brunton and Prof Margaret Frame at the University of Edinburgh, UK. 
 
Eleven FVB mice and twelve CD1 nude mice were anesthetised by isoflurane and 
implanted in the left 4th mammary fat pad with one million MetBo2 cells. Tumours were 
allowed to grow until they reached around 50 mm3 (FVB) or 40 mm3 (CD1) in size 
after which mice were randomly allocated into two groups. Mice were treated with 
vehicle (3 mM sodium citrate buffer pH 3.0) or eCF506 (40 mg/kg, dissolved at 4 
mg/mL in vehicle) once daily by oral gavage (100 µL per 10 g mouse weight) for 28 
days. Tumour size was measured by calliper and mice weighed twice a week. Mice 
were culled by cervical dislocation once tumour size reached 15 mm in diameter. After 
the initial treatment phase, surviving mice were monitored until tumours relapsed and 
treatment restarted once average tumour size reached 280 mm3 (FVB) or 250 mm3 
(CD1), except for one mouse that showed no tumour regrowth. Mice were dosed 2 
hours prior to culling by cervical dislocation after which tumours were removed and 






Formalin-fixed tissues were embedded in paraffin wax blocks from which sections 
were cut for haemotoxylin and eosin (H&E) staining and immunohistochemical 
analysis. H&E staining was performed according to standard procedures by the 
Pathology Technical Services team at the Institute of Genetics and Molecular 
Medicine, University of Edinburgh, UK. Immunohistochemistry was performed by me 
as described in the following. 
Paraffin embedded tumours were cut into 5 µm thick sections using a microtome, 
placed on SuperFrost PlusTM (Thermo Scientific) slides and dried at 40°C for 24 hours. 
Paraffin was removed by immersion of slides in xylene for 5 minutes, followed by 
rehydration in decreasing ethanol baths (100%, 100%, 80%, 50%) for 3 minutes each 
and rinsing in water. Antigens were retrieved by boiling in citrate buffer pH 6.0 in a 
pressure cooker (121°C) for 8 minutes. Slides were left to cool and endogenous 
peroxidases were blocked using Dako REAL Peroxidase-Blocking solution (Agilent, 
S2023) for 5 minutes. After washing in water, slides were incubated with Dako Serum-
free Protein Block (Agilent, X0909) for 30 minutes before primary antibodies diluted 
in Dako Background Reducing Antibody Diluent (Agilent, S3022) were added and 
slides incubated in a humid chamber at 4°C overnight. Following two washes in TBST 
(0.025%) for 5 minutes, slides were incubated with Dako Goat Anti-Rabbit HRP-linked 
secondary antibody (Agilent, K4003) for 1 hour at room temperature. Slides were 
washed twice in TBST (0.025%) for 5 minutes followed by staining with Dako Envision 
DAB+ kit (Agilent, K3468) for 5 minutes, rinsing in water for 2 minutes and immersion 
in haematoxylin for 100 seconds. Slides were rinsed in water and immersed in Scott’s 
tap water for 4-8 minutes until tissue appeared blue, before being dehydrated in 
increasing ethanol baths (50%, 80%, 100%, 100%) and xylene for 2 minutes each. 
Dry slides were mounted onto coverslips using DPX, left to dry for 36 hours and 
imaged using the Nanozoomer (Hamamatsu).  
Images were analysed using the free QuPath software tool by automatically counting 





2.6.2. Acute toxicity model 
This work was done by Evotec, France.  
 
The aim of this study was to determine the maximum tolerated dose (MTD) of eCF506 
following a single oral administration by gavage to male and female Sprague-Dawley 
rats.  
6 to 8 week-old Sprague-Dawley rats were obtained from Janvier Labs, France. After 
an acclimatisation period of at least 5 days, the 9 male and 9 female rats were split 
randomly into five groups depending on their weight (Table 2.9). eCF506 was 
formulated in citrate buffer as shown in Table 2.9 and administered once by oral 
gavage, with the quantity being adjusted for the respective weight of the rat and 
received dose being within ±10% of the theoretical dose.  
The doses of groups 3 and 4 were chosen based on results from groups 2 and 3, 
respectively. The dose volume of group 3 was changed to maintain the same 
formulation as group 2, and the formulation of group 4 was changed to maintain the 
same pH and solubility as groups 2 and 3. The changed dose volume and formulation 
of the vehicle was tested on rats in group 5.  
 
Table 2.9. Treatment groups of acute toxicity study. 
Group No. of rats / 






1 2 - 10 50 mM citrate buffer pH 3.0 
2 2 200 10 50 mM citrate buffer pH 3.0 
3 2 400 20 50 mM citrate buffer pH 3.0 
4 2 700 20 100 mM citrate buffer pH 3.0 
5 1 - 20 100 mM citrate buffer pH 3.0 
 
Animal observations for adverse clinical signs or premature death were recorded pre-
dosing and 1, 2, 4, 6, 8 and 24 hours post-dosing and scored as described in Table 
2.10. Body temperatures were measured pre-dosing and 4, 8 and 24 hours post-
dosing and body weights were measured pre- and post-dosing. Blood samples were 
collected 24 hours after dosing from the vena cava and analysed on a VetScan HM5 
haematology analyser (Abaxis) for white blood cell count (109/L), lymphocyte count 
(109/L), monocyte count (109/L), neutrophil count (109/L), red blood cell count (1012/L), 




platelets (109/L). Post-mortem examinations were performed 24 hours after dosing. 
Rats were anaesthetised by isoflurane inhalation and exsanguinated prior to cervical 
dislocation. Necropsy was performed with animals being examined visually for 
external abnormalities and palpable masses; abnormalities in the abdominal, thoracic 
and cranial cavities and contents; and gross abnormalities on organs after their 
removal. No statistical analysis was performed due to the low number of animals per 
groups (n = 1 or 2).  
 
Table 2.10. Clinical scores. HEP = humane end point; - = no criteria defined. Total scoring 
































































































































































































2.6.3. Pharmacokinetic models 
2.6.3.1. Bioavailability and pharmacokinetics parameters assessment in 
rats 
This work was done by Evotec, France.  
 
Pharmacokinetic parameters were tested in 7-week-old male Sprague-Dawley rats, 
with three rats per dose and per route, which were treated as follows: intravenous (IV) 
injection (1 mg/kg eCF506 in 50 mM acetate buffer saline, pH 4.6, given at 2 mL/kg), 
oral (PO) gavage (10 mg/kg or 200 mg/kg in 50 mM citrate buffer, pH 3.0, given at 5 
mL/kg). Blood was collected from a cannula previously implanted under isoflurane 
anaesthesia in the jugular vein; serial blood micro-sampling (200 µL) was performed 
at the following time points: 
- IV dosing: 2 min, 7 min, 15 min, 30 min, 1 hr, 2 hrs, 4 hrs, 6 hrs, 7 hrs, 24 hrs 
- PO dosing: pre-dose, 15 min, 30 min, 45min, 1 hr, 2 hrs, 4 hrs, 6 hrs, 7 hrs, 
24 hrs 
Blood was centrifuged (10,000 x g, 3-4 minutes, 4°C) and two aliquots of plasma (at 
least 50 µL) were collected per time point in 2 mL Safelock tubes and immediately 
snap frozen. Plasma samples were analysed by LC-MS/MS, with a lower limit of 





2.6.3.2. Blood-brain-barrier penetration in mice 
This work was done by Dr Alaide Morcavallo and Nikita Locket (group of Prof Louis 
Chesler) and Louise D Johnson and Ruth R Ruddle (group of Dr Florence I Raynaud) 
at the Institute of Cancer Research, London, UK.  
 
17 NSG mice (highly immunodeficient; lack T-cells, B-cells, natural killer cells, some 
cytokine signalling pathways) were randomised into two groups and received 
intraperitoneal injections of either vehicle (3 mice) or 40 mg/kg eCF506 (14 mice). 
Mice in the treatment group were culled after 0.5, 1, 2, 4 or 8 hours at which point 
plasma samples and brain tissue samples were taken and frozen.  
Calibration standards 
Calibration and quality control solutions were prepared in DMSO from 1 mM stocks 
for eCF560. Calibration standards used for spiking were prepared on the Hamilton 
robot over the dynamic range 50 nM to 100 µM in DMSO. Quality control standards 
were also prepared at 150, 4000, and 75000 nM on the Hamilton robot. A stock 
solution of Olomoucine internal standard was prepared in DMSO at a concentration 
of 1 mM. A working internal standard solution was prepared at a concentration of 250 
nM in methanol. 
Plasma and tissues sample preparation 
Plasma and tissue samples were thawed on ice. All tissues were homogenised in 3 
mL/g PBS and kept on ice. 100 µL aliquots of untreated mouse plasma or tissue 
homogenates were spiked with 10 µL of the appropriate calibration or quality control 
standard solutions. 100 µL aliquots of the unknown samples were spiked with 10 µL 
DMSO. Where appropriate, unknown plasma samples were diluted with untreated 
plasma. 
Protein precipitation 
Spiked calibration standards, quality control standards and unknown samples were 
protein precipitated with 300 µL methanol containing 250 nM internal standard. Blank 
samples were prepared by spiking 100 µL untreated plasma/tissue with 10 µL DMSO 
and protein precipitated with 300 µL methanol. All samples were centrifuged at 3700 
rpm for 20 minutes at 4°C. Supernatants were transferred into a new 96-well plate 





Extracted plasma and tissue samples were analysed by LC-MS/MS for the 
quantification of eCF560 and Olomoucine (Sigma) as internal standard using an 
Acquity H Class LC system coupled with a Waters TQS triple mass spectrometer 
(Waters). Compounds were separated on a Kinetex C18, 2.6 µ 50x2.1 mm analytical 
column (Phenomenex) with a 2 µL injection volume. The mobile phase consisted of 
methanol and 0.1% formic acid with a constant flow rate of 0.6 mL/min at 55°C. A 
linear gradient was initiated from the 5% methanol/95% formic acid starting conditions 
over 3 minutes before sustaining at 100% organic for 1 minute. The column was then 
re-equilibrated with the original mobile phase for a further 1 minutes.  
Analytes were ionised by electrospray interface in positive mode and detected by 
multiple reaction monitoring. The characteristic ion transitions monitored were m/z 
511.25-410.17 for eCF560, and 299.1-176.2 for Olomoucine. Ionisation was 
optimised with a desolvation gas temperature of 600°C and flow rate of 1000 L/hr. 
The nebulizer gas flow was set to 7 bar with the capillary charge at 3 kV. 
Fragmentation in the presence of argon was achieved using a collision energy of 32 
V for eCF560 and 26 V for Olomoucine. Data acquisition was performed using 
Targetlynx V4.1 SCN876. The assay was linear over the range 5-1000 nM in plasma 
and 5-5000 nM in brain homogenate. 
 
2.6.3.3. Retinal phospho-SRC inhibition in mice 
This work was done by Oxurion (formerly Thrombogenics), Belgium. 
 
8-10-week-old male C57BL/6J mice received intraperitoneal injections of vehicle 
(PBS) or eCF506 (10 mg/kg). One hour later, mice received intravitreal injections of 
VEGF. After 30 minutes, mice were euthanized by an overdose of Nembutal and 
retinas were isolated after enucleation, stored at -80°C and analysed by Western blot 
for phospho-SRC and total SRC.  
 
 
2.7. Data analysis 
Graphs were plotted and statistical analysis was performed using GraphPad Prism 
7.0 software, unless stated otherwise. Details of statistical tests performed are 























Fraser et al. developed eCF506 as an inhibitor with high potency in breast cancer 
cells by using a ligand-based design approach coupled with phenotypic screening 1. 
In reiterative steps of design, synthesis and screening, they developed several new 
compounds that improved on the scaffold PP1’s anti-proliferative activity against two 
breast cancer cell lines (MCF-7, MDA-MB-231). This led to the discovery of the 
selective SRC/non-ABL inhibitor eCF506 with similar potency in cell viability and 
migration assays as the dual SRC/ABL inhibitor dasatinib.  
 
This chapter continues from these findings by screening eCF506 across many 
different cell lines to determine its potential use across various types and subtypes of 
cancer. Some of these cell lines were re-tested in a spheroid assay to determine the 
consistency between 2D and 3D models. In vitro models of angiogenesis were also 
assessed due to the established role of SRC in this hallmark of cancer. Furthermore, 
eCF506’s cytostatic properties were confirmed in a cell cycle assay and stratification 
of cell line response based on phospho-SRC levels was attempted.  
 
In vitro testing of eCF506 was done in comparison to dasatinib and other SRC and/or 
ABL inhibitors to identify the best-in-class inhibitor and establish eCF506’s relative 
potency. The outstanding selectivity of eCF506 in comparison to these clinically 
approved inhibitors is highlighted in a side-by-side comparison of their full kinome 
screening data. Further experiments were performed to confirm the unique selectivity 
for SRC over ABL in cellular models.  
 
This chapter explores the following aims:  
 
• Assessment of eCF506’s anti-proliferative properties in different cancers and 
comparison to other dual SRC/ABL inhibitors. 
 
• Comparison of eCF506’s anti-proliferative effects in a 3D spheroid model. 
 
• Validation of eCF506’s cytostatic effect in a cell cycle assay. 
 
• Exploration of the anti-angiogenic properties of eCF506. 
 




3.1. eCF506 has anti-proliferative and anti-angiogenic 
properties in vitro 
 
3.1.1. eCF506 is as potent as dasatinib at inhibiting proliferation in 2D 
cell viability assays 
In order to get an overview of which cancers show sensitivity to eCF506 treatment, it 
was screened against a genetically-characterised panel of hundreds of cell lines 
representing many different cancers at the Wellcome Sanger Institute, UK (see 
chapter 3.1.1.1). Based on these results, as well as the previous focus on breast 
cancer, eCF506 was then tested in more detail in 29 breast and ovarian cancer cell 
lines that were available in-house. The aim of this second screen was to establish the 
potency of eCF506 in comparison to four other SRC and/or ABL kinase inhibitors 
(dasatinib, bosutinib, saracatinib, imatinib) that are already used in the clinic or are in 
late stage development (see chapter 3.1.1.2). Last, eCF506 was included in a high-
throughput screen of oesophageal cancer cell lines that was performed by the Drug 
Discovery group of Prof Neil Carragher at the University of Edinburgh, in which 
dasatinib had previously been identified as a hit (see chapter 3.1.1.3).  
 
The testing of eCF506 in these three different screens and the comparison to other 
inhibitors with a similar target profile gives a better understanding of eCF506’s 
potential in different types of cancer. 
 
 
3.1.1.1. Genomics of Drug Sensitivity in Cancer (GDSC) cell line panel 
This work was done by the group of Dr Mathew Garnett at the Wellcome Sanger 
Institute, UK. 
 
eCF506 was screened against 750 cell lines across a variety of cancers from the 
Genomics of Drug Sensitivity in Cancer (GDSC) cell line collection at the Sanger 
Institute, UK. Cells were treated for 72 hours and cell viability determined using Cell 
Titer Glo 2.0® (Promega). Dose-response curves were fitted automatically to 
determine the IC50 values. After excluding cell lines that did not match quality control 





40 of 739 cell lines were classified as being sensitive to eCF506 by having an IC50 
value below 1 µM (Table 3.1); in comparison, dasatinib, which was previously 
screened by the Sanger Institute, inhibits 188 of 761 cell lines at the same cut-off 307. 
Only one breast cancer cell line (HDQ-P1) of the 43 tested was sensitive to eCF506; 
this set included MDA-MB-231 and MCF-7, which had IC50 values of 13.1 µM and 
81.9 µM, respectively. These concentrations were around one thousand-fold higher 
than those previously reported by Fraser et al. in the same cell lines (authenticated 
by STR analysis) 1. The lack of sensitivity is surprising and the previous screening of 
dasatinib also showed much higher IC50 values of 1.33 µM (MDA-MB-231) and 273 
µM (MCF-7). However, another study found dasatinib had similar potency in both cell 
lines as reported by Fraser et al. and thus supports the values reported in the paper 
308. A possible reason for the discrepancy could be the different screening set up used 
in the GDSC screen (1536-well plates, 3-day treatment, Cell Titer Glo® readout) 
compared to the previous experiments in the group (96-well plates, 5-day treatment, 
PrestoBlueTM readout), with the GDSC set up likely to favour the discovery of cytotoxic 
rather than cytostatic drug effects. Nevertheless, the third study showed similar 
results with dasatinib to Fraser et al. after only 48 hours of treatment (96-well plates, 
MTT assay readout). This unexplained loss of activity in the GDSC screen cautions 
against overinterpreting the results from this high-throughput screening. 
 
Seven of the 40 cell lines sensitive to eCF506 are classified as chronic myeloid 
leukaemia (CML), which is mostly caused by a mutant form of ABL kinase (see Table 
3.1). As only ten CML cell lines were tested in total, this suggests that eCF506 is still 
a potent inhibitor of ABL signalling with potential applications in CML, despite its 
superior selectivity for SRC kinase.  
A promising new finding was the apparent sensitivity of ovarian cancer; six of 24 
ovarian cancer cell lines responded at nanomolar levels to eCF506, three of which 
were among the top five results from the screen. The role of SRC in ovarian cancer 
has been studied by multiple groups who identified SRC as a potential target for 
ovarian cancer growth and stem cell survival; SRC inhibitors are also being tested in 
clinical trials of ovarian cancer 153,309–311.  
Several cancer subtypes appear to be mainly resistant to eCF506. While one acute 
myeloid leukaemia cell line was very sensitive, all other 17 cell lines had IC50 values 




nine had values below 100 µM. Unexpectedly, all 43 colorectal cancer cell lines had 
IC50 values of 3.5 µM or higher, even though this cancer type has repeatedly been 
associated with SRC hyperactivation 312. It is likely that the observed discrepancy 
between IC50 values from the GDSC screen and independent studies means that 
some of these cell lines could be found more sensitive in other assays. 
 
Analysis of the dataset by the Sanger Institute showed a correlation between 
sensitivity to eCF506 and the BCR-ABL fusion protein as well as mutations in BRAF, 
NRAS or KRAS. While the link to BCR-ABL is likely due to eCF506’s ability to inhibit 
ABL signalling, other studies have shown that SRC inhibition is indeed able to 
overcome acquired BRAF and NRAF mutations in vitro and can be useful in KRAS 
mutant pancreatic cancer 238,313–315. However, due to the discrepancy between 
sensitivity seen in the GDSC screen and in cell viability assays in our group, care 
should be taken not to overinterpret these results. Nevertheless, they served as a 
good starting point to investigate eCF506 in other cancers, such as ovarian cancer, 
and further investigation into the particular sensitivity of ovarian cancer cell lines will 






Table 3.1. List of cell lines from GDSC screen of eCF506 with IC50 values <1 µM.  
Cell line Cancer IC50 (µM) 
SU-DHL-6 lymphoid neoplasm diffuse large B-cell lymphoma 0.04838 
CTV-1 acute myeloid leukemia 0.07673 
OVMIU ovarian serous cystadenocarcinoma 0.10090 
IGROV-1 ovarian serous cystadenocarcinoma 0.10237 
DOV13 ovarian serous cystadenocarcinoma 0.13629 
NCI-H322M lung adenocarcinoma 0.17467 
JURL-MK1 chronic myelogenous leukemia 0.26472 
SW982 unclassified (Soft tissue) 0.33618 
NB69 brain neuroblastoma 0.35232 
HDQ-P1 breast invasive carcinoma 0.38067 
CAL-39 cervical squamous cell carcinoma and endocervical 
adenocarcinoma 
0.38743 
ALL-SIL acute lymphoblastic leukaemia 0.39530 
KU812 chronic myelogenous leukemia 0.40916 
NCI-H1755 lung adenocarcinoma 0.42715 
CAL-54 kidney renal clear cell carcinoma 0.44364 
NCI-H2795 mesothelioma 0.44421 
SU-DHL-5 lymphoid neoplasm diffuse large B-cell lymphoma 0.45453 
PA-1 unclassified (Ovary) 0.46028 
BPH-1 unclassified (Prostate) 0.50062 
LAMA-84 chronic myelogenous leukemia 0.51507 
FLO-1 oesophageal carcinoma 0.61079 
HCC1806 Unclassified (Breast) 0.61954 
LOXIMVI skin cutaneous melanoma 0.63853 
A704 kidney renal clear cell carcinoma 0.67268 
OVTOKO ovarian serous cystadenocarcinoma 0.69597 
BV-173 chronic myelogenous leukemia 0.71934 
CML-T1 chronic myelogenous leukemia 0.72407 
TOV-21G ovarian serous cystadenocarcinoma 0.73398 
CHP-212 brain neuroblastoma 0.73961 
PSN1 pancreatic adenocarcinoma 0.75017 
KARPAS-1106P lymphoid neoplasm diffuse large B-cell lymphoma 0.75290 
SW1710 bladder urothelial carcinoma 0.79980 
TE-8 oesophageal carcinoma 0.81202 
SAT head and neck squamous cell carcinoma 0.87338 
EM-2 chronic myelogenous leukemia 0.88603 
CAPAN-2 pancreatic adenocarcinom 0.89426 
OC-314 ovarian serous cystadenocarcinoma 0.90952 
MOG-G-CCM brain lower grade glioma 0.91521 
LXF-289 lung adenocarcinoma 0.94356 





3.1.1.2. Breast and Ovarian cancer cell line panel 
Part of the work with ovarian cancer cells was done by Anna Wijngaard as part of her 
honours project under my supervision.  
 
The anti-proliferative properties of eCF506 were tested alongside a panel of three 
approved or late stage dual SRC/ABL kinase inhibitors (dasatinib, bosutinib, 
saracatinib) and one ABL kinase inhibitor (imatinib) in 16 breast cancer and 13 ovarian 
cancer cell lines. Cells were seeded in 96-well plates with compounds being added 
two days later and plates were treated for a total of five days. Cell viability was 
assessed before and after treatment using the resazurin-based PrestoBlueTM 
(Invitrogen) reagent that measures metabolic activity. By taking into account the cell 
viability before treatment it is possible to distinguish between cytotoxic and cytostatic 
effects, which allows the calculation of the concentration needed to inhibit cell 
proliferation by 50% (growth inhibition 50%, GI50) or 100% (total growth inhibition, 
TGI). The GI50 and TGI values were determined for all 29 cells lines from three 
biological repeats, ranked by sensitivity to eCF506 and plotted in Figure 3.1; exact 
values are shown in Table 3.2. The data shows that the five tested SRC and ABL 
kinase inhibitors have mainly anti-proliferative but not cytotoxic effects in breast and 
ovarian cancer cell lines at sub-micromolar concentrations. While cytotoxic effects 
can be observed in the micromolar range (see Appendix A.1), those are likely due to 
off-target effects that commonly occur at high concentrations with kinase inhibitors 
that target the ATP-binding pocket 12. 
 
eCF506 and dasatinib exhibited the lowest GI50 values of all five inhibitors. Values 
were often similar for both compounds in the same cell line, with larger differences 
(e.g. MCF-7, ZR-75.1) often due to smaller shifts in the biphasic dose-response 
curves (see Appendix A.1). However, GI50 values for eCF506 and dasatinib also 
showed the greatest variability between the cell lines tested; while 50% growth 
inhibition was observed in some at low double-digit nanomolar concentrations, other 
cell lines required concentrations up to one thousand-fold higher. Bosutinib and 
saracatinib generally had less variability in their GI50 values between cell lines, as they 
were overall less potent, while imatinib consistently showed low potency with 
concentrations of at least 4 µM and in some cases more than 100 µM required to 
halve cell proliferation. In the subset of cell lines that can be classified as sensitive to 




worse in comparison and their GI50 values do not appear to correlate with sensitivity 
to eCF506 or dasatinib.  
 
Total growth inhibition is generally only observed at micromolar concentrations in 
most cell lines, with bosutinib often being more potent than the other inhibitors. One 
reason for this is that cell lines often exhibit a biphasic dose-response curve when 
treated with eCF506 and dasatinib, while bosutinib usually exhibits a normal nonlinear 
curve with a steep slope, albeit at higher concentrations (see Appendix A.1). 
Consequently, eCF506 and dasatinib are more potent at partially inhibiting cell 
proliferation but require much higher concentrations to stop cell growth completely. A 
possible explanation for this is that eCF506 and dasatinib are more potent SRC kinase 
inhibitors, as suggested by their IC50 values obtained in isolated kinase screens, while 
bosutinib is less potent but inhibits several targets at once, eliciting a stronger cellular 
effect at higher concentrations (see Table 1.3 in chapter 1.3.1). 
 
Seven of the 16 breast cancer cell lines tested are sensitive to eCF506 (GI50 <500 
nM) (see Figure 3.1). All of them are classified as either triple negative or oestrogen 
receptor positive breast cancer, with the exception of JIMT-1, which was derived from 
a HER2-positive patient with trastuzumab resistance. Source and type of the breast 
cancer cell lines does not appear to correlate with sensitivity (see Table 3.2).  
Of the 13 ovarian cancer cell lines tested, 8 were sensitive to eCF506 and half of 
these have been classified as clear cell carcinoma (see Figure 3.1 and Table 3.2). 
The PEO cell lines tested were taken from two high-grade serous ovarian cancer 
patients before and after diagnosis of clinical cisplatin resistance. While these cells 
often gave variable results, dasatinib was generally more potent than eCF506 in all 
five cell lines. Opposite trends were observed in the matched sets, with cisplatin-
resistant cells being less sensitive to kinase inhibitors in one set but showing higher 























Figure 3.1. Anti-proliferative effects of SRC/ABL kinase inhibitors in breast and ovarian 
cancer cell lines. (a) Panel of 16 human breast cancer cell lines tested and ranked by 
sensitivity to eCF506. (b) Panel of 13 human ovarian cancer cell lines tested and ranked by 
sensitivity to eCF506; PEO cell lines represent two patients before and after clinical cisplatin 
resistance. Effects on cell proliferation were measured after 5 days of treatment using 
PrestoBlueTM reagent and curves were fitted using GraphPad Prism 7. GI50 and TGI values 





Table 3.2. GI50 and TGI values. (a) Ovarian cancer cell lines. (b) Breast cancer cell lines. GI50 
(white) and TGI values (grey) values represent the average of three biological replicates 
rounded to three significant figures with standard deviation shown in brackets (in µM). Ovarian 
cancer subtypes: HGSOC = high-grade serous ovarian cancer, CCC = clear cell carcinoma, 
EC = endometrioid adenocarcinoma. Breast cancer sources: PBr = primary breast, PE = 
pleural effusion, A = ascites. Breast cancer type: AC = adenocarcinoma, DC = ductal 
carcinoma, MC = metaplastic carcinoma, M = medullary carcinoma, LC = lobular carcinoma. 
Breast cancer subtypes: HER2+ = HER2 amplified, ER+ = oestrogen receptor expressing, 
TNBC = triple negative breast cancer lacking ER, PrR and HER2. Breast cancer subgroups: 
Luminal A (ER+, PR±, HER2-, Ki67 low), Luminal B (ER+, PR±, HER2+, Ki67 high), Basal A 
(luminal-like), Basal B (basal-like, claudin-low), HER2 (ER-, PR-, HER2 amplified). 
 
(a) Ovarian cancer 
 Subtype eCF506 Dasatinib Bosutinib 
Ovarian 
ES-2 CCC / HGSOC 
4.80 (1.61) 2.12 (1.03) 0.856 (0.375) 
19.2 (5.47) 11.7 (1.92) 2.68 (1.24) 
IGROV-1 EC / CCC 
0.0130 (0.00128) 0.0173 (0.00267) 0.298 (0.0861) 
0.157 (0.158) 0.294 (0.0962) 3.64 (3.05) 
OVCAR-3 HGSOC 
0.285 (0.0606) 0.168 (0.0791) 9.74 (0.914) 
45.5 (12.4) 22.7 (11.3) 13.8 (2.32) 
OVMANA CCC 
0.113 (0.0337) 0.0485 (0.0190) 0.682 (0.181) 
5.58 (4.75) 0.239 (0.152) 1.32 (0.565) 
OVTOKO CCC 
0.0177 (0.00451) 0.0258 (0.0125) 0.486 (0.0234) 










































0.0744 (0.0964) 0.0111 (0.0142) 0.268 (0.133) 




0.950 (1.56) 0.0735 (0.0430) 3.95 (1.64) 
18.8 (4.79) 9.35 (3.92) 7.54 (6.49) 
PEO6 Prior to death 
0.120 (0.0830) 0.0291 (0.00815) 9.14 (0.704) 
































0.621 (0.575) 0.229 (0.371) 1.88 (0.985) 
5.41 (1.12) 4.95 (3.72) 6.07 (3.52) 
PEO23 Relapse 
0.0123 (0.00731) 0.00353 (0.000673) 0.228 (0.0757) 
0.0789 (0.0746) 0.0442 (0.0195) 7.06 (5.81) 
SK-OV-3 Unclassified 
2.80 (2.10) 0.474 (0.195) 0.864 (0.449) 
16.6 (2.49) 7.18 (3.72) 3.73 (0.898) 
TOV-112D EC 
15.0 (3.12) 7.75 (0.660) 2.58 (0.994) 
30.1 (3.74) 28.1 (17.9) 11.2 (3.42) 
TOV-21G CCC 
0.120 (0.0740) 0.0998 (0.0193) 0.515 (0.0785) 
25.1 (6.62) 7.98 (1.56) 4.11 (0.949) 
 
 




Table continued from previous page 
(b) Breast cancer 
  Source Type 
Subtype 
(Subgroup) 
eCF506 Dasatinib Bosutinib Saracatinib Imatinib 
Breast Cancer 





















































































































































































































































































































































































3.1.1.3. Oesophageal cancer cell line panel 
Work done by Dr Richard Elliott and Becka Hughes in the Drug Discovery group of 
Prof Neil Carragher at the University of Edinburgh, UK.  
 
From the GDSC screen at the Sanger Institute, only two of 31 oesophageal cancer 
cell lines in the GDSC screen were found to be sensitive to eCF506 (FLO-1, TE-8) 
(see Table 3.1). However, dasatinib was identified as a hit in an in-house high-
throughput screen of several thousand compounds against a panel of oesophageal 
cancer cell lines performed by Prof Carragher’s lab (unpublished data). Therefore, 
eCF506 was included in this screen and compared against dasatinib and imatinib to 
determine whether dasatinib’s efficacy was due to its SRC or ABL inhibition.  
 
Cells were treated 24 hours after seeding for a total of 2 days, after which they were 
fixed, stained with DAPI and the total number of cell nuclei counted automatically 
using the ImageXpress MicroXl platform. Of the eight cell lines used, six represent 
oesophageal cancer (FLO-1, OE33, MFD1, SKGT4, OAC-P4C, JHesoAD1) and two 
were included as non-malignant controls (normal oesophageal epithelial cell line, 
EPC2; Barrett’s cell line with non-dysplastic metaplasia, CP-A ).  
 
eCF506 was found to be superior to dasatinib and imatinib at inhibiting oesophageal 
cancer cell viability (see Table 3.3 and Appendix A.2). It showed good potency in three 
of the six cancer cell lines and selectivity for cancer over untransformed oesophageal 
cells. These results suggest that dasatinib’s potency in the oesophageal screen was 
not due to its ABL inhibition and that the selective SRC inhibitor eCF506 could have 
potential applications in a subset of oesophageal cancers.  
 
 
Table 3.3. Absolute EC50 values of eCF506, dasatinib and imatinib in oesophageal 
cancer screen. Absolute EC50 is the concentration at which 50% nuclei remained compared 
to DMSO control (in µM) and was calculated using GraphPad Prism 7 (blue = low EC50, red = 
high EC50). Data represent average of three technical repeats. 
  Cancer Non-cancer 
  FLO-1 OE33 MFD1 SKGT4 OAC-P4C JHesoAD1 EPC2 CP-A 
eCF506 0.02 0.28 0.6 1.05 10 10 10 10 
Dasatinib 0.99 0.79 1.02 0.96 10 10 10 1.98 





3.1.2. eCF506 induces cell cycle arrest in the G1 phase 
Previous studies have shown that SRC inhibition can induce cell cycle arrest in the 
G1 phase due to stabilisation of the CDK inhibitor p27, which inhibits progression into 
S phase (see chapter 1.2.3.2) 52,71. In agreement with this, the 2D cell viability 
experiments in this thesis found that the tested SRC kinase inhibitors generally have 
cytostatic rather than cytotoxic effects (see chapter 3.1.1.2). To confirm that the 
observed reduction in cell viability is due to changes in cell cycle progression rather 
than metabolic changes affecting PrestoBlueTM readout, eCF506 and dasatinib were 
tested in a cell cycle assay. Cells were treated at two different concentrations for 48 
hours, fixed and treated with pepsin to extract the cell nuclei. These were stained with 
DAPI and the DNA content was analysed by flow cytometry. 
 
The data shows that both eCF506 and dasatinib induce arrest in the G1 phase of the 
cell cycle (see Figure 3.2). In MDA-MB-231 cells, dasatinib was more potent at 
increasing the percentage of cells in the G1 phase (from 64% in untreated cells to 
90% and 91% at 100 nM and 1 µM, respectively), while eCF506 was less potent at 
both concentrations (82% and 84%, respectively). This agrees with data from 
previous cell viability assays, where dasatinib also had stronger anti-proliferative 
effects than eCF506 at both concentrations in this cell line (see Figure 3.2c). 
 
In MCF-7 cells, eCF506 is superior to dasatinib at inducing cell cycle arrest, as the 
latter only increased the G1 population by 3% at 100 nM but had no effect at 1 µM. 
While eCF506 does reduce cell viability considerably more than dasatinib in this cell 
line, it is interesting that no effect was observed for dasatinib at 1 µM in the cell cycle 
assay, as cell viability is reduced to 39% at this concentration. One possibility is that 
the different treatment times between the cell cycle assay and cell viability assay (48 
hours vs. 5 days, respectively) are responsible for this discrepancy. A longer 
treatment time of 5 days should be tested in the cell cycle assay to assess whether 
this leads to different results. The high heterogeneity of the MCF-7 cell line and 
changes over time in culture are likely also contributing factors, as these assays were 
performed at different time points. Nonetheless, another study reported the same 
results for dasatinib after 48 hours treatment: a dose-dependent increase in G1 arrest 
in MDA-MB-231 cells but only a slight increase in MCF-7 at 100 nM and none at 1 µM 
172. Therefore, it is a possibility that dasatinib’s antiproliferative mode of action in this 










 48 hours 5 days 
 G1 M G2 Viability 
MDA-MB-231 
DMSO 63.5 19.6 16.9 100.0 
eCF506 (0.1 µM) 82.2 9.4 8.3 20.3 
eCF506 (1 µM) 84.4 8.8 6.7 7.6 
Dasatinib (0.1 µM) 89.9 4.7 5.4 5.0 
Dasatinib (1 µM) 90.6 4.9 4.5 0.7 
MCF-7 
DMSO 64.6 21.4 13.9 100.0 
eCF506 (0.1 µM) 74.4 14.2 11.4 26.9 
eCF506 (1 µM) 76.1 13.7 10.2 19.1 
Dasatinib (0.1 µM) 67.4 19.5 13.1 70.1 
Dasatinib (1 µM) 64.5 20.4 15.0 38.7 
  
Figure 3.2. eCF506 and dasatinib induce G1 cell cycle arrest and reduce proliferation. 
Cell cycle assay of (a) MDA-MB-231 and (b) MCF-7 cells treated with eCF506 or dasatinib for 
48 hours and analysed by flow cytometry. Changes in G1 phase were compared to DMSO 
treated control samples using one-way ANOVA with Dunnett correction for multiple 
comparison; p>0.05 (ns), p<0.05 (*), p<0.0001 (****). Data represents three biological 








3.1.3. Phospho-SRC (Y416) is not a reliable biomarker to predict cell 
line sensitivity to eCF506 
Elevated SRC activity has been found in many solid tumours and drug resistance 
mechanisms but the challenge remains to find reliable biomarkers that can predict 
(patient) response to SRC inhibition (see chapter 1.2.4). A thorough screening for and 
testing of several candidates in different in vitro, in vivo and patient-derived models 
would be necessary to identify reliable and novel biomarkers, which was beyond the 
scope of this PhD project. However, in order to check whether the anti-proliferative 
effects of eCF506 observed in chapter 3.1.1.2 can be linked to quantity or activity of 
the target, the amount of total and phosphorylated SRC kinase was quantified in all 
cell lines by Western blotting. The protein amounts relative to a reference cell line 
(MDA-MB-231) were plotted against the respective growth inhibition values (GI25, 
GI50, GI75, GI90, TGI) for eCF506 and analysed for correlation between the two. 
 
In general, using GI25 values, GI50 values or total SRC levels in the analysis did not 
give statistically significant results (see Figure 3.3a and Appendix A.3). When 
comparing phospho-SRC levels or the ratio of phospho-SRC to SRC (pSRC/SRC) 
with their respective GI75, GI90 or TGI values of the cell lines, all analyses showed 
statistically significant correlations (p<0.05). Phospho-SRC levels plotted against GI90 
values correlated the strongest (p=0.0045, r=-0.512; R2=0.262) (see Figure 3.3b). As 
cell lines with a biphasic dose-response curve are those for which GI25, GI50, GI90 and 
TGI values would differ the most, this suggests that the relative amount of phospho-
SRC only gives information on near total growth inhibition by eCF506 rather than 
partial response. However, when looking at the plotted data and the low coefficient of 
determination (R2), it becomes clear that even the strongest correlation found still has 
large variability between cell lines. While it is notable that those cell lines with relatively 
low amounts of phospho-SRC (<100% compared to MDA-MB-231) all have high GI90 
values, the large variability in eCF506 sensitivity between cell lines with higher 
amounts of phospho-SRC (e.g. HCC-1954 vs. IGROV-1) limits the use of this 
approach to predict cell line sensitivity with a good degree of certainty. It is possible 
that this analysis could be improved by including a second biomarker, yet the key 
question remains of how well these findings from 2D cell line assays can ever 




patient samples for testing the response to eCF506 and presence of biomarkers and 






Figure 3.3. Correlation between cell line sensitivity to eCF506 and (phospho)-SRC 
levels. SRC protein and phosphorylation levels were determined for all cell lines from Western 
blots and are plotted against eCF506 sensitivity from 2D cell viability assays (see Appendix 
A.3). Protein levels were determined from two biological replicates, normalised to MDA-MB-
231 and are shown with standard error. Correlation analysis of combined breast and ovarian 
data shows (a) no correlation for GI50 and pSRC (R2 = 0.0351, p>0.05) and some correlation 




3.1.4. eCF506 is less potent than dasatinib at inhibiting 3D spheroid 
growth 
2D assays, such as the cell viability assays performed in chapter 3.1.1, are commonly 
used in high-throughput screens to reduce labour, cost and variability in drug 
discovery. However, results from these assays do not always translate into 3D models 
or animal experiments. In order to determine whether eCF506’s potency in the tested 
cell lines is assay-dependent, a 3D spheroid assay was performed in three cell lines 
classified as being sensitive in chapter 3.1.1.2 (MDA-MB-231, MCF-7, T-47D). Cells 
were seeded in ultra-low adherent U-bottom plates, spun down and left for two to 
three days to form spheroids. Compounds were added to the wells and cells treated 
for a total of seven days. Spheroids were imaged before, during and after treatment 
and spheroid area was measured using CellProfiler. Graphs of spheroid size and 
representative images are shown in Figure 3.4 with the full dataset in Appendix A.4.  
 
Spheroid growth patterns differed between the cell lines over the treatment period. 
MDA-MB-231 cells formed very loose spheroids which shrank to half the size over 
time. MCF-7 spheroids did not change in size during the seven days, whereas T-47D 
spheroids grew by two thirds over the same period.  
Concentrations in the micromolar range are necessary for eCF506 to have a 
significant effect on spheroid size in any of the three cell lines tested (see Figure 3.4). 
Dasatinib has similar low potency to eCF506 in MCF-7 cells, with both compounds 
reducing spheroid size by only 21% at 10 µM compared to DMSO. Dasatinib is more 
potent in T-47D cells than eCF506 (44% and 23% size reduction at 10 µM, 
respectively), although only the highest concentration was able to fully stop spheroid 
growth during the treatment period. In MDA-MB-231 cells, dasatinib is able to reduce 
spheroid size at sub-micromolar concentrations, with a 25% reduction in size at 30 
nM and a 55% reduction at 3 µM. In contrast, eCF506 only achieves a maximum 17% 
reduction in spheroid size in this cell line. Longer treatment (7 days instead of 4 days) 
generally increased the effect of both compounds slightly.  
Spheroids were stained with calcein-AM and propidium iodide on the final day of 
treatment to visualise live and dead cells, respectively (see Figure 3.4). Increased 
propidium iodide staining could only be observed in MDA-MB-231 cells at very high 
concentrations, which suggests that the compounds did not have cytotoxic effects 
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Figure 3.4. Breast cancer spheroids treated with eCF506 or dasatinib. (a) MDA-MB-231, 
(b) MCF-7 and (c) T-47D cells were grown as spheroids and imaged prior to and after four or 
seven days of treatment using ImageXpress. Spheroid size was measured from a collapsed 
Z-stack image using CellProfiler software. Data was normalised to spheroid size prior to 
treatment start. Data represents average of three biological replicates with standard deviation. 
Statistical analysis was done using two-way ANOVA with Dunnett correction for multiple 
comparison; p<0.05 *, p<0.01 **, p<0.001 ***, p<0.0001 ****. Images show representative 
spheroids using brightfield microscopy or fluorescent microscopy after staining with calcein 





3.1.5. eCF506 has anti-angiogenic properties 
Part of this work was done by Oxurion (formerly Thrombogenics), Belgium. 
 
As SRC kinase and its downstream target FAK have been found to play important 
roles in angiogenesis (see chapter 1.2.3.4), eCF506 has potential anti-angiogenic 
properties that could lead to applications in cancer and other diseases involving 
abnormal blood vessel growth.  
 
Primary human umbilical vein endothelial cells (HUVEC) were used as a model for 
endothelial cells in angiogenesis. eCF506 was tested alongside four other SRC/ABL 
kinase inhibitors (dasatinib, bosutinib, saracatinib, imatinib), the FAK inhibitor VS-
4718 (which has previously been tested in phase 1 clinical trials for cancer), and the 
approved VEGFR inhibitor sunitinib. The effects of all seven compounds on cell 
proliferation were assessed in a 2D cell viability assay, as described previously in 
chapter 3.1.1.2, and the results are shown in Figure 3.5a. eCF506 was the most 
potent inhibitor of HUVEC cell growth with a GI50 of 35.6 nM; it was slightly better than 
dasatinib (GI50 49.8 nM) and more potent than both sunitinib and VS-4718 (GI50 0.852 
µM and 2.45 µM, respectively). Similar results in the low micromolar range have been 
reported previously with sunitinib in HUVEC cell proliferation and cytotoxicity assays 
316,317.  
As endothelial cell migration is equally as important as proliferation for blood vessel 
formation, a scratch wound assay was performed with HUVEC cells to determine the 
anti-migratory effects of eCF506, VS-4718 and sunitinib. Only eCF506 slightly 
reduced HUVEC migration in this assay at concentrations between 0.1 to 1 µM, while 
the other two compounds had no significant effects (see Figure 3.5b). These results 
and the nearly 20-fold lower potency of sunitinib in the cell viability assays compared 
to eCF506 are surprising as it is an approved angiogenesis inhibitor; however, a 
previous study reports slightly stronger activity of 1 µM sunitinib in a HUVEC wound 
healing assay than found here 318.  
 
A collaboration with the Belgian research company Thrombogenics was established 
to further test the anti-angiogenic properties of eCF506 in their standardised in vitro 
and in vivo assays for non-cancer applications. The in vitro cytotoxicity of eCF506, 
dasatinib and saracatinib was assessed in primary human retinal microvascular 




hours at concentrations up to 10 µM (see Figure 3.6). A second assay tested the 
efficacy of eCF506 at inhibiting the vessel outgrowth from ex vivo murine choroid 
explants; eCF506 was as good as dasatinib (IC50 4.85 nM and 6.72 nM, respectively) 
and clearly superior to saracatinib (IC50 396 nM) (see Figure 3.7). These results 
suggest that eCF506 could have potential applications in angiogenesis-related 
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Figure 3.5. Effects of different kinase inhibitors on HUVEC proliferation and migration. 
(a) HUVEC cell viability after 5 days of treatment with different kinase inhibitors was 
determined with PrestoBlueTM reagent. Table shows the GI50 and TGI values from three 
biological repeats with standard deviation in brackets. (b) Migration of HUVEC cells treated 
with eCF506, VS-4718 or sunitinib. Cells were pre-treated for 2 hours prior to wounding and 
treated again post-wounding. Data shows relative wound density 6 hours after wounding and 
represents the average of three experiments with standard deviation. Analysis was done using 
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Figure 3.6. Cytotoxicity of kinase inhibitors in primary human retinal microvascular 
endothelial cells (hRMVEC). Cells were treated with compounds for 24 hours and analysed 
using the CellToxTM Green Cytotoxicity assay (Promega). Higher fluorescent signal indicates 
dead cells. Data shows fluorescent signal minus background fluorescence from cell-free wells 





























     
Figure 3.7. Vessel outgrowth from ex vivo murine choroid explants. (a) The vessel 
outgrowth area of murine choroid explants was calculated and normalised to DMSO treated 
control. Data represents three biological replicates with standard deviation from which IC50 
was calculated using GraphPad Prism 7. (b) Representative images of vessel outgrowth of 




3.2. eCF506 selectively inhibits SRC kinase over ABL kinase 
3.2.1. eCF506 has superior potency and selectivity for SRC kinase  
3.2.1.1. Comparison of kinome screen data 
eCF506 and dasatinib have previously been tested by Reaction Biology against 14 
wild-type kinases to determine their IC50 values in cell-free assays 1. This revealed 
approximately thousand-fold selectivity of eCF506 for SRC kinase over ABL kinase 
(IC50 <0.5 nM vs 479). In order to test for potential “off-targets” in the rest of the human 
kinome, which currently includes 538 identified kinases, eCF506 was screened in a 
panel of 340 wild-type kinases by Reaction Biology, which constituted the biggest 
commercially available panel at the time 9. Percentage inhibition of kinase activity was 
determined in duplicate at a single dose of eCF506 (1 µM) in the presence of 10 µM 
ATP and compared to DMSO. Part of the results were previously published in the 
thesis of Dr Craig Fraser and the full dataset is shown in Appendix A.6 319.  
 
In Figure 3.8a, the full results for eCF506 have been plotted in a kinome map using 
the free TREEspot™ Software Tool from DiscoveRx Corporation. All kinase targets 
that were inhibited more than 65% by eCF506 are also listed in Table 3.4. In addition, 
the results of a kinome screen with dasatinib and bosutinib, which were previously 
tested in the same assay as part of a large scale kinase inhibitor screen 221, are plotted 
in Figure 3.8b,c. No kinome screening data could be found for saracatinib. In the study 
by Reaction Biology Corporation, dasatinib and bosutinib were tested at 500 nM in a 
panel of 300 wild-type human kinases at 10 µM ATP. In Figure 3.8, red dots denote 
kinases that are inhibited by 65% or more, with SRC and ABL coloured in blue, and 
green dots show all other tested kinases that fall below this threshold.  
 
eCF506 is more than twice as selective in comparison to dasatinib and bosutinib. It 
inhibited 23 of 340 kinases at 65% or more, while the other two compounds targeted 
46 and 66 out of 300 kinases, respectively, at the same cut-off. Since eCF506 was 
screened at double the concentration, it would likely be even more selective when 
compared under the same conditions. eCF506 also inhibited SRC more strongly than 
any other kinase (0.1% activity remaining) closely followed by other SRC family 
kinases, with its main off-target being ARAF (see Table 3.4). Dasatinib and bosutinib’s 




EphB2, DDR2, MAP4K4 and MINK, and they inhibited SRC to a lesser degree (3.5% 
and 6.0% activity remaining). Both inhibited other SRC family kinases as well as ABL 
(ABL1) and ARG (ABL2) more strongly than SRC kinase. This comparison highlights 
eCF506’s superior selectivity for SRC kinase in particular, and SFKs in general across 




























Figure 3.8. Map of the protein kinome showing the selectivity of eCF506, dasatinib and 
bosutinib. (a) eCF506 was tested at double the concentration (1 µM) than (b) dasatinib (500 
nM) or (c) bosutinib (500 nM). Tested kinases are shown as circles in the map, with green 
indicating inhibition below threshold and red denoting inhibition of kinase activity by more than 
65%, depending on size of the circle. SRC and ABL1 are highlighted in blue. Atypical, mutant, 
lipid and pathogen kinases are not shown. The S-score denotes the selectivity of the 
compound at 35% cut-off. LYN B kinase could not be mapped. eCF506 was tested by Reaction 
Biology Corporation and the data for dasatinib and bosutinib stems from a published inhibitor 
screen by Anastassiadis et al. in the same assay 221. All compounds were tested at 10 μM 
ATP. Images generated using TREEspot™ Software Tool and reprinted with permission from 






Table 3.4. Kinase targets of eCF506, dasatinib and bosutinib. All targets with less than 
35% activity remaining after compound addition are shown. SFKs are highlighted in red, ABL 
kinases in blue. Data for dasatinib and bosutinib comes from Anastassiadis et al. assay 221. 
eCF506 was screened at 1 µM, while dasatinib and bosutinib were tested at 500 nM. Full 
results for eCF506 are shown in Appendix A.6. 
 eCF506 Dasatinib Bosutinib 
No. Kinase % Activity Kinase % Activity Kinase % Activity 
1 SRC 0.1 FRK -0.9 MAP4K4 1.0 
2 BRK 0.2 EPHB2 -0.2 MINK 1.2 
3 HCK 0.8 DDR2 0.2 ERBB4 1.5 
4 FGR 1.3 EPHA5 0.2 MAP4K5 1.7 
5 LYN 1.3 LCK 0.3 ABL1 1.8 
6 LCK 1.4 LYN 0.4 LCK 1.9 
7 ARAF 1.7 CSF1R 0.8 SIK2 1.9 
8 YES 1.8 HCK 0.8 LYN 2.1 
9 LYN B 2.0 EPHB3 1.0 ABL2 2.2 
10 FYN 2.3 EPHB4 1.2 MAP4K2 3.2 
11 FRK 2.4 TXK 1.4 ACK1 3.5 
12 BMX 2.8 LYN B 1.6 EGFR 3.8 
13 BTK 3.8 EPHA4 1.6 EPHA6 4.4 
14 ERBB4 4.5 FGR 1.7 BTK 5.7 
15 BLK 4.8 PDGFRa 1.8 MST4 5.9 
16 CSK 5.0 SIK2 1.9 LYN B 6.0 
17 TXK 9.1 YES 1.9 SRC 6.0 
18 RIPK3 12.1 FYN 2.0 YES 7.3 
19 RAF1 19.6 BTK 2.1 MST1 7.4 
20 ABL2 28.7 PDGFRb 2.5 MEK2 8.4 
21 LIMK2 30.0 BMX 2.5 NEK2 8.6 
22 MER 30.1 ACK1 2.6 EPHA2 9.6 
23 BRAF 34.5 EPHA1 2.7 PAK3 9.9 
24 
  
ABL2 2.7 YSK1 10.1 
25 
  
ABL1 2.8 EPHA8 10.5 
26 
  
BLK 3.0 CK1d 10.9 
27 
  
MAP4K5 3.1 MST3 11.0 
28 
  
pdg 3.3 ARK5 11.4 
29 
  
EPHA3 3.5 CK1e 11.4 
30 
  
SRC 3.5 FGR 11.5 
31 
  
ERBB4 4.0 PAK1 11.7 
32 
  
EPHA8 4.1 MAP3K3 11.8 
33 
  
BRK 4.6 EPHB1 11.8 
34 
  
EPHB1 4.8 HCK 11.9 
35 
  
EPHA2 6.8 CSK 12.3 
36 
  
CSK 7.1 EPHB4 12.5 
37 
  
ZAK 8.6 LOK 12.6 
38 
  
TEC 11.3 MLK3 13.5 
39 
  
ALK1 15.9 MST2 13.9 
40 
  
LIMK1 16.7 BMX 14.5 
41 
  
SRMS 17.0 NEK1 15.2 
42 
  
EGFR 21.1 TRKC 15.2 
43 
  
NEK11 21.7 MLK1 16.5 
44 
  
RIPK2 25.2 CAMK1d 16.6 
45 
  
NLK 27.5 EPHB2 17.4 
46 
  
ARAF 33.8 RET 18.9 
47 
    
BLK 20.7 
48 
    
SYK 21.1 
49 
    
SLK 21.6 
50 
    
CHK2 21.7 
51 
    
MLK2 22.9 
52 
    
MAP3K2 23.5 
53 
    
MELK 25.8 
54 
    
EPHA4 27.0 
55 
    
TXK 27.5 
56 
    
TAK1 28.3 
57 
    
MER 28.9 
58 
    
FRK 29.2 
59 
    
FYN 29.4 
60 
    
LRRK2 30.1 
61 
    
FLT3 30.3 
62 
    
EPHA3 31.7 
63 
    
MYLK2 32.1 
64 
    
PYK2 32.6 
65 
    
NEK4 32.6 
66 





3.2.1.2. Comparison of SRC activity in Western blots 
Previous Western blot experiments have shown that eCF506 can inhibit SRC 
phosphorylation at tyrosine 416, its autophosphorylation site necessary for full kinase 
activity, as much as or even better than dasatinib 1,319. These experiments were done 
after cells were serum starved for 24 hours, followed by compounds being added for 
1.5 hours and serum stimulation for 1 hour. While serum starvation is useful to assess 
downstream effects in signalling pathways, it does not give information on whether 
the compounds would also be able to inhibit SRC phosphorylation and downstream 
pathways in a serum-containing environment, which is relevant for mimicking in vivo 
conditions. Therefore, Western blots were performed in the same two breast cancer 
cell lines used previously, MDA-MB-231 and MCF-7, in normal serum conditions (10% 
FBS). Cells were treated with all four SRC/ABL inhibitors (eCF506, dasatinib, 
bosutinib, saracatinib) for 3 or 24 hours prior to cell lysis and Western blots were 
performed as described in methods 2.4.2. 
 
The results are similar to those obtained previously with serum starvation and 
stimulation (see Figure 3.9). eCF506 and dasatinib give almost complete inhibition of 
SRC phosphorylation at 100 nM in MDA-MB-231 cells, with little difference between 
3 and 24 hours of treatment. In contrast, dasatinib is less potent than eCF506 at 
inhibiting phospho-SRC (Y416) in MCF-7 cells, with >100 nM needed for complete 
inhibition compared to eCF506’s 30 nM after 24 hours of treatment. 
Bosutinib and saracatinib both appear to be weak inhibitors of SRC 
autophosphorylation at tyrosine 416, with concentrations in the micromolar range 
needed to see significant changes. Slightly stronger inhibition was observed after 
longer incubation, although 10 µM bosutinib and 30 µM saracatinib was necessary to 
achieve near full inhibition of SRC autophosphorylation. 
 
Dasatinib seems to be slightly less potent in MCF-7 cells than eCF506, both at 
inhibiting SRC phosphorylation as well as at inhibiting cell proliferation (see chapter 
3.1.1.2). In order to test whether differences in the cell viability assays could be due 
to variable potency of the inhibitors against SRC, five other cell lines with little (CAMA-
1, MDA-MB-436), biphasic (T-47D, ZR-75.1) and high (JIMT-1) anti-proliferative 
response were assessed in Western blots (see Figure 3.10). In all five, eCF506 
achieves maximum inhibition around 100 - 300 nM, although some residual signal 




ZR75.1 cells where it was slightly weaker, which again correlates with reduced anti-
proliferative properties in these cell lines compared to eCF506 (see Figure 3.1). Full 
phospho-SRC (Y416) inhibition at 100 nM eCF506 or dasatinib was also found by 
collaborators at McGill University who tested eCF506 in two HER2-positive murine 
breast cancer cell lines 77. 
 
Activated SRC kinase phosphorylates FAK on several tyrosine residues, one of which 
is tyrosine 861. Phosphorylation at this position can therefore act as a marker of 
pathway activation downstream of SRC. Previous Western blots using serum 
starvation showed that phospho-FAK (Y861) inhibition mimicked the response of 
phospho-SRC (Y416) in both cell lines, with full inhibition at 100 nM. Similar results 
were obtained when FAK phosphorylation was assessed again in the presence of 
serum (see Figure 3.9). Bosutinib and saracatinib showed efficacy at similar 
concentrations as for SRC autophosphorylation, which confirms that high 
concentrations of both are needed to inhibit SRC activity.  
 
The results of these Western blots agree with the findings from the kinome screen in 
the previous section (chapter 3.2.1.1) and confirm that eCF506 is the most potent 
inhibitor of SRC kinase both in cell-free and cellular assays. It has similar and at times 
slightly superior potency compared to the current best-in-class SRC inhibitor dasatinib 
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Figure 3.9. Western blot analysis of eCF506, dasatinib, bosutinib and saracatinib for 
phospho-SRC (Y416) and phospho-FAK (Y861). (a) MDA-MB-231 cells were treated for 3 
or 24 hours prior to cell lysis and analysis by Western blot. Protein levels were normalised to 
GAPDH. Graphs show average of three biological replicates with standard error. (b) 
Representative Western blot of MDA-MB-231 cells. (c) Western blot of MCF-7 cells treated for 
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Figure 3.10. Western blot analysis of eCF506 and dasatinib in different breast cancer 
cell lines. Five different cell lines were treated for 24 hours prior to cell lysis and analysis by 






3.2.2. eCF506 is one thousand-fold less potent at inhibiting ABL 
kinase than dasatinib 
One distinguishing property of eCF506 is its approx. 1000-fold selectivity for SRC 
kinase over ABL kinase, as identified in cell-free kinase assays 1. This is unique 
among all currently available small molecule SRC inhibitors (see chapter 1.3.1). While 
its high potency against SRC kinase was confirmed in vitro by Western blots, the 
comparatively lower potency against ABL kinase has not yet been confirmed in cells.  
 
One challenge when trying to assess ABL activity by Western blot is its lack of sites 
that are exclusively autophosphorylated to determine ABL kinase activity, as is the 
case for SRC tyrosine 416. Two residues have been identified that contribute to ABL’s 
activity, tyrosine 245 and tyrosine 412 320. Importantly, there is evidence that both of 
these sites are phosphorylated by the SFKs HCK, LYN and FYN 321. Assessment of 
phospho-ABL Y245 after treatment with eCF506 and dasatinib showed only minor 
differences between both compounds, which correlates well with the similar effect of 
these compounds on HCK, LYN and FYN activity (see Figure 3.11a and Table 3.4). 
Assessment of phospho-ABL Y412 by Western blot was unsuccessful (data not 
shown).  
Studies in CML have frequently used the SH2/SH3 adapter protein CRKL as a 
surrogate for BCR-ABL activity. CRKL is a kinase that is directly phosphorylated by 
BCR-ABL at tyrosine 207 and can therefore act as an indirect measure of BCR-ABL 
or ABL activity 322. The effects of eCF506 and dasatinib on CRKL phosphorylation in 
MDA-MB-231 cells were assessed by Western blot and the results are shown in 
Figure 3.11b. As eCF506 has approx. one thousand-fold less activity against ABL 
than dasatinib in cell-free assays, the assumption would be that eCF506 inhibits 
CRKL phosphorylation at nearly one thousand-fold lower potency than dasatinib. The 
results in Figure 3.11b show that dasatinib is indeed superior at reducing phospho-
CRKL (Y207) levels, although eCF506 is only around 10-fold less potent, much lower 
than expected. However, the reliability of CRKL as a readout of ABL activity depends 
on whether its phosphorylation status is largely independent of other kinases and 
especially SRC. To test whether phospho-CRKL (Y207) can be affected by eCF506’s 
actions on non-ABL kinases, an ABL1 knockout strain of the MDA-MB-231 cell line 
and a second strain re-expressing ABL1, both created by Dr Henry Beetham at The 




show that eCF506 and dasatinib maintain their 10-fold potency difference and reduce 
CRKL phosphorylation to the same degree in the presence and absence of ABL 
kinase; this suggests that CRKL phosphorylation is not a specific marker of ABL 
activity. However, one limitation of this experiment is that only ABL1 but not ABL2 was 
knocked out in these cell lines and the latter might have compensated for ABL1 loss. 
MDA-MB-231 cells show very similar sensitivity to eCF506 and dasatinib in cell 
viability assays with or without ABL1, indicating that ABL1 inhibition does not 
contribute to potency in this cell line (see Appendix A.7).  
 
Another way of measuring whether a compound binds to a target is to assess the 
thermal stability of the protein in the presence and absence of the potential inhibitor. 
This method is based on the finding that proteins bound to an inhibitor are more 
resistant to heat-induced unfolding 323. Jafari et al. published an adapted method that 
uses this principle in live cells and therefore assesses not only whether the compound 
binds the target protein but also whether it reaches its subcellular localisation 296.  
To assess whether eCF506 binds ABL kinase in the cell, a thermal shift assay was 
performed based on the method by Jafari et al. and as described in methods 2.4.3. 
Dasatinib was used as a positive control and both compounds were tested at 300 nM, 
as it is expected that ABL would be strongly inhibited by dasatinib but not eCF506 at 
this concentration based on their IC50 values in isolated kinase assays (<0.5 and 479 
nM, respectively). Protein levels were assessed by Western blot after unfolded 
proteins, which form aggregates, were removed from the heat-treated cell lysates by 
centrifugation. The results of three biological replicates are plotted in Figure 3.13. 
Neither dasatinib nor eCF506 significantly shifted the apparent melting temperature 
(Tm) of ABL kinase. This was unexpected, as dasatinib is a well-established ABL 
inhibitor. However, a literature search revealed that dasatinib had previously been 
tested in a large screen of kinase inhibitors by thermal profiling of the proteome in 
living cells where it also failed to stabilise BCR-ABL 324. It appears that (BCR-)ABL’s 
heat stability, unlike other proteins tested such as p38α, is unaffected by the binding 
of at least some inhibitors, which renders this method unsuitable to show that eCF506 
does not significantly inhibit ABL at the tested concentration.  
 
As the attempts to confirm eCF506’s potency gap between SRC and ABL in cells by 
Western blot or thermal profiling fell short, chronic myeloid leukaemia (CML) cells 




driven by the Philadelphia chromosome, in which a chromosomal translocation fuses 
the BCR and ABL gene together, giving rise to the hyperactive BCR-ABL protein that 
drives abnormal proliferation. The potency of eCF506 in comparison to other dual 
SRC/ABL inhibitors at reducing cell viability in this model is therefore an indirect 
measure of the degree of BCR-ABL inhibition. Three different CML cell lines were 
tested in the same assay as discussed in chapter 3.1.1.2 and the results are plotted 
in Figure 3.14.  
Dasatinib is by far the most potent inhibitor of CML cell proliferation in this assay, with 
GI50 and TGI values in the high picomolar range, followed by bosutinib, which is more 
than 50 times less potent. Notably, eCF506 is one to two thousand-fold less potent 
than dasatinib in all three cell lines, which is very similar to the difference in IC50 values 
between both compounds in cell-free ABL kinase assays. Moreover, the range of their 
GI50 values in the cell assays is the same order of magnitude as their IC50 values, with 
dasatinib ranging from 98-384 pM (IC50 <500 pM) and eCF506 from 93-902 nM (IC50 
479 nM). Notably, the first approved ABL inhibitor for CML, imatinib, performed 
comparatively poorly in this assay, with similar efficacy to eCF506; however, imatinib 
does indeed have low potency (IC50 25-200 nM against ABL in isolated kinase assays) 
so these results are expected and in line with previous experiments in these cells 
325,326. The results of this cell viability experiment suggest that CML cell proliferation 
can be used as a surrogate readout for ABL inhibition and support eCF506’s 
































































Figure 3.11. Effects of eCF506 and dasatinib on markers of ABL kinase activity. MDA-
MB-231 cells were treated with eCF506 or dasatinib for 3 hours prior to cell lysis and analysis 
by Western blot. (a) Phospho-ABL (Y245) was normalised to GAPDH and is shown as percent 
of DMSO. Graph shows average of two biological repeats with standard deviation. (b) 
Phospho-CRKL (Y207) was normalised to GAPDH and is shown as percent of DMSO. Graph 
shows average of three biological repeats with standard deviation. (c) Representative Western 
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Figure 3.12. CRKL phosphorylation in MDA-MB-231 cells with and without ABL1. Three 
MDA-MB-231 cell lines (wild-type, ABL1 knockout, ABL1 re-expressed) were treated for 3 
hours with eCF506 or dasatinib and phospho-CRKL (Y207) levels were analysed by Western 
blot. (a) Control Western blot to confirm ABL knockout and re-expression. (b) Graph shows 
average of three (WT) or two (ABL1 -/-, ABL1 +) biological repeats with standard deviation. 











eCF506 48.6 (p>0.05) 


















































Figure 3.13. Thermal shift assay of ABL kinase after treatment with eCF506 and 
dasatinib. MDA-MB-231 cells were treated with eCF506 (300 nM), dasatinib (300 nM) or 
DMSO for one hour prior to heating, cell lysis and analysis by Western blot. Band intensities 
were quantified using Bio-Rad ImageLab® software and normalised to the lowest temperature 
band for each condition. The top graph shows the average of three biological repeats with 
standard deviation. The table shows average Tm values calculated by GraphPad Prism 7 and 
compared to DMSO by one-way ANOVA with Dunnett correction for multiple comparison. The 







































































































































Figure 3.14. Anti-proliferative effects of SRC/ABL kinase inhibitors in CML cell lines. A 
panel of three CML cell lines was tested against five kinase inhibitors. Effects on cell 
proliferation were measured after 5 days of treatment using PrestoBlueTM reagent and curves 
were fitted using GraphPad Prism 7. GI50 (left) and TGI (right) values represent the average 
of three biological replicates with standard error and values are summarised in table below. 









Previous work by Dr Craig Fraser in the Innovative Therapeutics group identified 
eCF506 as a potent SRC kinase inhibitor with selectivity over ABL kinase in cell-free 
kinase assays and anti-proliferative properties similar to dasatinib in two breast 
cancer cell lines 1. Further in vitro analysis and comparison to three other dual 
SRC/ABL inhibitors reveals that eCF506 is the most potent and selective inhibitor of 
SRC signalling. It has similar anti-proliferative properties to the current gold-standard 
SRC inhibitor dasatinib in various cancer types, with ovarian cancer being especially 
sensitive, and exhibits anti-angiogenic properties in non-cancer models.  
 
 
3.3.1. eCF506 is the most selective and potent SRC kinase inhibitor 
Western blot analysis of different breast cancer cell lines shows that eCF506 is able 
to potently inhibit SRC kinase autophosphorylation and signalling via downstream 
pathways such as FAK at nanomolar concentrations (see Figure 3.9 and Figure 3.10). 
It has similar potency to dasatinib in cells and was slightly better in Western blots of 
three cell lines (MCF-7, T-47D, ZR-75.1). In these, eCF506 is also somewhat more 
potent than dasatinib at inhibiting cell proliferation at lower concentrations (see 
chapter 3.1.1.2), suggesting that these two findings might be linked. 
It was surprising that bosutinib and saracatinib only achieved potent SRC inhibition at 
micromolar concentrations. Both have been studied extensively for their activity 
against SRC kinase in vitro, in vivo and in clinical trials 261,262,327,328. Previous papers 
report much higher efficacy of saracatinib against SRC autophosphorylation, with full 
inhibition at 0.25 µM in two prostate cancer cell lines after 30 minutes and at 0.1 µM 
after 24 hours in a lung cancer cell model; near full inhibition was also seen at 0.5 µM 
in gemcitabine resistant breast cancer cells after 48 hours 328–330. However, another 
study shows that phospho-SRC (Y416) inhibition differs between three gastric cancer 
cell lines, depending on their levels of phospho-SRC, and full inhibition was not 
achieved at saracatinib concentrations up to 5 µM; a study in breast cancer cells also 
showed only partial phospho-SRC inhibition at 1 µM in MCF-7 and T-47D cells, similar 
to what is shown in Figure 3.9 175,331. Bosutinib, on the other hand, has similar potency 
reported in the literature as found in this thesis, with SRC inhibition around 1 µM 
reported in the breast cancer cell line MDA-MB-436 and three biliary tract cancer cell 




While, interestingly, saracatinib is slightly better at inhibiting downstream signalling 
via FAK than SRC autophosphorylation itself (see Figure 3.9), it is still considerably 
less potent than eCF506 or dasatinib. Taken together, the data shows that eCF506 is 
the most consistently potent SRC activity inhibitor in 2D cell models out of the four 
tested.  
 
The screening of eCF506 against the kinase panel and comparison to previous data 
sets for dasatinib and bosutinib highlights its superior selectivity for SRC kinase and 
SRC family kinases across the whole kinome (see chapter 3.2.1.1). Not only do 
dasatinib and bosutinib have two- and three-fold more off-targets at half the 
concentration, respectively, they also inhibit several kinases much more potently than 
SRC or ABL (see Table 3.4). These off-targets likely affect their potency and/or 
toxicity, which renders their general labelling as dual SRC/ABL inhibitors inadequate 
and highlights the importance of comprehensive target-deconvolution studies as 
discussed in a recent paper by Lin et al. 333. In contrast, eCF506’s primary kinase 
target is SRC kinase followed by other SFKs, although no information is available yet 
about possible non-kinase targets. Its superior selectivity profile and thousand-fold 
selectivity for SRC over ABL kinase clearly distinguishes eCF506 from dual SRC/ABL 
inhibitors and can address the concerns of ABL-inhibition linked cardiotoxicity and the 
emerging role of ABL as a tumour suppressor in certain cancers (see chapter 1.3.3) 
282,288. 
In order to confirm this key finding again in a cell model, several experiments have 
been attempted to test for the selectivity gap. It was found that measuring of phospho-
CRKL (Y207) levels is not a specific readout of wild-type ABL1 kinase activity, despite 
its repeated use in the literature, as it was still inhibited by eCF506 and dasatinib in 
ABL1 knockout cell lines (see Figure 3.12). While it is possible that ABL2 (ARG) 
somewhat compensates for ABL1 loss in this model, it is likely that SRC inhibition 
alone also affects CRKL phosphorylation; studies have found that SRC activity can 
trigger translocation of the adapter protein to focal adhesions where it interacts with 
the SRC substrate p130Cas 334. Since SRC inhibition affects focal adhesion formation 
and turnover (see chapter 1.2.3.1), it is likely that a SRC inhibitor would affect CRKL 
activity in the cell.  
Measuring phosphorylation of tyrosine 245 on ABL kinase, which was found to 
increase ABL activity, showed similar potency for eCF506 and dasatinib (see Figure 




and affect its kinase activity; HCK, FYN and LYN in particular were found to 
phosphorylate tyrosine 245 and other residues on ABL 320,321,335,336. The finding that 
SFKs can phosphorylate and activate ABL could explain the difficulty in trying to 
assess eCF506’s distinct inhibitory effects on each kinase. However, since the effect 
of SFKs on ABL activation is additive to the autophosphorylation of ABL, it is unlikely 
that SFK inhibition would fully inhibit ABL functions; for example, the Zebrafish assay 
by Fraser et al. showed that the SRC/ABL inhibitor dasatinib but not the SRC inhibitor 
eCF506 induces cardiac hyperplasia, an observation closely linked to ABL activity 
1,287. However, it is possible that SFK inhibition and consequent effects on ABL 
signalling contribute to eCF506’s potency in CML cell lines (see chapter 3.1.1.1). 
A thermal stability assay was unable to confirm binding of eCF506 or dasatinib to ABL 
kinase (see Figure 3.13). However, using three CML cell lines as an indirect measure 
of BCR-ABL inhibition successfully confirmed a more than thousand-fold potency 
difference between eCF506 and dasatinib. GI50 values for CML cells were in the same 
range as the IC50 data for wild-type ABL from the kinase panel, which makes a strong 
case for this model as a readout of ABL inhibition; yet it is important to point out that 
this assay has drawbacks, such as the assumption that cell viability fully depends on 
BCR-ABL activity and that compounds would bind ABL kinase the same as BCR-ABL. 
All the same, the CML data gives confidence that the findings from isolated kinase 
assays can translate into cellular models and that eCF506 is indeed a thousand-fold 
more selective for SRC over ABL than dasatinib; this strengthens its unique status 
among the small molecule SRC inhibitors (see Table 1.3). 
 
 
3.3.2. eCF506 inhibits cell proliferation by inducing cell cycle arrest in 
the G1 phase  
The testing of eCF506 in several different screens showed that it is similar to dasatinib 
and much better than bosutinib, saracatinib and imatinib at inhibiting the proliferation 
of solid cancer cell lines in 2D models. The screen of oesophageal cell lines also 
showed selectivity of SRC inhibitors for cancer cell lines over normal tissue. eCF506’s 
potency varied considerably between cell lines over a 3 log-fold range (GI50 range: 
14.7 nM to 50.8 µM); breast cancer cell lines with HER2 amplification were generally 
more resistant than those classified as triple negative or ER positive, while ovarian 




The shape of the dose-response curves was often biphasic (see Appendix A.1). One 
possible explanation for this is that SRC, unlike v-Src, is not the only driver of 
proliferation in cancer but rather a contributing factor; therefore, treatment with lower 
concentrations would only cause a drop in cell proliferation to the degree of SRC’s 
contribution, while the second drop in the dose-response curve is likely due to off-
target effects that occur at higher concentrations (see chapter 3.2.1.1).  
 
The degree to which eCF506’s anti-proliferative effects are due to changes in the cell 
cycle or cell death was only partially assessed by Fraser et al. and required further 
investigation. It has previously been shown that the compound was able to increase 
caspase 3/7 activity, a measure of apoptosis, after 5 days in MCF-7 cells; however, 
the ratio of apoptotic to non-apoptotic cells only doubled at 100 nM compared to 
DMSO, which cannot explain the potent effects seen in cell viability assays at this 
concentration 1. In this thesis, a cell cycle assay in the same cell line as well as MDA-
MB-231 cells showed that eCF506 significantly increases the proportion of cells in the 
G1 phase at 100 nM after 48 hours (see Figure 3.2); the proportion of MDA-MB-231 
cells in the M and G2 phase of the cell cycle was more than halved, although lesser 
effects were seen in MCF-7 cells. Consequently, eCF506 appears to have mainly 
cytostatic rather than apoptotic or cytotoxic effects at sub-micromolar concentrations 
by triggering cell cycle arrest in the G1 phase. Other studies have also found G1 cell 
cycle arrest for the SRC inhibitors dasatinib, bosutinib and saracatinib in solid tumours 
331,332,337. SRC activity can promote cell cycle progression by phosphorylating and thus 
destabilising the CDK inhibitor p27 and its inhibition was shown to increase p27 
stability and reduce G1 to S phase progression (see chapter 1.2.3.211) 52,71. It is 
therefore likely that the eCF506-induced arrest in G1 phase is linked to stabilisation 
of p27 but further studies should be done to confirm this.  
 
While eCF506 and dasatinib had potent anti-proliferative effects in the 2D screens, 
their ability to reduce the size of 3D spheroids of the same cell lines was much lower. 
3D models such as spheroids more closely mimic the features of tumours than 2D 
models, for example structural organisation, cell-cell adhesion and gradients of 
oxygen and nutrients which allow the formation of a necrotic core 338. 
Micromolar concentrations of eCF506 were needed to significantly reduce spheroid 
size in comparison to DMSO treated controls in most cases. Dasatinib was more 




reduced spheroid size by 44% at 300 nM and even more at higher doses. The effects 
of both compounds were stronger after 7 days than 4 days of treatment, confirming 
that they remain stable and active in solution for at least one week and that cells are 
not able to overcome their effects during this time. 
Staining with calcein-AM and propidium iodide showed only some treatment-induced 
cell death in MDA-MB-231 cells at high concentrations. This suggests that eCF506 
and dasatinib have mainly cytostatic effects in MCF-7 and T-47D cells, as seen in the 
2D assays of chapter 3.1.1.2. However, the variability of spheroid growth between cell 
lines (T-47D grew in size, while MCF-7 did not, and MDA-MB-231 shrank) means their 
antiproliferative effects may be hidden in this assay when measuring only spheroid 
size; yet, even in the growing T-47D spheroids eCF506 had only little effects at 
nanomolar concentrations (see Figure 3.4). Future Western blots and cell cycle 
analysis of the spheroids will be able to show whether eCF506 is still able to inhibit 
SRC phosphorylation and induce G1 cell cycle arrest at similar concentrations as in 
the 2D assays or whether it does not achieve sufficient target inhibition in 3D, for 
example due to the drug gradient across the spheroid. Another possible explanation 
for the low potency is that 3D features, such as increased cell-cell adhesion and lack 
of adhesion to the microenvironment via focal adhesions in 2D assays, might reduce 
the cells’ dependency on SRC kinase and consequently the effects of SRC inhibition. 
A preliminary comparison of the amounts of phospho-SRC and total SRC between 
cells grown in 2D or 3D shows different trends between cell lines, with significantly 
more SRC phosphorylation in 3D than 2D in MDA-MB-231 cells, but little difference 
in MCF-7 cells (see Appendix A.5). Further assays are needed to clarify the effects of 
eCF506 and dasatinib in 3D models with endpoints other than spheroid size and 
live/dead cell staining. Nevertheless, current results suggest that high concentrations 
of eCF506 might be needed to reduce tumours of these three cell lines in in vivo 
models when given as monotherapy. Future studies should also look at bosutinib and 
saracatinib to assess whether they are similarly less potent in 3D spheroids compared 
to 2D models. 
 
Several previous studies have tried to identify a biomarker that can predict sensitivity 
to SRC inhibition. The obvious place to start is to assess the relative quantity and 
activity of SRC kinase; two studies found that gastric and colorectal cancer cell lines 
sensitive to saracatinib had higher levels of phospho-SRC (Y416) compared to 




cell lines that were sensitive to dasatinib 331,337,339. An analysis of the phospho-SRC 
(Y416) and total SRC levels by Western blot in a panel of 29 breast and ovarian 
cancer cell lines showed a significant correlation between sensitivity to eCF506 and 
phospho-SRC Y416 status, but not total SRC amounts (see Figure 3.3 and Appendix 
A.3). However, this link does not appear to be strong enough to reliably predict cell 
line response and so far no clinical trial with SRC inhibitors was successful enough in 
stratifying patient response to gain regulatory approval (see chapter 1.3.2). Further 
in-depth analysis of the GDSC screening data could help identify better biomarkers 
for sensitivity to eCF506 by using the sequencing and gene expression data available 
for all the cell lines; however, comparison between the GDSC and in-house and other 
published results suggests that the GDSC methodology is tailored to identify cytotoxic 
effects, which explains why the majority of BCR-ABL-dependent CML cell lines were 
found to be sensitive but breast cancer ones were not. It might be possible to identify 
cytostatic effects better through improved curve fitting (e.g. biphasic curves) and 
taking into account pre-treatment cell viability. Proper analysis of this dataset with 
advanced bioinformatics and gene expression analysis could therefore provide 
potential candidate biomarkers. One possible biomarker for SRC sensitivity is 




3.3.3. ARID1A mutant ovarian clear cell carcinoma are especially 
sensitive to SRC inhibition 
The GDSC panel revealed that ovarian cancer cell lines appear to be especially 
sensitive to eCF506 compared to other solid cancer types. Several papers and clinical 
trials have previously investigated SRC inhibitors in ovarian cancer, often in 
combination with chemotherapy such as paclitaxel 167,257,309. Konecny et al. has 
previously tested a panel of 34 ovarian cancer cell lines against dasatinib with similar 
results as reported here (see chapter 3.1.1.2) 310. Both this thesis as well as Konecny 
et al. found that ovarian cancer cell lines classified as clear cell carcinoma (CCC) tend 
to be more sensitive to eCF506 or dasatinib than other subtypes. CCC generally 
respond poorly to standard platinum-based chemotherapy and new treatment options 
are needed 340. A previous study analysed hundreds of primary ovarian cancer tissues 




compared to other subtypes, with nearly 60% expressing the phospho-protein 341; 
however, no such trend was found in the analysis of phospho-SRC levels in this thesis 
(see Figure 3.3). Phospho-SRC expression in CCC was further linked to sensitivity to 
SRC inhibition and associated with shorter overall survival in patients 341.  
 
Several potential driver mutations have been identified in endometriosis-associated 
ovarian cancers, to which both CCC and endometrioid carcinoma (EC) belong. One 
is the tumour suppressor and epigenetic regulator ARID1A, which was mutated in 
46% of 119 tested CCC and 30% of 33 EC tumours, but in none of the 76 high-grade 
serous ovarian cancers (HGSOC) tested in one study 342. Another study found 
mutations in 57% of 42 tested CCC samples 343. Miller et al. showed that ARID1A 
mutant CCC cell lines are more sensitive to dasatinib than those with a wild-type copy 
344. This finding matches the results obtained in this study, with all ARID1A mutant 
CCC and EC cell lines (OVTOKO, TOV-21G, OVMANA, IGROV-1, OC-314) 
exhibiting much higher sensitivity to eCF506 and dasatinib than those with ARID1A 
wild-type copies (ES-2, TOV-112D). CCC as well as one breast and colorectal cancer 
cell line with wild-type ARID1A were also found to become more sensitive to dasatinib 
when ARID1A was knocked down by siRNA 344. Further analysis found that ARID1A 
mutant cells are addicted to the SRC family kinase YES1 and that SFK inhibition can 
thus result in synthetic lethal effects 344. These findings suggest that ARID1A could 
be a potential biomarker, along with phospho-SRC status, for sensitivity of 
endometriosis-associated ovarian cancer cell lines to eCF506 and dasatinib. A 
recently completed phase II clinical trial that tested dasatinib in ovarian cancer 
(NCT02059265) determined ARID1A mutation status in patients, although this data 
was not correlated to patient response; overall the trial results were negative, with an 
ORR of only 3.6%, PFS of 2.14 months and overall survival of 16.9 months 246.  
Several other synthetic lethal targets have also been identified in ARID1A mutant 
CCC, such as PARP, ATR and BET inhibitors, which are linked to ARID1A’s role in 
the DNA damage checkpoint 345,346. Comparative testing is needed to identify the best 
treatment option or combination therapy for ARID1A mutant CCC patients.  
 
ARID1A mutations were also found in pancreatic (8-47%), gastric (8-29%) and breast 
cancer samples (4-35%) 347. No link can be made about the ARID1A mutation status 
in the breast cancer cell lines used in chapter 3.1.1.2 and sensitivity to eCF506, as 




investigated the expression levels of ARID1A in breast cancer, which correlated with 
sensitivity to inhibitors of CDK4/6, mTOR 1/2, SHP 1/2 349, PI3K, AKT 350 as well as 
trastuzumab 351 and paclitaxel 352. The publicly available data of the GDSC screening 
project also shows that AKT inhibitors especially seem to be more potent across cell 
lines with ARID1A mutations 307. Interestingly, the unclassified ovarian cancer cell line 
SKOV-3 has a mutation in ARID1A but was only moderately sensitive to SRC 
inhibitors, while the non-CCC ovarian cancer cell line OC-314 is also mutated and 
was a hit in the GDSC screen (see Table 3.1 and Figure 3.1). Future assessment of 
ARID1A expression in the cell lines tested in this thesis could reveal whether this 
tumour suppressor gene is also linked to sensitivity to SRC inhibition in other cancers 
or whether the unique biology of CCC makes it especially sensitive. 
 
 
3.3.4. eCF506 has anti-angiogenic properties in non-cancer models 
SRC activity has been strongly linked to endothelial cell proliferation and migration 
which is essential in angiogenesis, as described in detail in chapter 1.2.3.4. An in vitro 
comparison of five SRC/ABL inhibitors, the FAK inhibitor VS-4718 and the FDA-
approved VEGFR inhibitor sunitinib showed that eCF506 was superior at inhibiting 
proliferation of human umbilical vein endothelial cells (HUVEC), which are a model of 
angiogenesis (see Figure 3.5). eCF506 also slightly inhibited HUVEC migration in a 
scratch wound assay, unlike VS-4718 and sunitinib. However, as seen in chapter 
3.1.2, 2D cell viability assays do not always translate into 3D models. Therefore, the 
blood vessel outgrowth from ex vivo murine choroid explants treated with eCF506, 
dasatinib or saracatinib was tested in collaboration with the company Thrombogenics. 
Both eCF506 and dasatinib but not saracatinib potently inhibited vessel outgrowth at 
low nanomolar concentrations (see Figure 3.7).  
 
These results are promising and suggest that eCF506 could be used to prevent 
tumour vascularisation as well as other angiogenesis-associated diseases. 
Pathological blood vessel growth is found in many diseases, such as arthritis, 
psoriasis and retinopathies 353. One common complication of diabetes is retinal 
damage caused by high glucose levels in the blood 354. Diabetic retinopathy develops 
in three stages and over the course of several years; the last stage, proliferative 
retinopathy, involves the formation of new blood vessels and can lead to loss of vision. 




treatment, eye surgery or injections of anti-VEGF compounds or antibodies 354,355. A 
previous study found that dasatinib can reduce diabetes-induced and VEGF-mediated 
retinal vascular leakage 186. eCF506 might be similarly potent and its superior 
solubility could allow for easier formulation for topical application 1. Therefore, further 
























eCF506 was developed in a phenotypic screening approach that used the kinase 
inhibitor PP1 as a scaffold 1. While PP1 is often described as a selective SRC inhibitor 
in the literature, it also inhibits KIT, ABL, EGFR and other kinases, making it similarly 
promiscuous as dasatinib but with much lower potency (see Table 1.3) 356. Sequential 
ligand-based design coupled to cell viability assays resulted in the discovery of 
eCF506, a molecule which shows high selectivity for SRC over the other kinase 
targets of PP1 and dasatinib. The results of Chapter 3 and Fraser et al. confirm its 
potency in in vitro assays of target inhibition, cell proliferation, migration and 
angiogenesis 1. While it was clearly superior to the SRC/ABL inhibitors bosutinib and 
saracatinib or the ABL inhibitor imatinib, it performed similarly well to dasatinib, the 
current gold standard SRC inhibitor. This raises the question in which ways other than 
its selectivity profile eCF506 distinguishes itself from dasatinib.  
 
This chapter identifies important differences between eCF506 and dasatinib in their 
binding mode to SRC kinase and their impact on overall kinase confirmation. This 
revelation allowed the interpretation of results from a reverse-phase protein array that 
was done in order to compare both compounds’ effects on downstream cell signalling 
pathways. As a result, inferences can be made on the role of the inhibitor-induced 
conformation of SRC’s αC helix and the kinase’s ability to bind its downstream target 
FAK.  
Another difference between eCF506 and dasatinib that has been identified in this 
thesis is the subcellular localisation of FAK and SRC kinase. Further investigations 
are needed to determine whether this is linked to the inhibitor’s differential effects on 
SRC-FAK interactions or to their selectivity profiles.  
 
This chapter explores the following aims:  
 
• Determination of eCF506’s binding mode to SRC kinase. 
 
• Screening of differential effects of eCF506 and dasatinib on downstream cell 
signalling pathways. 
 
• Comparison of the subcellular localisation of FAK and SRC with eCF506 and 




4.1. eCF506 and dasatinib have opposite effects on SRC 
conformation 
 
4.1.1. Thermal shift assay suggests eCF506 and dasatinib bind SRC 
differently 
In chapter 3.2.2 a thermal shift assay was performed to confirm the differential 
engagement of ABL kinase by eCF506 and dasatinib. This assay is based on the 
published methodology for thermal shift assays in live cells by Jafari et al. and used 
MDA-MB-231 cells treated with eCF506 (300 nM), dasatinib (300 nM) or control 
(DMSO) 296. While the assay did not show a significant shift in ABL stability, which 
was in line with previous findings, assessment of the same samples for SRC kinase 
stability yielded surprising results 324. eCF506 and dasatinib appeared to have 
significant but opposite effects on the apparent melting temperature (Tm) of SRC 
compared to DMSO, with the former stabilising but the latter destabilising the kinase 
(see Figure 4.1).  
 
One hypothesis for these results is that the compounds force SRC to take on different 
conformations that are either more or less likely to form insoluble aggregates when 
heated, as protein aggregates are subsequently removed from cell lysates by 
centrifugation. Previous studies report that SRC’s thermal stability is reduced in the 
presence of ATP or a peptide that binds its SH3 domain and forces SRC into an active 
conformation 357,358. Dasatinib is known to bind the active conformation of SRC kinase 
and taken together these findings indicate that binding of eCF506 to SRC kinase 



















eCF506 50.3 (p<0.01) 

















































Figure 4.1. Thermal shift assay of SRC kinase after treatment with eCF506 and 
dasatinib. MDA-MB-231 cells were treated with eCF506 (300 nM), dasatinib (300 nM) or 
DMSO for one hour prior to heating, cell lysis and analysis by Western blot. Band intensities 
were quantified using Bio-Rad ImageLab® software and normalised to the lowest temperature 
band for each condition. The top graph shows the average of three biological repeats with 
standard deviation. The table shows average Tm values calculated by GraphPad Prism 7 and 
compared to DMSO by one-way ANOVA with Dunnett correction for multiple comparison. The 





4.1.2. eCF506 binds SRC kinase in its closed and autoinhibited state  
4.1.2.1. X-ray crystallography of the SRC kinase domain reveals a 
TypeI1/2A binding mode for eCF506 
This work was done by Dr Daniel Lietha at the Centro de Investigaciones Biológicas 
(CIB) in Madrid, Spain.  
 
The observations made in the thermal shift assay in chapter 4.1.1 suggest that 
eCF506 is potentially inducing a different conformation in SRC kinase upon binding 
than dasatinib. This was further investigated by determining the crystal structure of 
eCF506 bound to SRC by X-ray crystallography.  
Dr Daniel Lietha generated a co-crystal structure with excellent resolution (1.5 Å) of 
eCF506 complexed with the kinase domain of SRC (see Figure 4.2). It shows that 
eCF506 binds strongly to SRC via numerous hydrogen bonds as well as hydrophobic 
interactions, which are highlighted in Figure 4.2b. The adenine-mimicking 
pyrazolopyrimidine core of the molecule perfectly overlays with the location of the 
purine ring of ATP bound to SRC, as previously predicted in in silico studies 1. The 
highly conserved DFG motif in the activation loop, which is involved in the catalysis 
of phosphate transfer, is in an “in” conformation, with the aspartate residue 
404/407 (chicken/human numbering) pointing inward as seen in the active SRC 
conformation. The tert-butyl group of the carbamate extends deep into the protein to 
reach a back-pocket beyond the so-called gatekeeper residue (T338/341) (see Figure 
4.2b). This distinguishes the binding mode of eCF506 from that of dasatinib, as 
binding to the back-pocket stabilises an inactive SRC confirmation with the αC helix 
in an “out” position (see Figure 4.3). eCF506’s induction of a “DFG-in” and “αC helix-
out” conformation is also called “SRC-like inactive”, as it was first observed in the 
autoinhibited conformation of SRC kinase, in which the phosphorylated Y527/530 
residue in the C-terminus binds to the SH2 domain, forcing the whole kinase into a 
“closed” and inactive conformation (see Figure 4.4) 361,362.  
 
eCF506’s binding mode is classified as TypeI1/2A based on Roskoski’s classification 
system, which places it between the Type I inhibitors that bind the active DFG-in state 
and the Type II inhibitors that bind an inactive DFG-out conformation (see Table 4.1) 
360. The most potent SRC inhibitors currently available, dasatinib, bosutinib, ruxolitinib 




“DFG-in” and “αC helix-in” conformation (see Figure 4.3) 360. Saracatinib has been 
described as a Type II inhibitor but papers differentially report its binding mode either 
as both motifs in an “in” position or as “DFG-in”, “αC helix-out”; the X-ray crystal 
structure available on PDB supports the latter and suggests that it might be a Type 
I1/2 inhibitor like eCF506 (see Figure 4.3g) 230,363,364. The dasatinib-derivative UM-164 
is a Type II inhibitor that induces a clear flip of the aspartate and phenylalanine of the 
DFG motif (see Figure 4.3h) and it binds to the protein in an “αC helix-in” 
conformation, opposite to eCF506; two other dasatinib derivatives were developed to 
bind an “αC helix-out” and “DFG-out” conformation 230,231,363.  
The only other inhibitor that has been reported to bind a similar SRC-like inactive 
conformation (i.e. DFG-in, αC helix-out) as eCF506 and likely saracatinib is the 
promiscuous inhibitor PP1, although this binding mode was found in HCK kinase and 
not investigated in SRC itself (see Figure 4.3c) 360. Given that eCF506 has been 
developed in a ligand-based phenotypic screening approach based on PP1, it is 
perhaps not surprising that it would bind in a similar way. However, it is important to 
note that PP1 appears to induce an “αC helix-out” confirmation in HCK without 







Figure 4.2. eCF506 bound to the ATP binding site of the SRC kinase domain. (a) Electron 
density map and (b) main interactions of eCF506 bound to SRC kinase domain. Red dotted 
lines = hydrogen bonds, grey dotted lines = hydrophobic interactions. Figures created by Dr 






(a) Active c-Src 
 
(b) Autoinhibited SRC 
 
 
(c) PP1 (HCK)  
 
 











Figure continued from previous page 
 
(e) Dasatinib (c-Src) 
 
(f) Bosutinib (SRC) 
 
 
(g) Saracatinib (SRC) 
 
 
(h) UM-164 (c-Src) 
 
Figure 4.3. Binding modes of SFK inhibitors. Figures show SRC in its (a) active or (b) 
autoinhibited state or (c-h) SRC or HCK bound to different inhibitors. Residues highlighted are 
D404 and F405 of the DFG motif in the activation loop and E310 in the αC helix. Figures were 
created with PyMOL using structures published on the PDB (see Table 4.1 for ID). SRC/HCK 






Figure 4.4. Autoinhibited conformation of SRC kinase. Phosphorylation of the Y527 
residue in the C-terminus allows binding to the SH2 domain, which locks the protein in an 
inactive, closed conformation. Residues highlighted are D404 and F405 of the DFG motif in 
the activation loop, E310 in the αC helix and Y527 in the C-terminus. Figure created with 
PyMOL using crystal structure published on the PDB (ID: 1FMK). 
 
 
Table 4.1. Binding mode of different SRC/ABL inhibitors to SRC and ABL kinase. 
Classification is based on Roskoski (2016) 360: Type I = DFG-in, αC helix-in; Type I1/2 = DFG-
in, αC helix-out; Type II = DFG-out, αC helix-in; A = extends into back pocket; B = does not 
extend into back pocket; SRC/HCK/ABL = human, c-Src = chicken, c-Abl = mouse. 
 
Inhibitor / State PDB ID Protein DFG C-helix Class 
Active c-Src kinase 3DQX c-Src In In - 
Autoinhibited SRC kinase 1FMK SRC In Out - 
eCF506 - SRC In  Out I1/2A 
Dasatinib 3G5D c-Src In In  I 
Bosutinib 4MXO SRC In In I 
Ruxolitinib 4U5J c-Src In In I 
AP23464 2BDJ SRC In In I 
Saracatinib 2H8H SRC In or Out Out  I1/2 or II 
Dasatinib-analogue CHO 4YBK c-Src Out Out II 
Dasatinib-analogue DFG-out (UM-164) 4YBJ c-Src Out In  II 
PP1 1QCF HCK In Out I1/2B 
Imatinib 1IEP c-Abl Out In IIA 
Dasatinib 2GQG ABL In In I 





4.1.2.2. SRC (Y527) is differentially phosphorylated by eCF506 compared 
to other SRC/ABL inhibitors 
The X-ray crystallography data revealed that binding of eCF506 to the SRC kinase 
domain is classified as Type I1/2A, different from the active Type I conformation seen 
with dasatinib and bosutinib or the previously reported Type II binding of saracatinib, 
although the latter may bind similarly to eCF506 (see chapter 4.1.2.1). However, as 
not the full-length protein was crystallised, it remained unclear whether eCF506 only 
induced a “SRC-like inactive” motif in the kinase domain or whether it had the capacity 
to induce a closed conformation of the whole kinase as seen in the autoinhibited state 
(see Figure 4.4). The closed SRC conformation is characterised by the 
phosphorylation of the tyrosine 527 residue in the C-terminus, which enables it to bind 
to the SH2 domain. Therefore, phospho-SRC (Y527) phosphorylation was assessed 
by Western blot for MDA-MB-231 and MCF-7 cells treated with eCF506, dasatinib, 
bosutinib or saracatinib for 3 or 24 hours. 
 
The Western blots show that eCF506 maintains phosphorylation of SRC (Y527) at 
similar levels to untreated control, while dasatinib induces a dose-dependent 
decrease in phosphorylation at the autoinhibition site (see Figure 4.5 and Appendix 
A.8). These findings are consistent with the hypothesis that eCF506 maintains SRC 
in a closed, autoinhibited state, whereas dasatinib forces the whole kinase into an 
open conformation. Consequently, while both compounds can potently inhibit kinase 
activity (see chapter 3.2.1.2), only eCF506 also inhibits the “scaffolding” functions of 
the open SRC conformation, such as binding of other proteins via its SH2 domain 130.  
Similar results were seen with bosutinib and saracatinib, albeit at higher 
concentrations due to their lower potency against SRC in cells (see chapter 3.2.1.2); 
bosutinib treatment caused consistent dephosphorylation of SRC (Y527), while 
saracatinib’s effects differed between biological repeats but generally reduced the 
levels of Y527 phosphorylation (see Figure 4.5).  
In conclusion, the results indicate that eCF506 not only binds a SRC-like inactive 
conformation in the kinase domain but also maintains the whole protein in a closed 
conformation that resembles the natural autoinhibited state of SRC. The different SRC 
structures induced upon binding of eCF506 or dasatinib could explain the opposite 
effects on the thermal stability of the kinase seen in chapter 4.1.1, as an open and 
flexible conformation might be more likely to form protein aggregates that precipitate 
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Figure 4.5. Western Blot analysis of phospho-SRC (Y527) in MDA-MB-231. MDA-MB-231 
cells were treated for 3 or 24 hours with (a) eCF506 and dasatinib or (b) bosutinib and 
saracatinib at the concentrations specified. Representative Western blots of three biological 
replicates. Concentrations in µM. (c) Summary of MDA-MB-231 phospho-SRC (Y527) 
Western blots showing average of three biological replicates with standard deviation. Band 
intensities were quantified using Bio-Rad ImageLab® software, adjusted for loading using 
GAPDH and normalised to DMSO. Statistical analysis was performed comparing treated 
against DMSO using two-way ANOVA with Dunnett’s correction for multiple comparison; 




4.2. SRC conformation differentially affects downstream FAK 
with unclear functional consequences 
Structural investigation of eCF506 bound to SRC revealed opposite effects compared 
to dasatinib, with the former maintaining the kinase in a closed conformation similar 
to the natural autoinhibited state, while the latter forces it into an active-like open 
conformation (see chapter 4.1). While both compounds still potently inhibit SRC’s 
kinase function, the question remained whether eCF506 inhibited scaffolding 
functions that are involved in downstream signalling. In order to compare eCF506 and 
dasatinib’s effects, changes in the levels of downstream proteins were investigated in 
a reverse phase protein array (see chapter 4.2.1). The screening revealed that, 
although most signalling pathways were similarly affected by both compounds, they 
had opposite effects on the FAK autophosphorylation site. This can be linked to the 
different SRC conformations, which either enable or inhibit binding of SRC to FAK 
(see chapter 4.2.2). Further investigations were made into the potential impact of 
these findings on protein localisation and gene expression (chapter 4.3).  
 
 
4.2.1. Reverse phase protein array shows FAK (Y397) is differentially 
phosphorylated by eCF506 and dasatinib 
This work was done together with Kenneth Macleod from the Drug Discovery group 
of Prof Neil Carragher at the University of Edinburgh, UK.  
 
A reverse phase protein array (RPPA) was performed to identify differences in cell 
signalling between eCF506 and dasatinib treatment. MDA-MB-231 and MCF-7 cells 
were treated with either compound for 3 or 24 hours, after which samples were 
analysed by RPPA on the Zeptosens platform. Results are shown as heat maps (see 
Figure 4.6) with protein levels expressed in units of relative fluorescence intensity 
(RFI) normalised to the respective DMSO control. After the exclusion of proteins with 
low signal (RFI <0.05), a total of 95 (MDA-MB-231) and 93 (MCF-7) proteins were 







Cell line and SRC-specific proteins 
The cell lines exhibited characteristic differences in protein expression, with no 
Caspase 3 present in MCF-7 cells and no E-cadherin in MDA-MB-231 cells. As 
expected, a strong upregulation of total SRC and downregulation of SRC-
phosphorylation sites on FAK (Y576/577, Y861, Y925) was observed with both 
compounds (Figure 4.6). Both SRC inhibitors also induced further characteristic 
changes in proteins associated with SRC signalling pathways; these include reduced 
phosphorylation of MET (Y1349) and JNK (Y185) as well as compensatory 
upregulation of proteins like total MET, the MAPK pathway (ERK1/2, p38 MAPK, 
MAPKAPK-2) and other downstream targets such as c-Jun, FRA1, STAT3, PI3K and 
NFkB (see chapter 1.2.3). 
 
Apoptotis and cell cycle proteins 
An overall increase in pro-apoptotic proteins (BAK, BAX, BID, BIM) and decrease in 
anti-apoptotic proteins (BCL-2, Survivin, XIAP) could be observed for both 
compounds (Figure 4.6) 365. Although apoptotic cells can be washed off during the 
experiment, which can affect signal intensity of these proteins, the general trend of 
increased apoptosis signalling ties into the results of the caspase 3/7 apoptosis assay 
performed by Fraser et al. 1. The upregulation of PTEN and downregulation of CDK2 
indicates increased cell cycle arrest, which was confirmed in the cell cycle assay done 
in chapter 3.1.2 366.  
 
Other confirmed and refuted changes 
The levels of several other proteins were found to be changed in response to eCF506 
or dasatinib treatment in the RPPA, but this could not always be confirmed by Western 
blot. Both inhibitors seem to influence mTOR signalling by decreasing mTOR (Y2481) 
and increasing total mTOR protein. mTOR (Y2448) also seems to increase but 
Western blot analysis could not confirm this and indeed found levels to be reduced 
using the same antibody (see Appendix A.9). Similarly, β-catenin appears to be highly 
upregulated in both cell lines, but this was not found in Western blots, and the 
upregulation of JNK and downregulation of the oncogene c-Myc could also not be 
confirmed (see Appendix A.9). However, different antibodies were used for these 
Western blots than in the RPPA and the quality of the c-Myc and JNK Western blots 
in particular was poor. Nevertheless, these discrepancies highlight the need for 





The dramatic decrease of BRCA1 and Rb protein in MDA-MB-231 cells after 24 hours 
of treatment with both compounds could be confirmed by Western blot (see Figure 
4.6 and Appendix A.9). Tau protein is also dramatically downregulated in this cell line, 
although none of these three proteins showed a big change in MCF-7 cells. An 
increase in E-cadherin levels in MCF-7 cells and decrease in the E-cadherin 
downregulating protein Slug in MDA-MB-231 cells suggests greater cell-cell adhesion 
with SRC inhibition, which ties into the role of SRC in the turnover of adherens 
junctions (see chapter 1.2.3.1) 367. eCF506 and dasatinib increase H2AX, ATM and 
p53 in the cells and reduce the amount of phospho-Chk, which indicates DNA 
damage, although Western blot confirmation for this is still outstanding 368.  
 
Phospho-FAK (Y397) 
The only consistent and clear difference between eCF506 and dasatinib found in the 
RPPA screening was the differential phosphorylation of tyrosine 397 on FAK; 
dasatinib increased and eCF506 decreased phosphorylation of this residue in a dose-
dependent manner. This was observed after short (3 hours) and longer (24 hours) 
treatment times in both MDA-MB-231 and MCF-7 cells and confirmed by Western blot 
(see Figure 4.7a,b and Appendix A.8). FAK (Y397) is autophosphorylated in response 
to integrin signalling and allows SRC to bind via its SH2 domain (see chapter 1.2.3.1). 
SRC kinase then phosphorylates multiple tyrosine residues on FAK (Y576, Y577, 
Y861, Y925), all of which were found to be downregulated by both eCF506 and 
dasatinib in the RPPA (see Figure 4.6). A previous paper reports a negative regulation 
of FAK (Y397) by phosphorylation of FAK (Y407), a site which has been suggested 
but not conclusively shown to be phosphorylated by SRC 369,370. Phospho-FAK (Y407) 
was not investigated in the RPPA but assessment by Western blot shows that both 
eCF506 and dasatinib reduce phosphorylation of this site, suggesting that this is not 
the cause of FAK’s differential autophosphorylation (see Figure 4.7c).  
 
A likely explanation is that the different inhibitor-induced SRC conformations either 
enable or prevent binding to phospho-FAK (Y397); the open SRC conformation upon 
binding of dasatinib frees the kinase’s SH2 domain to bind phospho-FAK (Y397), 
which could then protect this site from dephosphorylation by phosphatases. This 
hypothesis is supported by the inverse correlation between SRC (Y527) and FAK 




Another Type I inhibitor, bosutinib, had the same effect as dasatinib, while the 
reported Type II but possible Type I1/2 inhibitor saracatinib showed variable results 
with phospho-FAK (Y397) (see Figure 4.5). SYF cells, which are murine embryonic 
fibroblasts deficient for SRC, YES and FYN kinase, exhibited no dose-dependent 
changes in phospho-FAK (Y397) levels when treated with eCF506 or dasatinib (see 
Figure 4.9a). Knockdown of SRC kinase in MDA-MB-231 cells by siRNA found no 
reduction in FAK autophosphorylation, but large variability was observed between 
repeats (see Figure 4.9b). This data suggests that SRC kinase conformation might 
affect FAK autophosphorylation status and that this can be augmented through 



















Figure continued from previous page 
(b) 
 
 Figure 4.6. Hierarchical clustering analysis of the RPPA results. (a) MDA-MB-231 and 
(b) MCF-7 cells were treated with eCF506 or dasatinib for 3 or 24 hours, lysed and analysed 
by reverse-phase protein array on the Zeptosens platform. RFI values were normalised 
globally and are expressed as percentage of the respective DMSO control. Arrows indicate 
phospho-FAK proteins. Hierarchical clustering was done with the free Morpheus software 
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Figure 4.7. Western blot analysis of phospho-FAK in MDA-MB-231 cells treated with 
eCF506 or dasatinib. (a) Phospho-FAK (Y397) and phospho-SRC (Y527) Western blot 
analysis after treatment of MDA-MB-231 cells for 3 or 24 hours. Representative Western blot 
from three biological replicates. (b) Summary of phospho-SRC (Y527) and phospho-FAK 
(Y397) Western blots of MDA-MB-231 cells showing average of three biological replicates with 
standard deviation. Band intensities were quantified using Bio-Rad ImageLab® software, 
adjusted for loading using GAPDH and normalised to DMSO. (c) Western blot of the effect of 
eCF506 and dasatinib on phospho-FAK (Y407) in MDA-MB-231 cells after 24 hours of 
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Figure 4.8. Western blot analysis of phospho-FAK in MDA-MB-231 cells treated with 
bosutinib or saracatinib. (a) Phospho-FAK (Y397) and phospho-SRC (Y527) Western blot 
analysis after treatment of MDA-MB-231 cells for 3 or 24 hours. Representative Western blot 
from three biological replicates. (b) Summary of phospho-SRC (Y527) and phospho-FAK 
(Y397) Western blots of MDA-MB-231 cells showing average of three biological replicates with 
standard deviation. Band intensities were quantified using Bio-Rad ImageLab® software, 












































































































































Figure 4.9. Western Blot analysis of pFAK (Y397) in SYFSRC−/−, YES−/−, FYN−/− cells and SRC 
knockdown in MDA-MB-231 cells. (a) SYF cells were treated with eCF506 or dasatinib for 
24 hours prior to cell lysis and Western blot. DMSO-treated MDA-MB-231 cells were used as 
a control. Left: Representative Western blot. Right: Summary of phospho-FAK (Y397) data 
showing average of three biological replicates with standard deviation. Statistical analysis was 
performed against untreated cells using one-way ANOVA with Dunnett’s correction for multiple 
comparison; p>0.05 (ns). (b) siRNA knockdown of SRC kinase. Mock (lipofectamine), non-
silencing RNA (40 nM) and SRC siRNA (40 nM) were added for 24 hours prior to medium 
change and cells were lysed 96 hours later. Compounds were added to non-silencing RNA 
wells after medium change and treated for 96 hours prior to cell lysis and Western blot. Band 
intensities were quantified using Bio-Rad ImageLab® software, adjusted for loading by 
calculating pFAK (Y397)/FAK and SRC/GAPDH and normalised to DMSO. Left: 
Representative Western blot. Right: Summary graph of three biological replicates with 
standard deviation. Statistical analysis was performed against untreated cells using two-way 
ANOVA with Dunnett’s correction for multiple comparison; p>0.05 (ns), p<0.0001 (****). All 






4.2.2. Dasatinib but not eCF506 forces a stable SRC-FAK interaction 
The results of chapter 4.2.1 suggest that binding of SRC kinase to phospho-FAK 
(Y397) protects this site from dephosphorylation by phosphatases. Dasatinib appears 
to support binding of SRC to FAK, as suggested by FAK’s autophosphorylation status, 
but assessment of the actual protein-protein interaction is necessary to prove this 
hypothesis. Therefore, binding of FAK to SRC in MDA-MB-231 cells was tested in a 
co-immunoprecipitation experiment. Cells were treated for 6 hours with eCF506 (100 
nM), dasatinib (100 nM), bosutinib (1 µM) or saracatinib (1 µM) prior to lysis. SRC 
was immunoprecipitated by magnetic beads and bound proteins visualised by 
Western blot. As SRC inhibitors typically increase the amount of total SRC, FAK levels 
were normalised to the amount of immunoprecipitated SRC.  
The results show that bosutinib and dasatinib treatment significantly increase binding 
of FAK to SRC by two- to three-fold, respectively, compared to DMSO (see Figure 
4.10). Saracatinib also increased binding of SRC to FAK, whereas eCF506 decreased 
binding on average by 50%, although neither was significant when compared to 
DMSO. These findings support the hypothesis that the dasatinib- and bosutinib-
induced open SRC conformation enables stable binding of its SH2 domain to FAK via 
its tyrosine 397 residue, while eCF506 inhibits these interactions. A recent paper has 
made similar observations by showing that dasatinib and bosutinib treatment causes 
localisation of SRC to focal adhesions, while saracatinib does not affect localisation 
of SRC in the cell 363. 
 
SRC kinase has been shown to interact with other proteins in the cell via its SH2 and 
SH3 domains. It is therefore possible that its different conformations with eCF506 and 
dasatinib would also differentially affect targets other than FAK. Co-
immunoprecipitation experiments with other targets were attempted but either failed 
(oestrogen receptor α, paxillin) or limited results showed no changes in protein binding 
(p85 subunit of PI3K) (see Appendix A.10). Further optimisation of the method may 
be necessary to assess less stable or common SRC binding interactions than FAK, 
as bound proteins were potentially removed during washing steps or escaped 
detection due to low concentrations. Many SRC interactions are also formed in 
response to external signals, such as oestrogen inducing binding of SRC to the 
oestrogen receptor or PI3K, which might explain why these were not observed with 





In conclusion, the data presented in this chapter shows that dasatinib and bosutinib 
bind SRC in an active-like, open conformation that can stably bind to FAK and 
potentially other target proteins (= only catalytic activity is inhibited). Saracatinib may 
have similar effects on SRC-FAK binding but its effects are variable. In contrast, 
eCF506 inhibits both the catalytic activity of SRC and forces the protein into an 
inactive, closed conformation that is unable to interact with FAK (= both catalytic 
activity and scaffolding properties of active conformation are inhibited).  
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Figure 4.10. Co-immunoprecipitation of SRC and FAK after drug treatment. MDA-MB-
231 cells were treated with eCF506 (0.1 µM), dasatinib (0.1 µM), bosutinib (1 µM) or 
saracatinib (1 µM) for 6 hours prior to cell lysis and co-immunoprecipitation using SRC 
antibody overnight. Bound proteins were eluted and analysed using Western blot with total cell 
lysates as control. Band intensities were quantified using Bio-Rad ImageLab® software, 
adjusted for loading by calculating FAK/SRC ratio and normalised to DMSO. Left: 
Representative Western blots. Right: Summary graph of three biological replicates with 
standard deviation. Statistical analysis was done using one-way ANOVA with Dunnett’s 
correction for multiple comparison; p>0.05 (ns), p<0.01 (**), p<0.001 (***). All concentrations 




4.3. Dasatinib and eCF506 differentially affect localisation of 
FAK with unclear consequences 
4.3.1. Dasatinib causes nuclear translocation of FAK 
The X-ray crystallography data combined with the co-immunoprecipitation and 
phosphorylation results show clearly that eCF506 and dasatinib differ in their binding 
to SRC and its subsequent binding to FAK. The question remains whether the 
opposite effects on FAK (Y397) phosphorylation of both compounds would have 
different effects on FAK function. 
 
Integrin clusters form focal adhesions which recruit FAK to the cell membrane and 
trigger its autophosphorylation on tyrosine 397 that enables SRC binding (see chapter 
1.2.3.1). However, FAK has also been found in the cell nucleus and studies have 
shown that reduced cell adhesion or FAK inhibition can increase the amount of 
nuclear FAK 373. SRC inhibition affects focal adhesion turnover and eCF506 inhibits 
FAK autophosphorylation similar to the effects seen with FAK inhibitors. It was 
therefore investigated whether eCF506 and dasatinib have differential effects on the 
localisation of FAK in the cell. This was done by performing subcellular fractionations 
of treated breast cancer cells as described in methods 2.4.4; murine squamous 
cancer cells were included as they have previously been used to test the effects of 
nuclear FAK on gene expression 290,293. 
 
The results of the subcellular fractionations show that SRC kinase is mainly located 
in the perinuclear fraction, as described previously, while FAK is mostly in the 
cytoplasmic and perinuclear fractions (see Figure 4.11 and Appendix A.11) 34,373. Both 
eCF506 and dasatinib increase the amount of SRC in all fractions, which has also 
been seen in total cell lysates and is likely due to reduced degradation.  
 
Dasatinib but not eCF506 increases the amount of nuclear FAK in a human breast 
cancer (MDA-MB-231), murine breast cancer (MetBo2) and murine squamous cell 
carcinoma cell line (SCC) but not in three other human breast cancer cell lines (MCF-
7, T-47D, ZR-75.1) (see Figure 4.11 and Appendix A.11). The amount of cytoplasmic 
FAK slightly decreases and/or perinuclear FAK increases in MDA-MB-231 cells and 




is shuttled from the cytoplasm to the nucleus upon dasatinib treatment (see Figure 
4.11b,c). Nuclear translocation of FAK does not seem to be linked to general cell line 
sensitivity to eCF506 or dasatinib, as MDA-MB-231, MetBo-2 and MCF-7 cells are 
much more sensitive than SCC cells in cell viability assays (see Appendix A.12). 
 
Genetically modified SCC cells that were previously generated and validated by 
Serrels et al. were used next to investigate whether the increase in nuclear SRC with 
dasatinib treatment could be due to shuttling of FAK-bound SRC into the nucleus 
rather than reduced degradation 290. SCC cells deficient for FAK (SCC FAK -/-), with 
re-expressed wild-type FAK (SCC FAK WT) or with re-expressed mutant FAK lacking 
the nuclear localisation sequence (SCC FAK NLS) were treated with eCF506 or 
dasatinib and the amount of nuclear FAK and SRC was quantified (Figure 4.12a,b).  
SCC FAK WT and SCC FAK NLS had higher overall levels of FAK than unmodified 
SCC cells (see Figure 4.12c). However, less nuclear FAK was observed in SCC FAK 
NLS cells than in SCC FAK WT cells after dasatinib treatment, which suggests that 
the NLS sequence is at least partially necessary for the dasatinib-induced nuclear 
translocation of FAK (see Figure 4.12a,b). Moreover, the increase of nuclear SRC 
with dasatinib that is observed in SCC FAK WT cells is attenuated in SCC FAK NLS 
cells and reduced even further in SCC FAK -/- cells, even though all have similar 
amounts of total SRC. This indicates that at least some SRC is brought to the nucleus 
by FAK (see Figure 4.12a,b). FAK is still autophosphorylated in the nucleus and co-
immunoprecipitation of the nuclear fraction confirms that it is bound to SRC with 
dasatinib treatment but not with eCF506 or DMSO (see Figure 4.12a,d). Overall, the 
findings suggest that dasatinib induces nuclear translocation of the FAK-SRC 
complex in SCC cells. With the data available, it cannot be confirmed whether this is 
caused by the dasatinib-induced open conformation of SRC and its stable binding to 















































































Figure 4.11. Subcellular fractionation of MDA-MB-231 cells. Subcellular fractionation of 
MDA-MB-231 cells treated with eCF506 or dasatinib (both 0.1 µM) for 6 or 24 hours prior to 
subcellular fractionation and analysis by Western blot. (a) Representative Western blot of cells 
treated for 6 hours and summary table of three biological replicates with standard deviation of 
cells treated for (b) 6 hours of (c) 24 hours. Band intensities were quantified using Bio-Rad 
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  WT 100 304 325 100 416 295 100 128 791 
NLS 100 230 300 100 227 272 100 158 407 




  WT 100 95 80 100 117 95 100 162 1071 
NLS 100 101 97 100 111 167 100 70 221  
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 Figure continued from previous page 
Figure 4.12. Subcellular fractionation and co-immunoprecipitation of SCC cells. (a, b) 
Subcellular fractionation of SCC cells treated with eCF506 or dasatinib (both 0.1 µM) for 6 
hours prior to subcellular fractionation and analysis by Western blot. Representative Western 
blots and summary table of three biological replicates with standard deviation. Band intensities 
were quantified using Bio-Rad ImageLab® software and normalised to DMSO for each 
fraction. L.E. = longer exposure. (c) Western blot of untreated SCC cells. Representative 
Western blot of three biological replicates. (d) Co-immunoprecipitation of FAK in cytoplasmic 
and nuclear fraction. SCC FAK WT cells were treated with eCF506 or dasatinib (both 0.1 µM) 
for 6 hours prior to subcellular fractionation followed by co-immunoprecipitation using FAK 
antibody overnight. Representative Western blot of three biological repeats. All concentrations 





4.3.2. The effects of dasatinib-induced nuclear FAK on gene 
expression are inconclusive 
The results of chapter 4.3.1 show that dasatinib but not eCF506 induces nuclear 
translocation of FAK. It is not clear whether this difference is related to their SRC 
activity or their off-target effects and further experiments are needed to determine the 
cause of FAK shuttling. Moreover, the functional consequences of dasatinib-induced 
nuclear FAK, if any, have not been determined. Serrels et al. have reported that 
nuclear FAK regulates the expression of cytokines and IGFBP3 in SCC cells and 
another study found it affects the expression of VEGFR2; the results of these studies 
are summarised in Table 4.2 290,293,374. The hypothesis is that dasatinib but not eCF506 
might induce similar changes. Thus, expression of these genes was determined by 
real-time PCR in SCC, MetBo2 and HUVEC cells and preliminary results are 
summarised in Figure 4.13. These experiments were only performed once and results 
are thus only indicative.  
 
Table 4.2. Summary of effects of nuclear FAK. 
Gene Proposed nuclear FAK effect Cells Ref 
CCL5 ↑ SCC 290 
CXCL10 ↑ SCC 290 
TGFB2 ↑ SCC 290 
IGFBP3 ↓ SCC 293 
VEGFR2 ↑ MS1 374 
 
Analysis of gene expression changes of known nuclear FAK targets shows that 
eCF506 and dasatinib generally have similar effects (see Figure 4.13). It is very likely 
that their common SRC inhibitory effects have a much greater impact on gene 
expression than differential presence of nuclear FAK. Moreover, the SCC cell lines 
used here exhibited different expression levels of IGFBP3 from what has previously 
been reported and VEGFR2 expression in HUVEC cells, which were used instead of 
mouse endothelial cells (MS1), was very low 293,374. In conclusion, no convincing 
changes consistent with nuclear FAK were observed in the preliminary gene 


























CCL5 1.00 0.17 - 
CXCL10 1.00 0.36 - 
TGFB2 1.00 0.41 - 
IGFBP3 1.00 0.13 0.23 
 



























































CCL5 1.00 0.74 0.7 1.00 1.17 1.45 1.00 0.88 0.78 
CXCL10 1.00 0.59 0.29 1.00 0.38 0.68 1.00 0.20 0.50 
TGFB2 1.00 1.10 1.06 1.00 0.89 0.88 1.00 0.94 0.91 























CCL5 1.00 2.67 2.38 
CXCL10 1.00 0.92 0.91 






























VEGFR2 1.01 3.60 2.08 
 
Figure 4.13. Gene expression changes with eCF506 and dasatinib. SCC, MetBo2 and 
HUVEC cells were treated for 24 hours prior to cDNA extraction and real-time PCR analysis. 
Data represents one average of three technical replicates and was normalised to DMSO 
(except IGFBP3 in MetBo2 for which n = 3 is shown with standard deviation); red = increase, 
blue = decrease relative to DMSO. (a) Relative expression of untreated SCC cell lines. (b) 
Relative gene expression in treated SCC cell lines. (c) Relative gene expression in treated 





4.4.1. eCF506 is a TypeI1/2A inhibitor which might contribute to its 
selectivity  
eCF506 and dasatinib exhibited opposite effects on SRC heat stability in a thermal 
shift assay, giving rise to the hypothesis that they induce different SRC conformations 
(see chapter 4.1.1). This was confirmed by Dr Daniel Lietha who crystallised eCF506 
bound to the SRC kinase domain, revealing its TypeI1/2A binding mode; this makes 
eCF506 the first confirmed compound to potently inhibit SRC in its natural 
autoinhibited state, although PP1 was found to bind HCK in a similar way and the 
reported Type II inhibitor saracatinib appears to actually bind a DFG-in conformation 
(see chapter 4.1.2.1). It is possible that this uncommon binding mode contributes to 
eCF506’s high selectivity across the kinome.  
 
Most kinase inhibitors identified to date are ATP-competitive and bind the ATP-
binding site between the N-lobe and C-lobe of the kinase domain 9,220. This site is 
highly conserved across the human kinome, which makes it difficult to develop highly 
selective inhibitors, and many promiscuous ones such as dasatinib and sunitinib 
interact with several kinases 221. The majority of kinase inhibitors developed to date 
are Type I, a subclass of ATP-competitive inhibitors that bind to the active 
conformation of the kinase. Nevertheless, utilisation of differences in the gatekeeper 
residues between kinases can improve selectivity, for example by enabling binding to 
adjacent hydrophobic pockets 9. X-ray crystallography of eCF506 bound to the SRC 
kinase domain has revealed that its tert-butyl group extends deep into the 
hydrophobic pocket present near the active site, which disrupts a key salt bridge 
between the catalytic lysine and a glutamate residue in the αC-helix (see Figure 4.2). 
As a result, SRC is in a “DFG-in” but “αC helix-out” conformation that resembles its 
natural autoinhibited state, causing eCF506 to be classified as a TypeI1/2A inhibitor 
9,360. This is a similar binding mode as its scaffold PP1 bound to the SFK HCK, which 
is classified as TypeI1/2B binding; however, PP1 is much more promiscuous than 
eCF506 and also inhibits ABL and KIT (see Table 1.3), which suggests that PP1 can 
adopt multiple binding modes. It is possible that this is in part because it does not 
extend beyond the gatekeeper residue and thus lacks additional interactions with 





A study with matched analogues of dasatinib compared the kinome selectivity of (i) 
dasatinib (DFG-in, αC helix-in), (ii) two analogues inducing “DFG-out”, “αC helix-in” 
conformations, and (iii) two analogues inducing “DFG-out”, “αC helix-out” 
conformations 231. It found that the DFG-out motif alone did not make dasatinib more 
selective and indeed was slightly more promiscuous by also binding kinases with non-
threonine gatekeepers; this contradicts previous assumptions that Type II inhibitors 
such as imatinib are generally more selective than Type I inhibitors 375,376. In contrast, 
the αC helix-out analogues were much more selective than αC helix-in analogues or 
dasatinib; in particular, these analogues were unable to bind the entire Ephrin receptor 
family. Notably, eCF506 is also unable to inhibit any of the 12 Ephrin kinases tested 
in the kinome screen (see Appendix A.6). The study of dasatinib analogues and their 
selectivity supports the theory that the αC helix-out conformation and binding in the 
hydrophobic pocket can improve inhibitor selectivity.  
 
While eCF506’s Type I1/2A binding mode might contribute to its superior selectivity 
profile observed in chapter 3.2.1.1, it does not explain its selectivity for SRC over ABL, 
as PP1 and the dasatinib αC helix-out analogues remain equipotent against both 
kinases 231. ABL has also been found to be able to adopt a SRC-like inactive 
conformation as induced by eCF506 in SRC 377. Fraser et al. have previously 
performed in silico docking studies with eCF506 which suggested that its large 
dimethylamino-piperidine group clashes with the tyrosine 253 located in the catalytic 
ATP-binding loop of ABL kinase. However, these studies also assumed that eCF506 
binds the active conformation of SRC; this highlights the fallibility of in silico studies 
and the need to determine eCF506’s binding mode to ABL kinase by X-ray 
crystallography to reliably determine the cause of its selectivity.  
 
A recent paper by Koudelkova et al. assessed several SRC kinase inhibitors in a 
fluorescence resonance energy transfer (FRET) based assay and found a similar 
correlation between binding type and SRC tyrosine 527 phosphorylation as done in 
chapter 4.1.2.2 363. Surprisingly, it showed differences between the two reported Type 
II inhibitors saracatinib and UM-164, with the former inducing a closed autoinhibited 
conformation, while the latter decreased SRC Y527 phosphorylation resulting in an 
open SRC structure that accumulated at focal adhesions. This shows that the general 
kinase inhibitor classification system, in which Type II inhibitors are described as 




its “DFG-inactive” and “autoinhibited-inactive” states are not based on the same 
conformations in the kinase domain. The autoinhibited conformation of SRC kinase 
appears to be defined by an αC helix-out conformation alone, independent of the 
orientation of the DFG motif in the activation loop. This is a likely reason for the 
mislabelling of saracatinib as a Type II inhibitor in the literature, when it actually 
appears to be a Type I1/2 based on its crystal structure. 
  
As kinases undergo switching between different conformations during their catalytic 
cycle, it is unclear whether eCF506 and saracatinib bind the closed, autoinhibited 
SRC kinase and dasatinib and bosutinib only bind the active conformation and 
stabilise these, or whether they can actively force SRC into their preferred 
conformations. The paper by Koudelkova et al. employed a FRET-based SRC 
biosensor and found that dasatinib decreases FRET in WT and constitutively 
activated Y527F SRC, indicating a less compact structure of the kinase; conversely, 
SKI-1, which maintains SRC in an autoinhibited state like saracatinib, increased FRET 
signalling in the constitutively active kinase 363. This indicates that binding of SKI-1 
can partially close SRC even in the absence of the stabilising SH2-binding residue 
tyrosine 527. The authors conclude that inhibitors can have a direct effect on SRC 
opening or closing, based on their induced αC helix orientation, with the conformation 
likely determining the liability of tyrosine 527 to be dephosphorylated by phosphatases 
363. It would be interesting to assess eCF506 in this model to determine whether it can 
also close the constitutively active Y527F SRC kinase or even v-SRC, which lacks 
the inhibitory C-terminus altogether. 
 
 
4.4.2. Inhibitor-induced SRC conformation affects its scaffolding 
functions 
Western blot analysis of tyrosine 527 phosphorylation confirmed that eCF506 and to 
some degree saracatinib maintain SRC kinase in its closed, autoinhibited state, 
whereas dasatinib and bosutinib force it into an open and active conformation. In the 
latter, the SH2 domain is no longer bound by the C-terminus, allowing it to bind other 
proteins and kinases. This means that while all four compounds inhibit the catalytic 




independent scaffolding functions, with eCF506 showing much higher potency 
against SRC than saracatinib.  
In order to determine whether eCF506 and dasatinib differ in their effects on 
downstream signalling pathways, they were tested in a reverse phase protein array 
of two different breast cancer cell lines. The results showed largely similar effects of 
both inhibitors, which agrees with assumptions that most of SRC’s functions are 
dependent on its kinase function. However, contrasting effects on the phosphorylation 
of FAK’s tyrosine 397 residue were observed, which is autophosphorylated upon 
integrin accumulation and forms the SRC binding site. Previous papers have reported 
that dasatinib increases FAK (Y397) phosphorylation but no convincing explanation 
has been offered to this date, although a recent publication suggests that this effect 
limits dasatinib’s potency in liver cancer 158,378,379. Co-immunoprecipitation 
experiments confirmed that this observation correlates with the formation of a stable 
SRC-FAK complex with dasatinib or bosutinib treatment, while eCF506 tends to 
decrease SRC-FAK binding to varying degrees (see Figure 4.10). Brunton et al. have 
previously shown that FAK is more phosphorylated in colon cancer cells with kinase-
defect SRC than with wild-type SRC; only mutation of SRC’s SH2 domain was able 
to reduce FAK tyrosine phosphorylation, while mutation of its SH3 domain or a SRC 
kinase inhibitor showed no changes 135. Addition of kinase-defect SRC to cells with 
kinase-defect FAK also increased FAK tyrosine 397 phosphorylation, proving that 
SRC can affect phosphorylation at this site but not by phosphorylating it directly. This 
agrees with our hypothesis that binding of SRC via its SH2 domain to phospho-FAK 
(Y397) protects this site from dephosphorylation; consequently, compound-induced 
changes of the SRC conformation that affect the SRC-FAK interaction can modulate 
FAK phosphorylation at this site.  
 
While the SRC-FAK complex is the best characterised interaction of SRC in the 
literature, other proteins have previously been found to interact with SRC, such as 
p85 subunit of PI3K and ERα 371,372. While co-immunoprecipitation experiments 
largely failed in non-optimised conditions, limited results indicate that binding of the 
PI3K subunit p85 to SRC’s SH3 domains is not affected by eCF506 or dasatinib (see 
Appendix A.10) 380. Further experiments should assess protein-protein interactions 
after specific stimulation of cell signalling events which are known to induce binding 





Several studies have tried to characterise the non-catalytic functions of SRC by re-
expressing kinase-defective SRC in SRC-deficient cells (see chapter 1.2.3.8). The 
scaffolding roles identified for SRC include the migration of fibroblasts on fibronectin, 
cytoskeletal organisation in osteoclasts, partial rescue of an osteopetrosis phenotype 
in SRC-deficient mice and prolactin receptor signalling via JAK2/STAT5 and 
JAK2/ERK1/2; other kinase-defective SFKs have been implicated in CD4 T-cell 
activation and B cell stimulation 130. Especially the former examples suggest that SRC 
kinase might have a kinase-independent scaffolding role in the cytoskeleton, which 
might be mediated through its interaction with FAK. eCF506, dasatinib and kinase-
defect SRC should be compared in these models to see whether the different inhibitor-
induced SRC conformations have distinct effects. One major limitation in such 
experiments is the promiscuity of kinase inhibitors such as dasatinib, which likely 
confound any differential effects of SRC scaffolding functions with off-target effects. 
Moreover, the limited number of studies on SRC’s kinase-independent roles have so 
far not taken into account protein conformation; while it is likely that cytoskeletal 
scaffolding functions that involve FAK would require the open and active 
conformation, little is known about any potential scaffolding roles of the closed, 
autoinhibited state that is induced by eCF506.  
 
 
4.4.3. Dasatinib but not eCF506 causes nuclear translocation of the 
FAK-SRC complex with unclear functional consequences 
Western blot and co-immunoprecipitation studies revealed differential effects of 
eCF506 and dasatinib on the SRC-FAK interaction and FAK (Y397) phosphorylation 
but the functional consequences of this are not yet clear. A paper utilising a FRET-
based SRC biosensor showed that dasatinib causes translocation of SRC to focal 
adhesions, whereas αC helix-out inhibitors did not, and Lim et al. found that kinase-
defect FAK or FAK inhibition increases FAK nuclear localisation 363,373. Since eCF506 
can decrease FAK (Y397) phosphorylation similar to a FAK inhibitor or kinase-defect 
FAK, and dasatinib induces the opposite effect, subcellular translocation of FAK after 
treatment with both compounds was studied. Subcellular fractionations were 
performed which, interestingly, revealed a big increase in nuclear FAK after dasatinib 
treatment but not with eCF506. Further experiments in SCC cells, previously used by 




partially dependent on the presence of FAK’s nuclear localisation sequence, with a 
five-times smaller increase after dasatinib treatment in FAK NLS mutant SCC cells 
compared to wild-type FAK (see Figure 4.12) 290. eCF506 and dasatinib both 
increased the amount of SRC in the cytoplasmic and perinuclear fraction, although a 
big increase in nuclear SRC was only seen with dasatinib, which was attenuated in 
FAK NLS and FAK KO cells. Further studies confirmed that the nuclear FAK seen 
with dasatinib is phosphorylated on tyrosine 397 and bound to SRC.  
Taken together, this suggests that dasatinib treatment induces FAK translocation from 
the cytoplasm to the nucleus, bringing SRC with it. This observation is opposite from 
what would have been expected based on the observations with FAK inhibitors and 
kinase-defect FAK. It could be that, rather than simply FAK (Y397) phosphorylation, 
the overall conformation of FAK protein plays a role in its subcellular localisation. The 
nuclear localisation sequence is located in the FAK FERM domain, which is bound to 
the kinase domain in autoinhibited FAK381,382; SRC binds to the phosphorylated 
tyrosine 397 residue in the active, open FAK conformation, so it is possible that the 
stable SRC-FAK interaction induced by dasatinib exposes the nuclear localisation 
sequence to cause translocation of the complex 381,382. It is important to note that the 
previous study by Koudelkova et al. showed SRC localises to focal adhesions with 
Type I inhibitors (i.e. dasatinib, bosutinib) and did not report a subsequent localisation 
to the nucleus 363; however, not all cell lines tested in this thesis exhibited nuclear 
translocation of FAK (e.g. MCF-7, ZR-75). Furthermore, several studies have found 
that FAK translocates to the nucleus in response to non-specific cellular stress, such 
as treatment with the highly promiscuous kinase inhibitor staurosporine or hydrogen 
peroxide or after detachment from the substratum 373. It is a possibility that dasatinib’s 
promiscuity exerts more cellular stress than eCF506, even though no inhibition of 
SCC cell proliferation was seen at the 100 nM used (see Appendix A.12). A recent 
conference report associates the presence of nuclear FAK with resistance to dasatinib 
treatment, indicating that the translocation might be a cellular resistance mechanism 
383. Further experiments are needed to determine whether FAK translocates in 
response to stable SRC binding or due to off-target effects of dasatinib on other 
kinases or proteins. This could be done by assessing FAK translocation in SRC 
knockout cells treated with dasatinib, such as SYF fibroblasts, or by comparing the 





Irrespective of the cause of FAK’s nuclear translocation with dasatinib, the question 
remains whether this has any functional consequences. Several studies have linked 
nuclear FAK to p53-degradation leading to increased cell proliferation and survival as 
well as gene expression changes linked to immune evasion 290,293,373. This thesis 
briefly explored the expression of several chemokines that have previously been 
linked to nuclear FAK (CCL5, CXCL10, TGFB2, IGFBP3) in the same SCC model as 
used by Serrels et al.; however, preliminary results identified no changes that could 
consistently be linked to dasatinib-induced nuclear translocation (see Figure 4.13). It 
is likely that any effects of nuclear FAK would be hidden by the potent inhibition of 
SRC kinase and other direct or downstream targets, as SRC activity is known to affect 
the expression of many genes, for example through its activation of STAT3 57. It is 
also possible that the stable dasatinib-induced SRC-FAK interaction that can be 
observed in the nucleus (see Figure 4.12) prevents FAK from interacting with and 
























Guidelines by the International Council for Harmonisation of Technical Requirements 
for Registration of Pharmaceuticals for Human Use (ICH) state three aims for the 
nonclinical evaluation of novel anticancer pharmaceuticals: (i) identification of the 
pharmacological properties, (ii) determination of a safe initial dose for humans, and 
(iii) understanding of toxicological profile of the pharmaceutical 384. The first two 
chapters of this thesis focus mainly on the pharmacological aspect by establishing 
eCF506’s in vitro potency in comparison to other inhibitors and investigating its 
binding mode. This chapter will focus on the in vivo properties of eCF506 by assessing 
its pharmacokinetic properties, toxicities and efficacy in different rodent models.  
 
The experiments presented in this chapter expand on the previous results published 
by Fraser et al., which included several key in vitro assays (cytochrome P450 enzyme 
inhibition profile; hERG channel inhibition; plasma protein binding; stability in 
microsomes, plasma and hepatocytes) and in vivo models (single dose 
pharmacokinetics in mice; SRC inhibition in a mouse xenograft; developmental effects 
in Zebrafish embryos) 1. The additional studies presented in this thesis provide a more 
comprehensive understanding of eCF506’s genotoxicity (Ames test), acute toxicity 
(single dose toxicity in rats), ADME profile (metabolite study; rat PK study) and in vivo 
anti-tumour properties. While more PK and toxicology studies, especially in non-
rodent species, are necessary prior to entry of the compound into clinical trials, the 
current pre-clinical profile of eCF506 shows a generally safe and well tolerated 
compound with some species-dependent variability in PK properties which exhibits 
high potency in certain murine breast cancer models.  
 
This chapter explores the following aims: 
 
• Evaluation of the mutagenicity and acute toxicity of eCF506. 
 
• Further testing of the pharmacokinetic properties of eCF506 in specific body 
compartments and a second rodent species. 
 





5.1. eCF506’s in vivo pharmacokinetic and safety profile  
5.1.1. eCF506 is not mutagenic and has a high maximum tolerated 
dose in rats 
5.1.1.1. Ames test 
This work was done by Sequani Limited, UK.  
 
The mutagenic potential of eCF506 was assessed in an Ames test by the company 
Sequani Limited. The Ames test is commonly used in drug development to detect 
potential carcinogenic effects of novel compounds during the lead identification and 
optimisation phase. It is therefore a critical hurdle that eCF506 needs to pass in order 
to move further into pre-clinical development.  
 
The Ames test determines whether a chemical compound causes mutations in the 
DNA of bacteria. It is performed in auxotrophic bacterial strains that cannot grow in 
the absence of histidine or tryptophan, as they have a genetic mutation in the 
biosynthesis pathway of this amino acid. Exposure to a mutagenic compound can 
reverse this mutation, allowing the growth of revertant bacterial colonies on minimal 
agar. An increased revertant rate compared to a control usually correlates with 
carcinogenicity in animals, with 80-90% accuracy 385. By including mammalian liver 
homogenates this test also detects pro-mutagens that require metabolic activation. 
The battery of strains used in the test of eCF506 included four Salmonella 
typhimurium strains (TA1535, TA1537, TA98, TA100) and one Escherichia coli strain 
(WP2 uvrA), in the presence and absence of a metabolic activation system (S-9 mix). 
This choice allows sensitive detection of both point and frame shift mutations caused 
by the test compound. The test produced no significant increase in the number of 
revertant colonies for any of the five strains over the expected normal variation found 
in the negative control number of revertants (see Figure 5.1). Bacteriotoxic effects 
were seen at the highest concentrations of eCF506 (≥ 1500 µg/plate); these are 
frequently observed at high doses and have also been reported for dasatinib (≥400 
µg/plate) and bosutinib (≥333 µg/plate) at even lower concentrations 386,387. 






5.1.1.2. Acute toxicity study of oral eCF506 in rats 
This work was done by Evotec, France. 
 
The general toxicity of novel small molecule compounds needs to be assessed in 
several repeat-dose toxicology experiments in both a rodent (e.g. mouse, rat) and 
non-rodent species (e.g. dog, pig) to fulfil regulatory requirements for progression into 
clinical trials 384. These involve maximum tolerated dose studies with a single dose or 
treatment for 7 days to determine a suitable dose-range and assess acute toxicity. 
After that, 14 or 28-day toxicity studies are required to determine side effects and 
toxicokinetics of repeated administration.  
 
The first of these studies has now been completed. The single-dose acute toxicity of 
eCF506 was assessed in Sprague-Dawley rats by Evotec (Reference: EVT06968). 
The aim of this study was to determine the maximum tolerated dose (MTD) of eCF506 
after oral administration by gavage of a single dose to male and female rats. 18 
Sprague-Dawley rats were split into five groups, dosed once, observed for 24 hours 
and examined post-mortem. Two different control groups were needed as the vehicle 
concentration had to be doubled to maintain solubility and pH at the highest dose 
tested (700 mg/kg).  
 
No clinical signs were observed for rats treated with 200 or 400 mg/kg eCF506 (see 
Table 5.1). In the group treated with 700 mg/kg, all four rats exhibited clinical signs, 
including faecal soiling, soft faeces, half closed eyes, drop in body temperature, 
tachypnoea and abnormal posture (see Table 5.1 and Figure 5.2a). These started 2 
hours post-dosing, with a peak at 4 hours, and then subsided without disappearing 
fully at 24 hours. Body weight pre- and post-dosing did not differ (Figure 5.2a).  
Haematological analysis found no changes in red blood cell count, haemoglobin 
concentration, haematocrit fraction and mean globular volume (see Figure 5.2b). 
However, a dose-dependent increase in white blood cells and a sharp drop in platelet 
count were observed, especially in female rats. Further analysis of the white blood 
cells showed no dose-dependent changes in lymphocyte numbers, whereas 
monocyte and neutrophil counts more than doubled and tripled, respectively, at most 
tested doses compared to vehicle. It is important to note that both male rats in vehicle 




expected and observed in the male rat of vehicle group 2 or both female vehicle 
groups; they were therefore disregarded in the comparison of haematology results.  
A necropsy was performed 24 hours post-dosing. The main observations were done 
on the digestive tract, with induration and dilation of the stomach, haemorrhagic areas 
and petechiae observed in all treated animals, and intensity of these signs increased 
in a dose-dependent manner. 11 of 12 treated rats also exhibited slight hyperaemia 
of the digestive tract. Reactive Peyer’s patches were observed on all four rats treated 
with 700 mg/kg. Some discoloured areas, petechiae or haemorrhagic areas were 
found on the lungs as well as petechiae on the thymus; however, these lesions are 
likely unrelated to the compound as some were also observed in vehicle animals. 
Granulomatous spleens were found in some treated animals at different doses. No 
notable observations were made on the brain or cranial cavity.  
 
The MTD was determined to be 700 mg/kg for both male and female Sprague Dawley 
rats after a single oral administration. While a lethal dose could not be determined in 
the dose range tested (200-700 mg/kg), clinical symptoms were observed at the 
highest dose tested and suggest that higher doses would have severe side effects or 
cause lethality.  
In comparison, the MTD of dasatinib in the same rat strain and route of administration 
was 30 mg/kg; severe renal and cardiac toxicities and lethality were observed at the 
next highest dose of 100 mg/kg (see Table 5.2) 388. The MTD reported for bosutinib 
in this model was the same as for eCF506 at 700 mg/kg 387. Reversible dose-
dependent gastrointestinal changes, as seen with eCF506, were observed for both 
compounds and dasatinib also caused dose-related bone marrow and lymphoid organ 
toxicities 387,388. No publicly available results have been found for the acute toxicity of 







Figure 5.1. Ames test of eCF506. The mutagenicity of eCF506 was tested in five different 
auxotrophic bacterial strains. Graphs show average of three biological repeats with standard 
deviation. Bacteriotoxic effects: srl = slightly reduced lawn, rl = reduced lawn, nl = no lawn. 
Statistical analysis was done by two-way ANOVA with Dunnett’s correction for multiple 
comparison showed no significant (p>0.05) changes for eCF506, while the controls all 
significantly increased the number of revertant colonies compared to the respective untreated 
control; p>0.05 (ns), p<0.05 (*), p<0.0001 (****). 
 
 
Table 5.1. Sum of clinical scores. Clinical scores describe the sum and severity of adverse 
effects observed in Sprague-Dawley rats at different time points as described in methods 
chapter 2.6.2. Vehicle group 1 received the same vehicle concentration as mice treated with 
200 mg/kg or 400 mg/kg eCF506, while vehicle group 2 received the same vehicle 




































































0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
2 0 0 0 0 0 0 0 4 3 0 0 0 0 0 0 0 2 0 
4 0 0 0 0 0 0 0 4 5 0 0 0 0 0 0 0 3 4 
6 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 1 0 
8 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 2 0 










   
   
   
Figure 5.2. Individual results of acute toxicity study. (a) Body weight and temperature and 
(b) haematology results of individual Sprague-Dawley rats treated with eCF506 in an acute 





Table 5.2. MTD or highest reported doses of eCF506, dasatinib and bosutinib in rodents. 
Summary of MTD as determined in toxicity studies (white background) or the highest dose 
used in published in vivo efficacy studies (grey background). Length of study shown in 
brackets. BID = twice daily. Doses given in mg/kg. 
  
Dose Route eCF506 Dasatinib Bosutinib 
Mice 
Single  
Oral 50 - 2,000 387 
IP 20 - 20 387  
Repeat Oral 40 (3 months) 50 (8 weeks, 5-on 2-off) 389 100 (21 days, BID) 390  
Rats 
Single  
Oral 700  30 (<100) 388 700 387 
IP - - 70 387 
Repeat Oral - 
15 (2 weeks, daily), 
15 (1 month, 5-on 2-off), 
4 (6 months, daily) 388 
100 (7 days, daily), 
70 (1 month, daily), 






5.1.2. Pharmacokinetic and metabolite profile of eCF506  
5.1.2.1. Pharmacokinetic evaluation in Sprague-Dawley rats 
This work was done by Evotec, France. 
 
The pharmacokinetic properties of eCF506 have previously been evaluated by Fraser 
et al. in a mouse model 1. In order to confirm that the high MTD of the acute toxicity 
study (see chapter 5.1.1.2) is not due inadequate exposure to eCF506, additional 
pharmacokinetic testing in Sprague-Dawley rats was performed by Evotec, France.  
 
Pharmacokinetic parameters were measured in male Sprague-Dawley rats after 
single intravenous (1 mg/kg) or oral dose (10 mg/kg, 200 mg/kg) for 24 hours. The 
plasma concentration time profile is shown in Figure 5.3 and the full dataset is shown 
in Appendix A.13. The systemic pharmacokinetic parameters for this study as well as 
previous reported studies with eCF506, dasatinib and bosutinib in mice and rats are 
shown in Table 5.3 for comparison.  
 
While eCF506 had a generally favourable pharmacokinetic profile in mice in 
comparison to dasatinib, it was unable to achieve comparable exposure times and 
concentrations in rats at the same dose. In mice, the maximum plasma concentration 
(Cmax) of eCF506 (oral gavage, 10 mg/kg) was nearly 200 nM, with dasatinib achieving 
half this concentration at half the dose (see Table 5.3) 391,392. However, in rats treated 
the same way, eCF506 only achieved a concentration of 32 nM in plasma, which was 
over 15 times lower than the reported value for dasatinib (490 nM) at the same dose 
391. Dasatinib was also able to sustain concentrations over 100 nM for the whole 
duration of the study (10 hours), while eCF506 was only detectable in the rats from 2-
7 hours post-dosing (see Figure 5.3) 391. Bosutinib also had a much lower exposure 
in male rats than dasatinib, with a similar Cmax and area under curve (AUC) reported 
at 50 mg/kg as for dasatinib at a fifth of the concentration; however, exposure was 
higher in female rats 393. 
The half-life (t1/2) of intravenous eCF506 was also significantly reduced in rats 
compared to mice (0.5 hours and 2.9 hours, respectively) as well as in comparison to 
dasatinib (3.3-6.7 hours), although it is important to note that eCF506 was tested at a 
ten-fold lower dose than dasatinib in rats (1 mg/kg vs 10 mg/kg). eCF506 showed a 




which indicates that it passes rapidly from blood to tissues; this could be a reason for 
its low plasma half-life in rats. However, bosutinib still achieved a better half-life with 
similar Vdss values in both rodent species and dasatinib had a much shorter half-life 
in mice than eCF506 despite a comparatively lower volume of distribution. Therefore, 
it currently remains unclear why eCF506 performed worse in rats than in mice when 
given via intravenous injection. 
 
After administration of eCF506 to male rats by oral gavage at 10 mg/kg, the compound 
only had an oral bioavailability of 13%, which was half that found in mice and of 
dasatinib in rats. The comparatively poor performance of eCF506 in rats when given 
orally could be due to a higher first pass metabolism than in mice. The sex-specific 
differences seen with bosutinib indicate that eCF506 could perform differently in 
female rats. 
 
The results of treating Sprague-Dawley rats orally with 10 mg/kg were suggesting that 
the toxicology study done in chapter 5.1.1.2 might have yielded good results due to 
low exposure of the test animals to the compound. However, the doses used in the 
toxicology study were more than 20-fold higher than in the pharmacokinetic one. As 
higher doses can saturate metabolic clearance pathways and can be absorbed in the 
gastrointestinal tract over a longer period, it was likely that higher exposure was 
achieved than could be predicted from using 10 mg/kg. Therefore, eCF506 was tested 
again in the rat pharmacokinetic model at a single dose of 200 mg/kg (see Table 5.3 
and Figure 5.3). Oral bioavailability was much improved at the higher dose (45%) and 
the plasma concentration was greater than 95 nM throughout the whole study; it even 
increased with time to over 700 nM at 24 hours and a longer study is needed to 
definitively determine the Cmax and Tmax at this dose. Even though the compound had 
not been cleared from the system after 24 hours, the AUC was 3.5-fold higher than 
expected based on results from the 10 mg/kg oral dose, demonstrating much higher 
exposure. 
 
This study gives confidence in the findings of the toxicology study by showing that 
high and sustained exposure to eCF506 was achieved in rats at the doses tested. 
However, it also highlights the fact that animals should have been observed for longer, 
even though clinical symptoms were subsiding over time, as plasma concentrations 




Table 5.3. In vivo pharmacokinetic data of eCF506, dasatinib and bosutinib. Data based 
on PK studies performed with eCF506 by Evotec or as reported in the literature. IV = 
intravenous administration, IA = intraarterial administration, IPT = intraportal administration, 
PO = oral administration, AUC = area under curve, t1/2 = half-life, Cmax = maximum plasma 
concentration, Tmax = time to reach maximum concentration, CL = clearance, Vdss = volume of 
distribution (steady-state), F = bioavailability. Diluent: a saline solution; b propylene glycol:water 
























































































































eCF506 10 a 8 F/3 2.07 2.9 - - 72.3 11.8 - 1 
Dasatinib 
10 b 6 F/3 2.86  0.9 - - 61.7 4.2 - 391 
5 b 24 F/3 0.92 0.8 - - 98 6.1 - 392 
Bosutinib 5 - - 2.22 4.8 - - 37.5 11.5 - 393 
PO 
eCF506 10 c 8 F/3 0.53 - 0.196 2 - - 25.3 1 
Dasatinib 
5 b 8 F/3 0.22 2.5 0.104 2 - - 17 391 
15 b 8 F/3 0.58 2.0 0.320 2 - - 14 391 
5 b 24 F/3 0.42 - 0.119 1 - - 45 392 
2.5 b 24 F/3 0.24 - 0.99 1 - - 51 392 
1.25 b 24 F/3 0.11 - 0.050 1 - - 48 392 




IV eCF506 1 d 24 M/3 0.06 0.5 0.484 - 252 14.2 -  
IA 
Dasatinib 
10 b 10 M/3 6.78 3.3 13.2 - 26.4 6.3 - 391 
IPT 10 d 10 M/3 7.66 6.7 7.5 0.5 - - - 391 
IV Bosutinib 5 - 
M 0.66 2.5 1.218 - 128 15.2 - 393 




10 e 24 M/3 0.08 - 0.032 - - - 13  
200 e 24 M/3 5.53 >24 0.806 2 621 - 45  
Dasatinib 10 b 10 M/3 1.85 3.1 0.49 2.3 - - 27 391 
Bosutinib 50 - 
M 1.51 3.7 0.422 3 - - 23 393 




Figure 5.3. Pharmacokinetics of single dose eCF506 in Sprague-Dawley rats. Graph 
shows average of three rats per experiment with standard deviation. Calculated parameters 




5.1.2.2. Metabolite study 
This work was done by Cyprotex, UK. 
 
eCF506 has previously been tested for its in vitro metabolic stability in human and 
mouse hepatocytes 1. However, it has not yet been determined what its main 
metabolites are after breakdown in the liver. This is important as metabolites that 
retain potency against the target can contribute to the overall efficacy of a drug. 
Conversely, other metabolites have been found to cause toxicity, one example being 
the paracetamol metabolite N-acetyl-p-benzoquinone imine that can damage the liver 
when not cleared fast enough 394. Therefore, it is important to determine the metabolite 
profile of a novel compound early on during drug development.  
In order to get a better understanding of how eCF506 is broken down by hepatocytes, 
it was tested in a second human hepatocyte stability assay that was followed by 
metabolite profiling (performed by Cyprotex, UK). Cryopreserved human hepatocytes 
were treated with eCF506 (3 µM) and samples analysed using a Q-Tof UPLC-MS/MS 
platform at different time points over the course of the 120-minute experiment (see 
Figure 5.4 and Appendix A.14). Metabolites are identified by comparison against a 
time zero control and quantified using the area percentage of the LC-MS 
chromatogram. The fragmentation patterns were used for structural elucidation of the 
metabolites which are shown in Figure 5.5. 
 
The calculated half-life of eCF506 in human hepatocytes was less than a third of that 
reported previously (212 and 751 minutes, respectively, see Figure 5.4b,c). Due to 
the expected differences between donors of primary hepatocytes, variability between 
experiments is expected and can be seen in the slower breakdown of the control 
compound umbelliferone and the faster clearance of verapamil in the second assay. 
In this experiment, approx. 70% of eCF506 remained after 2 hours of incubation, 
which is slightly lower than the 78% of dasatinib after 3 hours measured in a previous 
experiment with human hepatocytes 395. However, these two compounds should be 
tested head-to-head to properly compare them due to the high assay variability.  
 
Metabolite profiling revealed four major metabolites of eCF506 after 2 hours (see 
Figure 5.5). The main metabolite, making up 19% of the drug-related components, is 




metabolites are oxidations of different parts of the molecule and make up 1-7% of the 
drug-related components.  
 
Based on structure activity relationships found by the Innovative Therapeutics Lab for 
this scaffold, it is likely that the N-demethylated metabolite retains some activity 
against SRC kinase; this is currently being investigated further 1. A possible O-
demethylation of the methoxy-group on the benzene ring was not found in this assay, 
which is positive as this molecule has previously been found to have no activity in cell 
viability assays (EC50 = 9.71 µM in MDA-MB-231 cells, see compound 12s in Fraser 
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eCF506 6.55 0.334 212 
Verapamil 88.8 3.13 15.6 






(µL/min/106 cells)  





eCF506 1.84 0.989 751 
Verapamil 60.8 1.3 22.8 
Umbelliferone 150 0.8 9.7 
Mouse 
eCF506 12.5 0.447 110 
Verapamil 317 21.6 4.4 
Umbelliferone 983 135 1.4 
 
 
Figure 5.4. Hepatocyte stability of eCF506. (a, b) Human hepatocytes were incubated for 
120 minutes prior to analysis of drug metabolites in the medium by liquid chromatography and 
mass spectrometry. The average of six biological repeats was used to calculate intrinsic 
clearance (CLint) with standard error and half-life (t1/2). (c) Results of a previous study of 






Metabolite Formula [M + H]+ Time 
Peak area % 
0 min 60 min 120 min 
eCF506 C26H38N8O3 511.31 6.98 100 84.66 69.64 
Demethylation C25H36N8O3 497.30 6.84 0 10.33 19.10 
Oxidation 1 C26H38N8O4 527.31 5.16 0 1.66 7.05 
Oxidation 2 C26H38N8O4 527.31 5.37 0 2.29 1.14 






Figure 5.5. Metabolite profile of eCF506. (a) Summary table of results. (b) Structures of 
identified metabolites. Metabolites were analysed from their fragmentation patterns in the LC-
MS chromatogram after incubation of human hepatocytes with eCF506 for 60 or 120 minutes. 











5.1.3. eCF506 can reach the brain and retina in mouse models at 
efficacious concentrations 
5.1.3.1. eCF506 can cross the blood brain barrier in mice 
This work was done by Dr Alaide Morcavallo and Nikita Locket (group of Prof Louis 
Chesler) and Louise D Johnson and Ruth R Ruddle (group of Dr Florence I Raynaud) 
at the Institute of Cancer Research, London, UK. 
 
Elevated SRC signalling has recently been identified as a key hallmark in type 4 
medulloblastoma, the most common malignant brain tumour in children 162. A SRC 
inhibitor could therefore have potential efficacy in this setting. The group of Prof Louis 
Chesler at the Institute of Cancer Research in London is currently investigating the 
use of eCF506 in in vitro and in vivo medulloblastoma models. One important factor 
to consider in this disease setting is the ability of a SRC inhibitor to penetrate the 
blood brain barrier. This was assessed for eCF506 by Dr Alaide Morcavallo in a 
pharmacokinetic study done in highly immunodeficient NSG mice.  
 
eCF506 (40 mg/kg) was injected intraperitoneally and mice were sacrificed at different 
time points over an 8-hour period to collect blood and brain samples, from which the 
eCF506 concentration was determined by LC-MS/MS (see method 2.6.3.2). Plasma 
concentrations dropped over the course of the study from 4.2 to 1.8 µM (see Figure 
5.6). The concentration measured in the brain was more consistent and increased 
with time from 498 nM (0.5 hours) to 763 nM (8 hours). The brain to plasma ratio 
ranged from 12-43%, which is much higher than previously reported for dasatinib in a 
SCID mouse model with intracranial CML tumours (3.2-8.6%) 396. 
 
Both plasma and brain concentrations far exceeded those needed for effective 
phospho-SRC inhibition in vitro over the 8-hour period. This suggests that eCF506 
could potentially be used to treat SRC-related diseases in the brain or central nervous 










Average Concentration (nM) Brain:Plasma 
ratio Plasma Brain 
0.5 4158 (±714, n=3) 498 (±17, n=3) 0.12 
1 3455 (±1121, n=3) 714 (±225, n=3) 0.21 
2 2136 (±257, n=3) 655 (±127, n=3) 0.31 
4 1806 (±17, n=3) 657 (±101, n=3) 0.36 
8 1764 (±341, n=2) 763 (±152, n=3) 0.43 
 
Figure 5.6. Pharmacokinetic study of eCF506 in the brain. Analysis of concentration versus 
time in blood and brain samples from NSG mice after intraperitoneal administration of 40 
mg/kg eCF506. Table shows average with standard deviation and number of mice per group 






5.1.3.2. eCF506 can inhibit SRC activity in the retina of mice 
This work was done by Oxurion (formerly Thrombogenics), Belgium.  
 
Retinopathies have been linked to aberrant angiogenesis and eCF506 has been 
found to inhibit blood vessel outgrowth in an ex vivo murine choroid transplant (see 
chapter 3.1.5). As it was not clear whether eCF506 can reach the retina at biologically 
relevant concentrations, an in vivo experiment was done by Thrombogenics, Belgium, 
to assess target inhibition in mouse retinas.  
 
Male C57BL/6J mice received one intraperitoneal injection of eCF506 (10 mg/kg) one 
hour prior to stimulation of SRC phosphorylation by intravitreal injection of murine 
VEGF. Mice were culled after 30 minutes, enucleated and retinas isolated. Western 
blot analysis was performed to assess levels of total and autophosphorylated SRC 
kinase (see Figure 5.7). eCF506 was able to significantly reduce the amount of 
phospho-SRC (Y416) by more than 50% compared to control. This suggests that 
eCF506 is present and functionally active in the retina for at least 90 minutes and is 
able to inhibit SRC phosphorylation induced by VEGF pulse. It is likely that higher 






Figure 5.7. SRC levels and activation in mouse retinas after eCF506 treatment and VEGF 
stimulation. Phospho-SRC Y416 (left) and total SRC (right) were assessed by Western blot 
and signal normalised to loading control (β-actin). Graphs show average of four retina samples 




5.2. eCF506 shows model-dependent efficacy in vivo 
 
5.2.1. eCF506 and dasatinib were not potent in an MDA-MB-231 mouse 
xenograft model 
This work was done by Dr John Dawson and Morwenna Muir at the Institute of 
Genetics and Molecular Medicine, University of Edinburgh, UK. 
 
The human breast cancer cell line MDA-MB-231 has been shown to be highly 
sensitive to eCF506, with inhibition of proliferation and migration seen at nanomolar 
concentrations in vitro (see chapter 3.1.1.2) 1. It was therefore further investigated in 
a murine xenograft to compare eCF506’s potency against dasatinib in vivo. 
 
CD-1 nude mice received subcutaneous bilateral implantations of MDA-MB-231 
fragments and tumours were allowed to grow until they reached 20 mm3 in size. Mice 
were treated with eCF506, dasatinib (both 25 mg/kg) or vehicle (saline) once daily by 
oral gavage for 25 days and the measured tumour sizes are plotted in Figure 5.8. 
Both eCF506 and dasatinib were unable to prevent the growth of MDA-MB-231 
xenografts, although the latter showed some significant effect towards the end of the 
treatment period. Tumours treated with eCF506 were slightly but not significantly 
bigger than controls throughout the study, while those treated with dasatinib were 
smaller; this correlates with corresponding slight differences in tumour size between 
the groups at the start of the study. On the final day of the study, a small decline in 
tumour size was observed for 3 of the 4 remaining tumours treated with eCF506 and 
8 of the 10 dasatinib treated ones. However, this was only found to be significant for 
dasatinib (p = 0.0002) when compared to control; notably 5 of the 9 remaining vehicle-
treated tumours also slightly reduced in size.  
 
The results of this study suggest that the treatment with daily doses of eCF506 at 25 
mg/kg does not have antiproliferative effects in a murine xenograft of MDA-MB-231 
breast cancer cells, while dasatinib only showed limited potency after three weeks. A 
longer study would be needed to determine whether the reduction in tumour size on 
the final day is treatment-related and whether eCF506 could produce significant 









Figure 5.8. MDA-MB-231 xenograft in mice treated with eCF506 or dasatinib. (a) Graphs 
show average tumour volume with standard error (top) and individual tumour volumes (bottom) 
of CD-1 nude mice treated with saline, eCF506 or dasatinib (both 25 mg/kg). eCF506 and 
dasatinib were compared to vehicle group by two-way ANOVA with Dunnett’s correction for 
multiple comparison; eCF506 did not differ significantly from vehicle at any point, while 
dasatinib was significantly more potent at the last two measurements, with p<0.05 (*), p<0.001 




5.2.2. eCF506 potently reduces tumour growth in syngeneic mouse 
models of metastatic breast cancer 
5.2.2.1. MetBo2 cells as a murine model of metastatic breast cancer 
Due to the role of SRC kinase in cell migration and the bone environment, SRC 
inhibitors have frequently been tested in models of cancer metastasis and in particular 
in patients with breast cancer bone metastases (see chapters 1.2.3.1, 1.2.3.5, 1.3.2). 
Therefore, the in vivo potency of eCF506 was tested in the murine breast cancer cell 
line MetBo2 which has similar characteristics to human triple negative breast cancer 
and preferentially metastasises to the bone.  
This cell line was created by the group of Dr Bin-Zhi Qian at the University of 
Edinburgh, UK, by cardiac injection of the murine breast cancer cell line Met1 into 
syngeneic mice and selection of metastatic lesions in the bone; the selection process 
was repeated in a second round to obtain the bone-tropic cell line MetBo2. 
 
Prior to testing this cell line in vivo, it was assessed in several in vitro assays for its 
sensitivity to eCF506. Western blot analysis of the parental Met1 and derived MetBo2 
cell line revealed a doubling of SRC activation in the latter but only minor changes in 
downstream FAK activity between the two (see Figure 5.9a). This was expected, as 
Zhang et al. have previously shown that bone metastatic MDA-MB-231-derived cells 
have increased levels of SRC autophosphorylation 92. However, when both cell lines 
were tested in a 2D cell viability assay, they did not exhibit differences in their 
sensitivity to eCF506 (see Figure 5.9b). When MetBo2 sensitivity was tested in a 
panel of five SRC/ABL inhibitors, it was found that they were nearly ten-fold more 
sensitive to dasatinib than eCF506 (GI50 of 41 nM and 297 nM, respectively) (see 
Figure 5.9c,d and Appendix A.15).  
 
However, previous experiments have shown that results obtained in this 2D cell 
viability assay do not necessarily translate into 3D (see chapter 3.1.4); therefore, 
MetBo2 cells were further assessed in a 3D spheroid assay as performed previously 
(see methods 2.2.2.4). The results from this experiment differed strongly from those 
obtained previously in three other human breast cancer cell lines, as MetBo2 cells 
remained highly sensitive to treatment in the spheroid assay (see Figure 5.10 and 
Figure 3.4). While untreated MetBo2 spheroids doubled in size during the seven days, 




50% compared to pre-treatment size. This is opposite from what has been observed 
for human breast cancer spheroids, where only high concentrations of eCF506 or 
dasatinib were able to reduce spheroid size significantly. Furthermore, eCF506 was 
significantly more potent at reducing spheroid size at 10 nM than at one thousand-
fold higher concentration and it appeared slightly better than dasatinib at lower 
concentrations, which is opposite from what would have been expected from the 2D 
cell viability assays (see Figure 5.9 and Figure 5.10). However, staining with calcein-
AM and propidium iodide for live and dead cells, respectively, shows more dead cells 
after treatment with dasatinib than with eCF506 and at higher concentrations of both 
compounds; this suggests that spheroid size does not directly reflect cytotoxicity in 
this cell line.  
 
Based on the potent results of the spheroid assay, a second 3D mammosphere assay 
was performed to assess the effects of eCF506 and dasatinib on the MetBo2 stem-
like cell subpopulation. Cancer stem cells have the capacity to self-renew and have 
been reported to be especially resistant to treatment; targeting them effectively is 
therefore essential to prevent relapse 397. Previous studies have found that SRC and 
FAK inhibitors can target cancer stem cells, which highlights the potential benefit of 
combining standard therapy with SRC inhibitors 398,399. The mammosphere assay 
performed in this thesis is based on the protocol published by Shaw et al. and modified 
as described in methods 2.2.2.5 295. A single cell suspension was seeded sparsely in 
serum-free mammosphere medium in non-adherent plates, treated with eCF506 or 
dasatinib (both 100 nM) and allowed to form mammospheres for 5 days. These were 
disaggregated, re-seeded as single cells and treated again for 5 days in a second 
generation. Only mammospheres with a diameter over 50 µm were counted after each 
generation and the mammosphere forming efficiency (MFE) and self-renewal rate 
were calculated as described by Shaw et al. 295. The results of three biological repeats, 
plotted in Figure 5.11, show that both eCF506 and dasatinib were able to significantly 
decrease the MFE and self-renewal rate of MetBo2 cells. As seen previously in the 
spheroid assay, eCF506 was slightly but not significantly more potent than dasatinib. 
Shaw et al. have previously assessed the mammosphere forming ability of several 
breast cancer cell lines in their assay and found a maximum MFE of around 2.5% 295. 
MetBo2 cells have a MFE nearly twice as high, which suggests they have a high 
proportion of stem-like cells; this is in line with unpublished findings by the group of 




The self-renewal rate is a measure of the ability of one cell from a primary 
mammosphere to self-renew and form another mammosphere in the second 
generation. Shaw et al. found that mammospheres undergo asymmetric self-renewal, 
while other groups found symmetric self-renewal based on an increase in 
mammosphere number in later generations 295,400. MetBo2 had a self-renewal rate of 
around 2, with twice as many mammospheres observed in the second generation; 
this suggests symmetric self-renewal and combined with high MFE it supports the 
hypothesis of high stem cell activity in this cell line.  
One limitation of this study is the pre-defined mammosphere size cut-off of 50 µM, 
which excludes detection of stem cells with reduced proliferative ability that result in 
smaller spheroids. eCF506 and dasatinib are both potent inhibitors of cell proliferation 
and 3D spheroid size which likely could have skewed the MFE results in the primary 
generation. However, by comparing mammospheres between the second and first 
generation, it is possible to distinguish between inhibition of proliferation or self-
renewal 295. Therefore, eCF506 appears to be a potent inhibitor of both cell 
proliferation and self-renewal of MetBo2 stem cells in vitro. Further experiments 
should be done to confirm the stem cell-targeting properties of eCF506, for example 
an in vivo assay with serial transplantation, which is the gold-standard for assessing 
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(d)  eCF506 Dasatinib Bosutinib Saracatinib Imatinib 
Met1 0.108 (0.0184) 0.0408 (0.0188) 0.597 (0.200) 0.429 (0.0853) 7.80 (1.74) 
MetBo2 0.297 (0.0955) 0.0406 (0.0112) 0.729 (0.244) 0.854 (0.184) 12.5 (5.82) 
  
Figure 5.9. In vitro sensitivity and SRC signature of Met1 and MetBo2 cells. (a) The 
amount of phospho-SRC (Y416) and phospho-FAK (Y861) was quantified relative to the 
amount of total protein in both Met1 and MetBo2 cells. Statistical analysis by unpaired t-test; 
p<0.05 (*), p<0.01 (**). (b) Cell proliferation of Met1 and MetBo2 cells treated for 5 days with 
eCF506. Viability was measured using PrestoBlueTM reagent and adjusted to viability prior to 
treatment. Graph shows average of three biological repeats with standard deviation. (c) Cell 
proliferation of MetBo2 cells treated for 5 days with different kinase inhibitors. Viability was 
measured using PrestoBlueTM reagent and adjusted to viability prior to treatment. Graph shows 
average of three biological repeats with standard deviation. (d) Summary of GI50 values of 
Met1 and MetBo2 cells treated with different kinase inhibitors. Values were calculated from 
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Figure 5.10. MetBo2 spheroids treated with eCF506 or dasatinib. Spheroids size was 
measured before and after four or seven days of treatment from a collapsed Z-stack image 
using CellProfiler software. Data was normalised to spheroid size prior to treatment start. Data 
represents average of three biological replicates with standard deviation. Top left: Graph 
showing spheroids size as percentage of size prior to treatment start. Top right: Comparison 
of spheroid size after seven days of treatment. Statistical analysis was done using two-way 
ANOVA with Tukey correction; p>0.05 (ns), p<0.01 (**), p<0.0001 (****). Images show 
representative spheroids using brightfield microscopy or fluorescent microscopy after staining 
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Figure 5.11. MetBo2 mammosphere assay. A single cell suspension of MetBo2 cells in non-
adherent plates was treated for five days with eCF506 or dasatinib (both 100 nM). First 
generation mammospheres were disaggregated, re-seeded at the same density and treated 
again for five days. First and second generation mammospheres were imaged using the 
ImageXpress platform and quantified using CellProfiler, with only mammospheres with a 
diameter over 50 µm being included. Graphs show mammosphere forming efficiency (MFE) 
and self-renewal rate calculated as described by Shaw et al. from three biological repeats with 
standard deviation 295. Photos show representative second generation mammospheres. Scale 





5.2.2.2. eCF506 and dasatinib affect MetBo2 cytokine signalling  
The cytokine array was done by Kenneth Macleod from the Drug Discovery group of 
Prof Neil Carragher at the University of Edinburgh, UK.  
 
Several papers have previously shown that nuclear FAK and FAK inhibitors affect 
cytokine expression and secretion by murine squamous cell carcinoma (SCC) cells 
290,293. eCF506 and dasatinib have different effects on nuclear FAK (see chapter 4.3.1) 
but no consistent changes in gene expression could be identified in SCC cells (see 
chapter 4.3.2). Nonetheless, it is possible that eCF506 and dasatinib differ in their 
effects on cytokine secretion, whether due to their differences in nuclear FAK or 
selectivity across the kinome. As eCF506 is tested in multiple in vivo models of 
MetBo2 cells that show high potency and might involve immune system activation 
(see following chapter), its effect on cytokine secretion was tested in this cell line and 
compared to dasatinib in a cytokine array. Cells were treated with four concentrations 
of each compound (3 nM, 10 nM, 30 nM, 100 nM) for 48 hours prior to collection of 
the supernatant and analysis using capture antibodies in a microarray. Cytokine levels 
were adjusted for protein concentration of cell lysates. 22 of 64 antibodies tested gave 
a signal that was significantly above background and their results are plotted in Figure 
5.12 as percent secretion of DMSO control.  
In general, eCF506 and dasatinib had very similar effects, although dasatinib 
appeared to be more potent than eCF506 at upregulating cytokine secretion; this is 
affected by normalisation to protein concentration, as dasatinib is a stronger inhibitor 
of MetBo2 cell viability (see Figure 5.9c). While dasatinib but not eCF506 treatment 
caused nuclear translocation of FAK in MetBo2 cells (see Appendix A.11), this did not 
seem to differentially affect cytokine secretion and results could thus not be linked to 
previous findings in SCC cells 290,293. 
 
Both eCF506 and dasatinib upregulated secretion of several cytokines, especially at 
high concentrations (e.g. amphiregulin, CCL2, CCL3, CCL5, CXCL1, G-CSF, 
IGFBP5, IL-6, IL-1RA, lipocalin-2, osteopontin, pentraxin-3, PIGF2). Most notably, IL-
1RA was 6.5- and 30-fold increased and IGFBP5 was increased 3- and 4.5-fold by 
100 nM eCF506 and dasatinib, respectively. IL-6 and CCL11 were mostly decreased 
by eCF506 and lower concentrations of dasatinib, but increased 12-fold (IL-6) and 3-




Several cytokines were downregulated by eCF506 and dasatinib. In particular, levels 
of VEGF and CXCL2 were reduced by 70-90% and moderate inhibition (<50%) was 
seen for TNF-alpha, IL-12, MMP-3 and GM-CSF.  
Overall, both compounds affected secretion of several cytokines, with IL1-RA, IL-6, 
IGFBP5, CXCL2 and VEGF showing the biggest changes. While the question remains 
to which degree these signalling changes would also be observed in an in vivo model 





Figure 5.12. Cytokine array of MetBo2 cells. MetBo2 cells were treated with eCF506 or 
dasatinib for 48 hours prior to analysis of the medium by capture antibodies. Concentration of 
secreted proteins was adjusted for protein concentration of lysed cells and normalised to 
DMSO control (blue = decreased, red = increased secretion relative to DMSO). Clustering was 
performed using Morpheus software by the Broad Institute using Euclidian distance and 




5.2.2.3. eCF506 reduces bone metastases in a murine breast cancer 
model 
This work was done by Dr Xue-Feng Li in the group of Dr Bin-Zhi Qian at the University 
of Edinburgh, UK. 
 
After in vitro assessment of eCF506 in the bone-tropic murine breast cancer cell line 
MetBo2 indicated high sensitivity (see chapter 5.2.2.1), an in vivo experiment in a 
syngeneic bone metastasis model was performed by the group of Dr Bin-Zhi Qian at 
the QMRI, University of Edinburgh, UK. 
 
Immunocompetent FVB mice received intracardiac injections of MetBo2 cells, which 
leads to metastasis formation in the hind legs and jaw bones. As MetBo2 cells were 
engineered to express luciferase, metastasis growth was monitored via 
bioluminescence imaging twice a week. Metastases were allowed to develop until 
bioluminescence intensity (BLI) in the hind legs was greater than 2000 for each group, 
before treatment with daily eCF506 (40 mg/kg) or vehicle by oral gavage was started 
for 28 days. No obvious toxicity was observed in the treatment group during the 
duration of the study and the mice exhibited normal behaviour and slight weight gain. 
 
BLI of hind leg bone metastases were quantified and plotted in Figure 5.13a. This 
model is highly aggressive with bone metastases progressing quickly and control 
mice having to be sacrificed after one to three weeks. eCF506 was able to significantly 
reduce BLI after four days of treatment compared to vehicle-treated mice (see Figure 
5.13b). Four of the six eCF506 treated mice showed significant regression of hind leg 
metastases (see Figure 5.13c), while the other two exhibited slower growth than 
control mice. Treatment was stopped after 28 days and the residual BLI in the hind 
legs of the surviving treated mice remained stable during the following five weeks. 
However, two mice developed metastasis in the thoracic cavity during this time and 
their treatment was resumed at day 63 to establish whether these tumours would still 
respond (see Figure 5.13d). The relapsed metastases of both mice differed vastly in 
size but both regressed during 7 days of re-treatment (see Figure 5.13), after which 














Figure 5.13. eCF506 in a syngeneic murine breast cancer bone metastasis model. (a) 
Left: % BLI in hind legs of vehicle- and eCF506-treated mice relative to day 0. Each hind limb 
is shown separately. Treatment was continued for 28 days and then stopped. Right: 
Representative images of mice 7 days after treatment start. (b) Comparison of % BLI between 
vehicle- and eCF506 treated mice 4 days post treatment. Each hind limb was quantified 
separately. Statistical analysis by unpaired t-test. (c) Comparison of absolute BLI signals of 
the four eCF506-treated mice that exhibited regression. Statistical analysis by paired t-test. 
(d) Left: Absolute BLI in total body of the two relapsed eCF506-treated mice. Treatment was 





5.2.2.4. eCF506 triggers regression of MetBo2 mammary fat pad tumours 
but resistance develops during second round treatment 
This work was done by Dr John Dawson and Morwenna Muir of the groups of Profs 
Valerie Brunton and Margaret Frame at the University of Edinburgh, UK. 
 
The in vivo testing of eCF506 in a breast cancer bone metastasis model showed high 
potency of the compound (see previous chapter 5.2.2.3). However, it was unclear 
whether this was due to eCF506’s effects on MetBo2 cancer cells or on the bone 
microenvironment. Several papers have shown that SRC kinase plays an important 
role in bone resorption by osteoclasts and this has been implicated in the formation 
of bone metastatic lesions (see chapter 1.2.3.5).  
 
In order to determine the potency of eCF506 independent of the bone 
microenvironment, it was tested in a second in vivo model in which MetBo2 cells were 
injected into the mammary fat pad of immunocompetent (FVB) or nude (CD-1) mice. 
Tumours were allowed to grow for 8-9 days to 40-50 mm3 prior to treatment with daily 
eCF506 (40 mg/kg) by oral gavage. Treatment was stopped after 28 days and 
tumours allowed to regrow to a bigger size, after which eCF506 treatment was re-
started for another 28 days. Tumour measurements are plotted in Figure 5.14 and 
Figure 5.16.  
 
The first experiment was done in immunocompetent mice and eCF506 was found to 
have potent anti-tumour effects (see Figure 5.14a). It was able to significantly inhibit 
the growth of MetBo2 mammary fat pad tumours compared to control as early as 4 
days after start of treatment (see Figure 5.14b). After 11 days, eCF506-treated 
tumours had significantly regressed by an average of 50% compared to pre-treatment 
size and maintained this level throughout the initial treatment phase (see Figure 
5.14c). One mouse in the treatment group, which had the smallest tumour at the start 
of treatment, was completely cleared and remained tumour free until the end of the 
study. Treatment was stopped after 28 days to see whether residual tumours would 
regrow, which they did after an initial lag phase of 1.5 weeks. Second round treatment 
was started once tumours had regrown to 0.3 cm3, six-fold bigger than at the start of 
the previous round. After a 3-day lag phase, tumour size reduced drastically by an 
average of 35% in all four mice for 10 days, after which tumours started to grow again 




tumours appear to become resistant to eCF506 during round two treatment; 
nevertheless, eCF506 was able to significantly prolong survival without obvious side 
effects (see Figure 5.14d,e).  
 
The strong anti-tumour response observed in FVB mice was surprising, as previous 
studies have found SRC inhibitors to only slow growth but not trigger regression in 
solid tumours 337,390,401,402. One possible explanation could be the involvement of the 
immune system in clearing of treated MetBo2 tumours. Therefore, 
immunohistochemical analysis of the tumour samples was performed to assess cell 
proliferation and cytotoxic T-cell infiltration. Staining with Ki67 and CD8 antibodies 
was performed as described in methods 2.6.1.4. Both control and treated tumours 
exhibited large necrotic cores and proliferating patches around the edges (see 
Appendix A.16). A significant difference between both groups was seen with CD8 
staining; only very few positive cells were found in the control mice, while high 
infiltration of CD8 positive cells was found in all five mice treated with eCF506, both 
in proliferating and non-proliferating areas of the tumour (see Figure 5.15). This could 
suggest that eCF506 induces infiltration of CD8 positive cytotoxic T-cells. However, 
control and treatment mice were sacrificed at different times of the experiment, with 
all control mice being culled within the first four weeks of treatment and treated mice 
up to 9 weeks later. Cytotoxic T-cell infiltration could therefore be related to time rather 
than treatment and a properly controlled experiment is needed in which mice are 
culled at the same time to be able to draw any definitive conclusions. 
 
After the initial in vivo experiments in FVB mice saw strong tumour responses to 
eCF506 treatment, it was hypothesized that these could be in part due to the 
involvement of the immune system. Therefore, the experiment was repeated in 
immunocompromised CD1 mice (see Figure 5.16a). A very similar pattern of response 
was observed in these nude mice, with initial treatment significantly reducing tumour 
growth after 4 days compared to control and triggering regression (see Figure 
5.16b,c). Tumour size was stable during the 28-day treatment phase, but regrowth 
occurred immediately after treatment stop, which was much quicker than in FVB mice. 
Re-treatment was started at a slightly smaller tumour size than in FVB (0.25 cm3) and 
again triggered a strong reduction in size by 42% on average. This was followed by a 
quick relapse and regrowth after 10 days as seen before. Notably, tumour growth in 




although some mice had to be culled as maximum tumour size was reached. Again, 
eCF506 treatment significantly prolonged survival and only some treatment-related 
side effects such as ruffled fur were observed (see Figure 5.16d,e). 
 
The results of these two studies show that eCF506 is able to trigger and maintain 
tumour regression for at least four weeks in MetBo2 mammary fat pad models. While 
the similar response between FVB and CD1 nude mice initially suggests that the 
immune system was not involved, the longer delay until relapse that was seen only in 
FVB mice could suggest that an immune response might be activated during the initial 
treatment phase. Treatment of relapsed tumours still elicits regression in both models, 
although resistance mechanisms are activated quickly, and tumours regrow similarly 
fast as in the control groups. CD1 tumours may respond again later on in round two 
treatment and it is unclear whether FVB mouse tumours could also have been 




















Figure 5.14. eCF506 in MetBo2 mammary fat pad tumours in immunocompetent FVB 
mice. (a) Tumour size of vehicle- and eCF506-treated mice. (b) Comparison of tumour size 
between groups at day 0 and day 4. Statistical analysis by two-way ANOVA with Sidak 
correction. (c) Comparison of tumour size in eCF506-treated mice between different days. 
Statistical analysis by repeated measures one-way ANOVA with Greenhouse-Geisser and 
Dunnett correction. (d) Weight of mice over the course of the study. p>0.05 (ns), p<0.01 (**). 
(d) Kaplan-Meyer survival plot showing deaths due to tumour size or sickness. Statistical 














   








   
   
 
 
% CD8+ cells of total cells 
Mouse Vehicle  Treated 
1 0.021 2.634 
2 0.122 2.262 
3 0.090 1.127 
4 0.242 3.775 
5 0.032 3.957 
 
Figure 5.15. Immunohistochemical analysis of MetBo2 mammary fat pad tumours in 
FVB mice. Images were quantified using QuPath and the percentage of CD8+ cells of total 
cell number was plotted with exact numbers shown in the table on the right. Statistical analysis 














Figure 5.16. eCF506 in MetBo2 mammary fat pad tumours in immunodeficient CD1 nude 
mice. (a) Tumour size of vehicle- and eCF506-treated mice. (b) Comparison of tumour size 
between groups at day 0 and day 4. Statistical analysis by two-way ANOVA with Sidak 
correction. (c) Comparison of tumour size in eCF506-treated mice between different days. 
Statistical analysis by repeated measures one-way ANOVA with Greenhouse-Geisser and 
Dunnett correction. (d) Weight of mice over the course of the study. p>0.05 (ns), p<0.001 (***). 
(d) Kaplan-Meyer survival plot showing deaths due to tumour size or sickness. Statistical 





5.3.1. eCF506’s pharmacokinetic and safety profile differs from 
dasatinib in rat models  
The assessment of eCF506’s pharmacokinetic properties shows that it has a 
favourable PK profile in mice but appears to be metabolised faster than dasatinib in 
rats. At the same dose of 10 mg/kg by oral gavage, eCF506 had a 15-fold lower 
maximum concentration and 23-fold lower AUC (concentration per hour) in 
comparison to previously reported values for dasatinib in Sprague-Dawley rats (see 
Table 5.3). Stability of eCF506 in rat plasma remains near 100% over 2 hours 
according to a previous study but it has not yet been tested in rat hepatocytes; future 
tests could confirm whether the PK results are due to a faster first-pass metabolism 
for eCF506 than dasatinib in rats 1. eCF506’s half-life in rats was also less than a sixth 
of that reported for dasatinib when administered directly into the circulation (0.5 hours 
and 3.3-6.7 hours, respectively), although this could have been affected by the very 
low dose used and the high volume of distribution of eCF506 in this species. In 
contrast, previous testing revealed similar Cmax and AUC values in mice and a three-
fold increased half-life for eCF506 compared to dasatinib in this species (see Table 
5.3) 1. One conclusion that can be drawn from the observed variability in exposure is 
that anti-tumour effects of eCF506 and dasatinib should only be compared to each 
other at the same dose in mouse but not rat models. Further, 10 mg/kg of eCF506 
daily by oral gavage is unlikely to achieve significant levels of SRC inhibition in rats, 
so much higher doses should be used in any potential efficacy studies in this species. 
Overall, the differences between mice and rats, two closely related species, highlight 
the need for further pharmacokinetic testing of eCF506 in other non-rodent species, 
such as dogs, in order to be able to predict a safe but efficacious starting dose for first 
use in humans. Testing eCF506 in in vitro hepatocyte stability assays using cells from 
different species prior to the next in vivo PK study can help in choosing an appropriate 
species with similar first-pass metabolism as humans. 
 
The comparatively poor performance of low dose eCF506 in the rat pharmacokinetic 
study led to the re-testing of the compound at the starting dose used in the acute 
toxicity study to determine whether adequate exposure had been achieved. At 200 
mg/kg, eCF506 exhibited more than 45% bioavailability in rats and achieved 




that are likely sufficient for strong SRC inhibition based on in vitro findings. These 
values indicate adequate exposure of eCF506 is obtained in rats at higher doses 
(>200 mg/kg), providing confidence in the toxicology results from chapter 5.1.1.2. It is 
important to note that the plasma concentration of eCF506 was still increasing at the 
end of the high dose PK study, which makes it likely that repeat dosing of daily 200 
mg/kg could lead to an accumulation of the compound (as suggested by its large 
volume of distribution) and possible toxicities over time; this should be considered 
when planning repeat dose toxicity studies.  
 
Based on the results of the pharmacokinetic studies, the big gap between the MTD in 
single dose toxicity studies of eCF506 and dasatinib in Sprague-Dawley rats (700 
mg/kg and 30 mg/kg, respectively) is likely due to their exposure differences in this 
species. Even though 200 mg/kg eCF506 was able to achieve concentrations of over 
95 nM and up to 806 nM for 24 hours, dasatinib was able to achieve comparable 
concentrations between 100 to 500 nM over at least 10 hours at a twentieth of the 
dose 391. This suggests that dasatinib’s lower MTD is at least in part related to much 
higher exposure and cannot be directly attributed to higher toxicity of the compound. 
Similar observations were made for the comparative exposure and safety of dasatinib 
and bosutinib in male rats, with the latter having a higher MTD of 700 mg/kg but also 
lower exposure (see Table 5.3) 387. It would be necessary to determine the therapeutic 
window of both eCF506 and dasatinib in order to state with confidence which drug is 
safer. However, due to already observed species-dependent differences, it is not until 
eCF506 has undergone pharmacokinetic and pharmacodynamic assessment in 
humans that definite and useful comparisons can be drawn to the safety profile of 
dasatinib.  
 
One aspect that was not taken into account in the pharmacokinetic studies is the 
potential activity of drug metabolites. eCF506 was found to be 30% metabolised by 
human hepatocytes after 2 hours and the main metabolite, an N-demethylated 
derivative representing two thirds of all metabolites, could retain activity against SRC 
kinase based on previous structure-activity studies (see chapter 5.1.2.2). This is 
currently being investigated further by synthesising the N-demethylated derivative of 
eCF506 and testing it in vitro in comparison to eCF506. The results of this study will 
indicate whether treatment with eCF506 might produce greater results than expected 




A previous study found several metabolites of dasatinib with pharmacological activity 
in humans (called M4, M5, M6, M20, M24 in publications) 395,403. The metabolite M4, 
result of a N-dealkylation of the hydroxyethyl moiety, had equipotency to dasatinib 
against SRC and ABL in cellular studies, with the other four exhibiting at least 10-fold 
less activity 403. However, only low levels of these active metabolites were found in a 
hepatocyte study and human plasma levels in a clinical trial, with M4 making up less 
than 5% of dasatinib’s AUC, which suggests they do not contribute significantly 
towards in vivo anti-tumour effects 395,403.  
It is important to add that even if eCF506’s main metabolite retains activity against 
SRC kinase in vitro, it has to be determined first whether it is present at relevant levels 
in the blood instead of being excreted or metabolised further, in order to determine its 
potential contribution towards eCF506’s in vivo efficacy. 
 
 
5.3.2. eCF506 can inhibit SRC activity in the brain, retina and 
subcutaneous tumours in mouse models 
Fraser et al. have previously shown that 50 mg/kg oral eCF506 can achieve in vivo 
phospho-SRC Y416 inhibition in a mouse colorectal cancer xenograft model 1. Further 
studies by collaborators (data not shown) found that eCF506 achieved similarly potent 
levels of SRC inhibition in an orthotopic murine breast cancer model when given orally 
(50 mg/kg) or intraperitoneally (10 or 20 mg/kg). These findings guided the dosing 
levels used in later efficacy studies; based on an oral bioavailability of 25% in mice 
and good target inhibition at 10 mg/kg via IP, 40 mg/kg given once daily by oral gavage 
was chosen as a suitable dosing regimen for mouse in vivo studies (see chapter 
5.3.4). Nevertheless, a comprehensive dose range study is still outstanding to 
determine the optimal dose level and schedule for sustained SRC inhibition. 
 
As SRC kinase plays a role in a specific type of brain cancer as well as diseases other 
than cancer, eCF506’s ability to reach organs and tissue sites needs to be evaluated 
alongside its potency in those settings. Two mouse studies have been performed to 
assess eCF506’s ability to cross the blood brain barrier and its anti-SRC activity in 
the retina of the eye (chapter 5.1.3.1 and 5.1.3.2). Both have found positive results, 




sustained for at least 8 hours and potent inhibition of VEGF-induced SRC activation 
in mouse retinas. 
Dasatinib has previously been evaluated for its ability to penetrate the blood brain 
barrier in SCID mice with intracranial CML tumours 396. Daily doses of oral dasatinib 
(50 mg/kg) achieved brain concentrations of >10 nM over 24 hours in this model, but 
peak concentration was more than 7-fold lower than for eCF506 at 40 mg/kg via IP 
administration (763 nM for eCF506 and <100 nM for dasatinib); it is important to note 
the difference in administration route between both studies, with the oral 
administration of dasatinib and its low bioavailability resulting in an overall lower 
exposure. Nevertheless, the brain:plasma ratio of dasatinib ranged between 0.032 to 
0.086 over 24 hours, much lower than the 0.12 to 0.43 of eCF506 over an 8-hour 
period. This discrepancy may be explained by the active removal of dasatinib from 
the brain, as several papers have found it to be a substrate for the multidrug efflux 
pumps P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) 404,405. 
These are expressed at the blood-brain barrier or in tumour cells to reduce exposure 
to harmful substances. Dasatinib is able to reach a brain:plasma ratio of 0.93 in a 
mouse Pgp and BCRP knockout model, 7-fold higher than in wild-type mice 404. 
Another study found a similar brain:plasma ratio for knockout mice and wild-type mice 
treated with the dual Pgp and BCRP inhibitor elacridar 405. This suggests that 
dasatinib’s brain penetration is limited by the activity of these two drug efflux pumps 
at the blood brain barrier. It is unclear whether eCF506 is also a Pgp substrate, as its 
higher brain:plasma ratio may have been achieved by saturation of the Pgp pumps 
due to its higher plasma concentration. Further studies are required to compare the 
brain exposure of eCF506 and dasatinib and to test whether eCF506 is a Pgp 
substrate, which is of importance for any potential use of eCF506 in CNS diseases. 
Nonetheless, the PK results obtained so far support eCF506’s potential application in 
SFK-related diseases of the central nervous system and retina, such as type 4 
medulloblastoma, Alzheimer’s disease and diabetic retinopathy. 
 
 
5.3.3. eCF506 and dasatinib have pro- and anti-tumour effects on 
MetBo2 cytokine secretion  
An in vitro cytokine array showed that eCF506 and dasatinib have beneficial effects 




IL-1 receptor antagonist (IL-1RA) and IGFBP5 secretion and a marked reduction of 
VEGF (see chapter 5.3.3).  
IL-1RA is a natural antagonist of IL-1α and IL-1β signalling. Its recombinant form 
(anakinra) is used clinically to treat rheumatoid arthritis and has been investigated in 
several clinical trials of different cancers with some promising results 406. IL-1β 
presence in the primary tumour was found to be a predictive biomarker for patients 
with stage II/III breast cancer that were at increased risk of disease recurrence and 
bone metastasis and it was found to drive breast cancer progression and bone 
metastasis in a mouse model 407,408. Treatment of the mice with anakinra lead to a 
reduction in bone metastases by more than 50% as well as a reduction in 
subcutaneous tumour growth, with even higher efficacy when given preventatively 408. 
This suggests that the increased secretion of IL-1RA in response to eCF506 and 
dasatinib treatment could at least in part be responsible for the strong anti-tumour 
effects seen in the MetBo2 bone metastasis and mammary fat pad studies.  
Levels of secreted IGFBP-5 were also increased by both SRC inhibitors in MetBo2 
cells. This factor has previously been associated with decreased cell migration of the 
MCF-7 cell line, tumour suppressor functions in human melanoma cells and inhibition 
of angiogenesis in an ex vivo assay 409–411. Increased IGFBP5 secretion could 
therefore also contribute to eCF506 and dasatinib’s anti-tumour effects. 
Lastly, eCF506 potently inhibited the secretion of VEGF by MetBo2 cells in vitro, 
which is a key driver of angiogenesis in cancer (see chapter 1.2.3.4). VEGF can also 
prevent T-lymphocyte infiltration by inhibiting their ability to adhere to endothelial cells, 
a necessary step for extravasation and tumour infiltration 412. SRC inhibition has 
previously been found to inhibit angiogenesis and this has been confirmed for eCF506 
in in vitro and ex vivo models (see chapter 3.1.5). The finding that eCF506 and 
dasatinib can also reduce the secretion of pro-angiogenic VEGF by tumour cells could 
thus potentiate their anti-angiogenic properties in cancer and enable increased T-
lymphocyte infiltration. High CD8+ T-cell infiltration was indeed observed in eCF506-
treated MetBo2 mammary fat pad tumours in FVB mice and it is possible this could 
be related to eCF506’s effects on MetBo2 cytokine signalling (see Figure 5.15); 
however, a better controlled study needs to confirm that this infiltration is indeed 






Several other changes in cytokine secretion were observed in treated MetBo2 cells 
whose potential consequences are less clear or maybe counterproductive. The strong 
reduction of secreted CXCL2 in the cytokine array by over 75% by both eCF506 and 
dasatinib would likely have beneficial anti-cancer effects in vivo. Secretion of 
CXCL1/2 was found to increase metastatic potential and chemoresistance in breast 
cancer and an inhibitor of the primary CXCL1/2 receptor CXCR2 sensitised two 
metastatic mouse models to chemotherapy 413. CXCL1/2 was also found to promote 
the expansion of myeloid-derived suppressor cells in tumours which hinder 
immunosurveillance 414. However, CXCL1 secretion was upregulated 2- to 4-fold in 
response to treatment in the cytokine array, meaning it could compensate for at least 
some of the CXCL2 reduction, which makes the potential impact of changes in 
CXCL1/2 secretion less clear.  
The moderate reduction of TNF-α secretion could either limit or promote tumour 
progression, as it was found to have context-dependent pro- and anti-tumour effects 
415. IL-6 secretion was decreased by low concentrations of both inhibitors but 
increased more than 12-fold by high doses of dasatinib; the roles of this cytokine in 
cancer are similarly complex, as IL-6 secreted by stromal cells or tumours promotes 
cell proliferation but also enables cytotoxic T-cell trafficking to the tumour 416. The 
reduction of MMP-3 secretion with eCF506 likely reduces the malignancy of MetBo2 
cells, as transgenic mice with activated MMP-3 develop invasive mammary tumours 
417,418. MMP-3 can also activate pro-MMP-9, which in turn increases tumour cell 
invasion and angiogenesis by releasing VEGF and promoting extracellular matrix 
degradation 419,420. However, the increased secretion of osteopontin in response to 
eCF506 and dasatinib treatment (2- and 4-fold, respectively) is likely having 
counterproductive effects, as this chemokine-like factor is implicated in cell 
proliferation, metastasis, angiogenesis and drug resistance pathways with a special 
role in the bone microenvironment 421. Moreover, CCL5 was increased by both 
compounds and has been linked to regulatory T-cell enrichment, which reduces anti-
tumour immunity 422,423. 
 
Overall, although the results from this study need to be taken with caution, the effects 
of eCF506 on IL-1RA and VEGF secretion could potentially contribute to its potent 
effects observed in the MetBo2 mouse models. Nevertheless, several cytokine 
changes in response to eCF506 or dasatinib treatment could indeed promote tumour 




patterns can be observed in vivo, in other cell lines and in other cancer models to 
conclude whether these are MetBo2-specific observations or general effects of SRC 
inhibitor treatment.  
A recent study found that combining anti-IL-1β and anti-PD-1 antibodies in 4T1 
mammary carcinoma in mice gave synergistic results by doubling CD8+ T-cell 
infiltration and almost completely abrogating tumour growth compared to 
monotherapy 424. This provides an interesting rationale for testing the combination of 
eCF506 with PD-1 inhibitors in a MetBo2 mouse model, provided that the increased 
secretion of IL-1RA also occurs in vivo. Furthermore, inhibition of the SRC 
downstream target FAK is currently being tested in combination with anti-PD-1 and 
gemcitabine in a Phase 1/2 clinical trial of patients with advanced pancreatic cancer, 
based on synergistic results in mouse models 425,426. Due to the close link between 
SRC and FAK activity, it is possible that eCF506 might produce a similar effect; 
however, unlike FAK, SFK inhibition might prevent T-cell activation due to the role of 
LCK in the TCR (discussed further in the following chapter), which would abolish the 
effect of PD-1 inhibition 104,427. Comparing the effects of FAK and SRC inhibition in 
combination with anti-PD-1 in the pancreatic mouse model would be an interesting 
experiment to determine the impact of eCF506 on the anti-tumour immune response.  
 
 
5.3.4. eCF506 is a potent inhibitor of tumour growth in some in vivo 
models 
The efficacy of eCF506 in vivo has been assessed for the first time in different breast 
cancer models in mice with varying success; no potent anti-tumour activity was 
observed in a MDA-MB-231 xenograft model with either eCF506 or dasatinib (see 
chapter 5.2.1), while sustained tumour regression was seen with eCF506 in a bone 
metastasis and orthotopic murine breast cancer model (see chapter 5.2.2.3 and 
5.2.2.4). 
 
The results of the first in vivo study with eCF506 in an MDA-MB-231 xenograft were 
disappointing based on the high in vitro activity found in 2D culture. eCF506 had no 
impact on tumour growth whatsoever and dasatinib only inhibited it slightly toward the 
end of the study (see Figure 5.8). Since dasatinib has been studied extensively in 




findings were surprising 172,308,428–430. However, a search in the literature revealed only 
one published study in which dasatinib was tested in an in vivo model of this cell line, 
as the majority of papers only reports in vitro experiments 430. In this study, 10 mg/kg 
dasatinib was given to nude mice every other day by oral gavage for a total of eight 
administrations, starting one week after inoculation with MDA-MB-231 cells (one 
million cells injected with Matrigel). Tumours were allowed to growth for four weeks 
after the end of treatment and significant differences in tumour size were first found 5 
weeks after inoculation, with dasatinib reducing size by around 50% compared to 
control. While the study conducted in chapter 5.2.1 differs from the one done by Qian 
et al. in several ways (later treatment start, 2.5-fold higher dose, doubled dosing 
frequency, longer treatment period), stronger effects with dasatinib than those 
observed would still have been expected within the 25-day treatment period 430. It is 
possible that the additional time prior to treatment start could have allowed tumours 
to be more established, compacted and treatment resistant due to either poor drug 
penetration and/or reduced dependency upon SRC for growth and survival in a 
complete 3D environment. This hypothesis is based on results from chapter 3.1.4, in 
which both eCF506 and dasatinib were much less potent against MDA-MB-231 
spheroids than in 2D cell viability assays. Nonetheless, tumour sizes appeared to 
decrease after three weeks of treatment in the MDA-MB-231 mouse study (see Figure 
5.8) and a longer observation period post-treatment as used by Qian et al. is needed 
to determine whether this trend is treatment-related, as some tumours in the control 
group also shrunk 430.  
 
In contrast to the MDA-MB-231 xenograft, eCF506 caused tumour regression and 
even complete response in mouse studies with the bone-metastatic murine breast 
cancer cell line MetBo2. This cell line has been created and characterised by the 
group of Dr Bin-Zhi Qian and was found to be highly resistant to standard 
chemotherapy (unpublished data). Three in vivo experiments with MetBo2 have so 
far been completed: one in a bone metastasis model in immunocompetent mice and 
two in mammary fat pad primary tumours in immunocompetent and immunodeficient 
mice. eCF506 was able to reduce MetBo2 tumour size in nearly all mice (except for 
two in the bone metastasis model) and smaller size was maintained throughout the 
four weeks of initial treatment. Future studies with an open-ended initial treatment 




While one mouse was cured in the mammary fat pad study, and two in the bone 
metastasis one maintained negligible BLI signal, the majority relapsed after treatment 
was stopped and exhibited re-growth of the original tumour (mammary fat pad 
experiment) or metastases in other sites of the body (bone metastasis experiment). 
Relapse can occur due to the survival of cancer stem cells and the results of an in 
vitro mammosphere assay suggest eCF506 can reduce stem cell activity but was 
unable to fully inhibit self-renewal at the concentration tested (chapter 5.2.2.1).  
During the second round of treatment, all mice initially responded with a reduction in 
tumour size. However, in mammary fat pad tumours resistance emerged after around 
10 days and tumours regrew at a similar rate to untreated controls in both mouse 
strains. Further investigation is currently under way using NanoString and Reverse 
Phase Protein Array methods to profile the pathways that are involved in this 
resistance mechanism. By mapping compensatory signalling pathways to drug target 
databases, the results could point toward rational drug combinations which increase 
the duration of response following eCF506 treatment.  
 
A comparison of eCF506 in immunocompetent and immunocompromised mice 
showed similar efficacy in both models, which suggests that eCF506’s anti-tumour 
activity is largely independent of the immune system. Therefore, the infiltration of 
CD8+ cells in eCF506-treated tumours of FVB mice does not appear to have 
contributed to tumour regression, as a similar reduction in size was found in CD1 nude 
mice, which lack a thymus and are thus unable to produce mature, differentiated T-
cells 431. CD8 is a marker for cytotoxic T lymphocytes which play important roles in 
immunosurveillance; their presence in the tumour microenvironment often correlates 
with better prognosis in breast and other cancers 432,433. CD4+ and CD8+ T-cells are 
activated by binding of the T-cell receptor (TCR) to the antigen-presenting major 
histocompatibility complex (MHC) on antigen-presenting cells. This is the first in a 
multi-step process causing naïve CD8+ T-cells to become cytotoxic T-cells that can 
kill virus-infected or tumour cells by releasing cytotoxic granules or inducing 
apoptosis. One important protein downstream of the TCR is LCK kinase, a SRC 
kinase family member which is also potently inhibited by eCF506 and dasatinib (see 
chapter 1.2.3.6 and Table 3.4). Multiple studies have found that LCK inhibition by 
dasatinib inhibits TCR function and thus prevents CD8+ T-cell activation and effector 
functions in vitro and in vivo 434–438. Increased cytotoxic T-cell mobilisation is observed 




infiltration of CD8+ T-cells with dasatinib treatment, although one showed that these 
had a higher expression of PD-1, a marker of T-cell exhaustion 401,439,440. It has 
recently been suggested to use dasatinib as a pharmacologic switch for chimeric 
antigen receptor T-cells (CAR-T) to temporarily reduce acute toxicity due to excessive 
activity 427. Taken together, these findings suggest that eCF506 potentially induces T-
cell infiltration into MetBo2 mammary fat pad tumours but simultaneously inhibits their 
activation and anti-tumour effects. This potential inactivation of the 
immunosurveillance could explain the similarity between the results seen in FVB and 
nude mice. Nevertheless, it is important to note that relapse in FVB mice after initial 
treatment only occurred after a lag phase of over one week, while the same tumours 
regrew immediately in CD1 nude mice. This does indicate that the presence of 
functional T lymphocytes might have some beneficial effect in this model during the 
initial treatment phase. Further studies are being considered to investigate the effect 
of eCF506 on T-cell infiltration and activation in this model and to compare it to 
























The non-receptor tyrosine kinase SRC has repeatedly been associated with the 
progression of different cancers and the pathology of other diseases, such as 
Alzheimer’s. Attempts to repurpose existing dual SRC/ABL inhibitors have so far been 
unsuccessful in gaining regulatory approval for their SRC inhibition alone. The recent 
discovery of the SRC/non-ABL inhibitor eCF506 offers the first opportunity to 
selectively inhibit SRC but not ABL kinase, which has the potential to improve upon 
the efficacy and safety profile of existing inhibitors. This thesis presents the continued 
preclinical investigation eCF506 in comparison to other SRC/ABL inhibitors in 
different models of cancer, which was carried out in collaboration with several partners 
from industry and academia.  
 
The results of several in vitro experiments confirm that eCF506 is a potent inhibitor of 
SRC kinase activity with similar potency as the current best-in-class SRC/ABL 
inhibitor dasatinib. Both compounds were superior at inhibiting SRC signalling and 2D 
cell proliferation compared to the SRC/ABL inhibitors bosutinib and saracatinib. These 
results correlate directly with the relative potencies in cell-free kinase assays, where 
eCF506 and dasatinib showed the highest potency against SFKs. Kinome-wide 
profiling confirmed the overall selectivity of eCF506 for SFKs, with SRC identified as 
its main target and only one non-family member included in its top 10; dasatinib and 
bosutinib on the other hand exhibited relatively high promiscuity, as neither had SRC 
as one of their top 15 targets.  
The attempts to confirm eCF506’s selectivity over ABL in a cellular assay lead to the 
serendipitous discovery that eCF506 and dasatinib had opposite effects on the 
thermal stability of SRC kinase. Further investigation revealed that eCF506 has a 
distinct binding mode from dasatinib and bosutinib, as it stabilises SRC in its natural 
autoinhibited state, while the other two force it into an open conformation. As a result, 
dasatinib and bosutinib support the interaction between SRC and FAK, whereas 
eCF506 appears to prevent it. eCF506 can therefore inhibit both SRC’s kinase and 
scaffolding activities. Saracatinib appears to bind SRC in a similar way as eCF506 
based on its X-ray crystallography data, however its effects on the phosphorylation of 
SRC Y527 and FAK Y397 and the binding of SRC to FAK appear to be more similar 
to dasatinib and bosutinib. It is possible that the binding of saracatinib does not force 
SRC into a specific conformation, as eCF506 and dasatinib/bosutinib appear to do, 
and that the SRC-saracatinib complex can switch between open and closed 




While the differences in the SRC binding mode of eCF506 compared to the other 
inhibitors are interesting, it is not yet clear whether this has any wider implications on 
cellular signalling. Subcellular fractionations showed that dasatinib induces nuclear 
translocation of the SRC-FAK complex, however it is unclear whether this is due to 
the actions on SRC or overall increased cellular stress. Since both eCF506 and 
dasatinib gave very similar results when assessed by RPPA and in a cytokine 
secretion assay in different cell lines, it appears that the inhibition of SRC kinase 
activity may overshadow any scaffolding roles of the protein.  
 
The last chapter of this thesis focuses on the assessment of eCF506 for its PK, toxicity 
and efficacy properties in vivo. The results of a first single dose toxicity study in rats 
revealed a high MTD (700 mg/kg); however, assessment of PK parameters in this 
species showed that eCF506 does not achieve the same high levels of exposure 
previously found in mice. The significantly better PK properties of dasatinib in rats are 
likely the reason it exhibits a much lower MTD than eCF506, which prevents a direct 
comparison of the toxicity of the two compounds in this species. It is possible that 
eCF506’s main metabolite that was identified in a human hepatocyte stability assay 
retains potency; its activity and presence in rats need to be assessed, which will 
inform whether future PK studies should measure both compounds to accurately 
determine exposure. Nevertheless, additional PK experiments in mice confirmed 
eCF506’s favourable properties in this species, as the compound was able to reach 
the brain and retina at relevant concentrations.  
Efficacy studies with eCF506 in different in vivo models of breast cancer revealed cell 
line-specific differences, with no effect observed in a human xenograft model (MDA-
MB-231), whereas tumours regressed and even disappeared in some cases in 
models of a murine bone metastatic breast cancer cell line (MetBo2). Interestingly, 
MetBo2 cells showed similar sensitivity to eCF506 as MDA-MB-231 cells in a 2D cell 
proliferation assay but much higher sensitivity in a 3D spheroid assay. This suggests 
that 3D assays might be the main predictor of in vivo response to eCF506, as the 
reduction in MetBo2 tumour size in vivo correlates with the reduction in spheroid size 
at low eCF506 concentrations in vitro. Nonetheless, a bigger comparative study is 
needed to confirm the predictive value of this 3D spheroid assay for eCF506’s in vivo 
efficacy.  
The potent in vivo effects of eCF506 led to the suggestion that the immune system 




immunocompetent and immunodeficient mice showed little differences, the most 
notable one being a longer delay until relapse in the immunocompetent mice. The 
infiltration of eCF506 treated tumours with CD8+ T-cells could be linked to treatment 
or be a time-dependent phenomenon and a properly controlled study is needed to 
distinguish between the two. However, the role of LCK in the activation of T-cells and 
the recent finding that dasatinib could be used as an on/off switch for CAR-T therapy 
suggests that SFK inhibition might indeed hinder tumour clearance by the immune 
system. Additional studies which assess both T-cell infiltration and activity can 
determine what impact, if any, eCF506 has on the immune system and might shed 




The preclinical investigation of eCF506 in cancer for this thesis explored its potency 
and selectivity in vitro, identified distinct molecular properties and provides a starting 
point for further in vivo experiments assessing efficacy, pharmacokinetics and side 
effects. Many follow-up and potential new experiments have been mentioned 
throughout the chapters, which would continue the characterisation of eCF506 as a 
novel selective SRC/non-ABL inhibitor. The challenge of future investigations will be 
to define a clear goal for the assessment of eCF506. While it would be interesting 
from a molecular perspective to follow up on the potential impact of the stable SRC-
FAK interaction and nuclear translocation induced by dasatinib but not eCF506, the 
relevance of these observations for treatment outcomes is unclear. It is likely that the 
different selectivity profiles of SRC inhibitors lead to greater differences in cell 
signalling than differential conformations of kinase-inhibited SRC. 
 
Greater focus should instead be placed on identifying relevant disease settings in 
which eCF506 shows efficacy and for which it could enter clinical development. The 
recent discovery that elevated SRC-ErbB4 signalling is the distinguishing feature of 
type 4 medulloblastoma provides a clear rationale to assess eCF506 in models of this 
disease. Notably, the kinome screen data shows that ErbB4 is also potently inhibited 
by eCF506 as well as dasatinib and bosutinib. Furthermore, the findings of this thesis 
warrant continued investigation into the potency of eCF506 in ARID1A mutant ovarian 
CCC, which should involve the testing of cell lines in a 3D spheroid assay prior to 




CCC cells for sensitivity to eCF506 based on ARID1A status would be an important 
experiment in determining the clinical relevance of stratifying patients based on this 
marker. Lastly, an in-depth characterisation of the murine MetBo2 cell line could lead 
to potential new biomarkers for eCF506 sensitivity, which could then be screened for 
in human cancers.  
In addition to the efficacy studies, further PK and toxicity studies with eCF506 are 
necessary to gain approval for clinical testing. The PK parameters need to be 
assessed in a second non-rodent species and the activity of its main metabolite needs 
to be tested. Prior screening of eCF506 stability in primary hepatocytes from different 
species might explain the different PK results seen in rats and mice and could help 
with the selection of a non-rodent species. The next steps for toxicity testing involve 
repeat-dose experiments and the confirmation of the safety of eCF506 in other 
species.  
 
All of the PK, toxicology and in vivo efficacy experiments will require large quantities 
of pure eCF506, which exceeds the capacity of in-house synthesis. Therefore, the 
synthesis of a large batch of eCF506 has recently been outsourced with the support 
of the Institute of Genetics and Molecular Medicine. This will allow the continued 
preclinical development of eCF506 at the institute and in collaboration with partners 
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Appendix A.1. Dose-response curves of human breast and ovarian cancer (chapter 
3.1.1.2) and chronic myeloid leukaemia (chapter 3.2.2) cell lines. 16 breast cancer, 13 
ovarian cancer and 3 chronic myeloid leukaemia cell lines were treated with different SRC/ABL 
kinase inhibitors for 5 days. Effects on cell proliferation were measured using PrestoBlueTM 
reagent and curves were fitted using GraphPad Prism 7. Cell viability on the day of treatment 
was subtracted from final readings and results were normalised to DMSO treated control. All 








































































Appendix A.2. Dose-response curves of human oesophageal cancer high-throughput 
screen (chapter 3.1.1.3). Cells were treated for 48 hours prior to fixing, staining with DAPI 
and imaging. Number of cell nuclei is used as measure of cell survival and normalised to 




























Appendix A.3. Full (phospho)-SRC and cell line sensitivity correlation analysis (chapter 
3.1.3). (a) Phospho-SRC and total SRC levels were determined for all cell lines from Western 
blots and are plotted against eCF506 sensitivity from the 2D cell viability assays of chapter 
3.1.1.2. Protein levels were determined from two biological replicates, normalised to MDA-MB-
231 and are shown with standard error. Correlation analysis of combined breast and ovarian 
cancer cell line data was performed using GraphPad Prism 7.0. (b) Representative Western 
blots showing phospho-SRC and total SRC level of all cell lines. (c) GI25, GI50, GI75, GI90 and 
TGI values of all cell lines for eCF506 treatment. Values (in µM) determined from three 
biological repeats and rounded to three significant figures. 
 






R2 = 0.0175, p=0.494 
 
R2 = 0.0497, p=0.245 
 






R2 = 0.0351, p=0.330 
 
R2 = 0.0528, p=0.230 
 






R2 = 0.185, p=0.0199 * 
 
R2 = 0.0725, p=0.158 
 














R2 = 0.262, p=0.0045 ** 
 
R2 = 0.896, p=0.115 
 





R2 = 0.151, p=0.0369 * 
 
R2 = 0.0500, p=0.244 
 




















































































































































































































Figure continued from previous page 
(c) 
 GI25 GI50 GI75 GI90 TGI 
BT474 1.38 2.99 5.14 6.86 8.3 
BT549 0.0832 0.155 3.05 22.3 25.9 
CAMA 4.57 8.75 12.2 15.0 18.0 
ES2 2.78 4.80 8.12 12.4 19.2 
HCC1569 1.47 3.59 7.14 10.8 14.7 
HCC1954 0.183 1.79 7.45 11.3 12.8 
IGROV1 0.00693 0.0130 0.0234 0.0392 0.157 
JIMT1 0.0505 0.222 0.895 2.76 9.65 
KPL4 10.5 12.8 15.4 17.9 21.4 
MCF7 0.00368 0.0147 1.24 11.5 30.3 
MDAMB134VI 5.32 10.4 13.4 15.3 16.7 
MDAMB157 0.00647 0.0200 0.221 1.07 2.47 
MDAMB231 0.00868 0.0160 0.0944 0.518 3.04 
MDAMB436 21.5 27.0 33.2 38.5 43.9 
OVCAR3 0.0431 0.285 14.9 34.2 45.5 
OVMANA 0.0798 0.113 0.163 0.285 5.58 
OVTOKO 0.0121 0.0177 0.0260 0.0373 0.0596 
PEO1 0.0323 0.0744 0.218 8.19 25.1 
PEO14 0.0179 0.621 2.14 4.10 5.41 
PEO23 0.00555 0.0123 0.0254 0.0444 0.0789 
PEO4 0.0141 0.950 11.8 15.9 18.8 
PEO6 0.00860 0.120 9.68 16.3 21.7 
SKBR3 4.71 7.80 11.8 15.5 19.3 
SKOV3 0.0528 2.80 8.48 12.6 16.6 
SUM44PE 32.8 50.8 65.6 73.7 78.8 
T47D 0.0114 0.149 16.8 36.1 52.0 
TOV112D 0.0203 15.0 20.9 25.2 30.1 
TOV21G 0.0293 0.120 3.83 15.3 25.1 













Appendix A.4. Spheroid assay results (chapter 3.1.4 and 5.2.2.1). Raw data of spheroid 
area as measured by Cell Profiler from collapsed images taken after 4 or 7 days of treatment 
with eCF506 or dasatinib. Table shows average of three biological repeats. 
 
 
MDA-MB-231 MCF-7 T-47D MetBo2 
Concentration  
(µM) 
Day 4 Day 7 Day 4 Day 7 Day 4 Day 7 Day 4 Day 7 
eCF506 
10 38216 36324 56141 57265 61865 73619 34040 26519 
3 38530 35314 67444 70501 64526 84845 29592 27657 
1 42644 42910 72854 73878 66454 88379 24403 25008 
0.3 39737 42111 70098 76403 65994 89789 19351 18341 
0.1 39755 40914 66750 73332 68727 91654 18424 16401 
0.03 41548 42668 65254 73612 63402 84107 14218 13603 
0.01 39511 41447 74514 76715 69022 92256 14491 11197 
0.003 38074 38211 73891 76611 66134 90607 21502 18413 
DMSO 39720 42842 74817 83615 71154 95205 49517 75178 
Dasatinib 
10 30430 28487 57105 58266 42746 51007 33299 25578 
3 24704 20008 66688 67716 51444 63907 31760 28326 
1 27796 22028 72916 74668 56913 70316 26679 26175 
0.3 31382 24826 75611 74581 60071 77416 29562 26428 
0.1 33050 27909 84410 88795 57838 76936 27783 24345 
0.03 35465 33343 80475 81565 65359 86359 26335 23777 
0.01 35530 34041 80625 76581 68253 90210 22655 20432 
0.003 37840 38873 75142 80734 68172 91103 17549 13976 






Appendix A.5. Comparison of SRC activity between 2D and 3D cell models. Western blot 
comparison of phospho-SRC Y416 and total SRC amounts in MDA-MB-231 and MCF-7 cells 
grown on 6-well plates (2D) or as spheroids in non-adherent 96-well plates (3D) for a total of 
seven days. Data represents average of three biological replicates with standard deviation. 
Representative Western blots are shown. Statistical analysis was done using two-way ANOVA 







































Appendix A.6. Full results of kinome screen of eCF506 (chapter 3.2.1.1). Table shows all 
340 tested kinases in order of sensitivity to eCF506. % Activity shows the percentage of kinase 
activity left when treated with 1 µM eCF506 at 10 μM of ATP, relative to DMSO. Data 


























































SRC 0.1 MAP4K5 81.7 CK2a 92.8 PKG1a 96.6 
BRK 0.2 RSK4 83.3 ROCK2 92.8 LRRK2 96.6 
HCK 0.8 SGK3 83.4 CDK2/cyclin A1 92.9 CAMK1d 96.7 
FGR 1.3 ZAK 83.4 DYRK3 93.0 PKCg 96.7 
LYN 1.3 FGFR3 84.7 DAPK3 93.0 FLT3 96.8 
LCK 1.4 ALK1 85.9 EPHB3 93.1 TAOK2 96.9 
ARAF 1.7 EPHA1 86.7 NLK 93.1 ULK3 97.0 
YES 1.8 MAP4K3 87.0 SRPK1 93.3 MAPKAPK2 97.0 
LYN B 2.0 PAK3 87.3 CK1e 93.4 RSK2 97.1 
FYN 2.3 MET 87.5 SIK2 93.6 CDK1/cyclin A 97.1 
FRK 2.4 IKKa 87.6 VRK2 93.6 NEK9 97.1 
BMX 2.8 MUSK 89.0 PRKG2 93.7 CDK3/cyclin E 97.2 
BTK 3.8 LATS2 89.0 IKKe 93.8 TLK1 97.3 
ERBB4 4.5 PKCb2 89.1 ULK1 93.9 MAP4K4 97.3 
BLK 4.8 GSK3a 89.2 TESK1 94.3 MLK2 97.3 
CSK 5.0 ERK7 89.4 DYRK1B 94.6 MST2 97.4 
TXK 9.1 TYK2 89.6 GSK3b 94.6 p38-beta 97.4 
RIPK3 12.1 BMPR2 89.6 MAPKAPK5 94.6 CAMK1a 97.4 
RAF1 19.6 WNK3 90.3 PKG1b 94.6 JAK2 97.5 
ABL2 28.7 CDK16/cyclin Y  90.4 FGFR4 94.9 PDPK1 97.5 
LIMK2 30.0 PIM3 90.6 MSSK1 94.9 p38-alpha 97.5 
MER 30.1 MAP4K2 90.6 TAOK1 95.0 NEK2 97.7 
BRAF 34.5 CAMK1b 90.7 JNK3 95.1 MAPKAPK3 97.7 
TEC 43.9 RON 90.9 ARK5 95.1 PKCd 97.8 
SRMS 46.2 p38-gamma 90.9 HIPK2 95.2 MNK1 97.8 
ACK1 54.3 CK1g2 90.9 HIPK3 95.2 MRCKa 97.9 
ABL1 56.3 ACVR1B 90.9 CLK3 95.2 NEK3 98.0 
AXL 64.1 RPS6KA5 91.1 CDK1/cyclin B 95.3 EPHA7 98.1 
EPHB2 66.6 MEK1 91.1 PHKg2 95.3 TNIK 98.1 
EPHB4 68.5 LCK2 91.2 DYRK1A 95.3 DYRK2 98.2 
PAK2 71.2 CAMK2a 91.5 RPS6KB1 95.4 ALK3 98.2 
RSK1 72.2 CAMK1g 91.5 MLK1 95.5 ITK 98.2 
PKAcb 74.3 DMPK2 91.5 EPHA8 95.6 CK1g3 98.2 
MAP3K8 74.6 IRAK1 91.8 CDK9/cyclin K 95.7 ERK5 98.4 
Kit 75.1 EPHA5 92.0 STK16 95.7 PHKg1 98.5 
NEK11 75.3 PKN1 92.1 PIM1 95.9 PKN3 98.5 
RIPK2 76.8 CLK2 92.1 TRKB 95.9 RET 98.6 
FGFR1 78.0 PKCtheta 92.1 STK33 96.2 PRKX 98.6 
MEK2 78.8 IRAK4 92.4 WEE1 96.2 GRK7 98.6 
DDR1 79.6 LTK 92.4 TAOK3 96.2 MARK4 98.6 
LIMK1 79.8 MELK 92.5 BRSK2 96.4 MST4 98.7 
MEKK3 80.2 CDK6/cyclin D3 92.6 PKCzeta 96.5 SIK1 98.9 
NEK7 81.3 CAMK4 92.7 CDK4/cyclin D3 96.6 SGK1 98.9 





























































CHK2 98.9 INSRR 101.4 SIK3 104.0 MNK2 107.3 
CDK5/p25 98.9 PIM2 101.4 GRK1 104.0 FER 107.5 
TBK1 99.1 GRK5 101.5 TIE2 104.1 MAP3K12 108.2 
AURKB 99.1 ROS1 101.5 AKT3 104.2 RPS6KB2 108.2 
RPS6KA4 99.2 CDK2/cyclin E 101.6 TGFBR2 104.3 NEK5 108.5 
WNK1 99.2 CK1d 101.6 SYK 104.3 PLK1 108.6 
STK39 99.2 PAK6 101.7 JNK2 104.3 FES 108.6 
PLK2 99.2 EPHA2 101.7 PDGFRb 104.3 PRKD1 108.7 
CK1g1 99.2 PKCiota 101.8 VRK1 104.4 IKKb 109.1 
MEKK2 99.3 PKAcg 101.8 LOK 104.5 GRK3 109.2 
TRKC 99.3 AURKA 101.9 GRK2 104.5 CDK9/cyclin T1 109.2 
GRK4 99.5 JAK1 101.9 TTBK1 104.5 ROCK1 109.7 
DAPK2 99.5 CAMK2g 101.9 DAPK1 104.6 FGFR2 109.8 
ERK2 99.5 CDK7/cyclin H 101.9 PKA 104.6 MLCK 109.8 
MARK2 99.5 SLK 102.0 EPHA3 104.7 MST3 110.0 
ASK1 99.6 CDK5/p35 102.0 MST1 105.0 RIPK5 110.0 
CHK1 99.7 LATS1 102.1 HIPK4 105.0 TGFBR1 110.2 
NEK6 99.7 TAK1 102.1 SNARK 105.0 TYRO3 110.5 
MAP4K1 99.8 AURKC 102.2 PRKD3 105.0 PASK 110.6 
PKCb1 99.8 CDK2/cyclin A 102.3 PLK3 105.1 PKN2 110.8 
PKCepsilon 99.9 DDR2 102.4 CDK6/cyclin D1 105.2 JAK3 111.1 
PKCa 99.9 GRK6 102.4 DMPK 105.2 CK1a1 111.4 
SRPK2 100.0 ALK 102.5 MYO3b 105.2 IR 111.8 
EPHA6 100.1 STK22D 102.5 ERK1 105.2 TSSK3 112.0 
MEKK1 100.1 ZAP70 102.5 Haspin 105.3 YSK1 112.2 
LKB1 100.1 CAMK2d 102.5 WNK2 105.4 PRKD2 113.0 
STK38L 100.1 DCAMKL2 102.5 MYLK2 105.5 FAK 113.5 
TRKA 100.1 TNK1 102.6 SGK2 105.6 BRSK1 114.7 
CLK1 100.2 PKCeta 102.7 MRCKb 105.7 PDGFRa 115.1 
MARK1 100.2 RSK3 102.8 ACVR1 105.7 EPHB1 115.5 
MLK3 100.2 NEK4 102.8 NEK1 105.9 STK32C 116.0 
HIPK1 100.3 DCAMKL1 102.8 TTBK2 106.0 CAMKK2 116.7 
TLK2 100.4 OSR1 103.1 JNK1 106.0 PLK4 116.8 
PYK2 100.5 SSTK 103.2 P38-delta 106.0 EGFR 117.3 
PAK1 100.5 CSF1R 103.3 CDK1/cyclin E 106.1 STK32B 118.6 
IGF1R 100.7 CAMK2b 103.5 AKT1 106.3 VEGFR2 119.5 
CLK4 100.7 PAK5 103.5 FLT1 106.3 TSSK2 123.4 
MEK3 100.8 STK17A 103.6 MAP2K6 106.3 ERBB2 126.3 
MARK3 101.0 CAMKK1 103.6 EPHA4 106.5 FLT4 127.6 
AKT2 101.0 CDK4/cyclin D1 103.7 CDC7/DBF4 106.9 MINK 128.9 
MYLK3 101.1 ULK2 103.8 MAP2K4 107.0 STK38 175.7 










Appendix A.7. Dose-response curves of ABL1 modified MDA-MB-231 cells (chapter 
3.2.2). MDA-MB-231 wild-type, MDA-MB-231 ABL1 knockout and MDA-MB-231 cells re-
expressing ABL1 were treated with eCF506 or dasatinib for 5 days. Effects on cell proliferation 
were measured using PrestoBlueTM reagent and curves were fitted using GraphPad Prism 7. 
Cell viability on the day of treatment was subtracted from final readings and normalised to 
DMSO treated control. All dose-response curves represent the average of three biological 







Appendix A.8. Western Blot analysis of pSRC (Y527) and pFAK (Y397) in MCF-7 cells 
(chapter 4.1.2.2 and 4.2.1). (a) Phospho-FAK (Y397) and Phospho-SRC (Y527) Western blot 
analysis after treatment of MCF-7 cells for 3 or 24 hours. Representative Western blot from 
three biological replicates. (b) Summary of phospho-SRC (Y527) and phospho-FAK (Y397) 
Western blots of MCF-7 cells showing average of three biological replicates with standard 
deviation. Band intensities were quantified using Bio-Rad ImageLab® software, adjusted for 
loading using GAPDH and normalised to DMSO. Concentrations given in µM. 
 
(a)  MCF-7 





















































































































Appendix A.9. Western blot analysis of selected proteins assessed in the RPPA 
(chapter 4.2.1). MDA-MB-231 cells were treated with eCF506 or dasatinib for the time 
specified prior to lysis and analysis by Western blot. Images represent one biological replicate. 
Concentrations given in µM.  
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Appendix A.10. Exploratory co-immunoprecipitation of SRC, FAK, p85 PI3K, paxillin and 
ERα (chapter 4.2.2). (a) MDA-MB-231 or (b) MCF-7 cells were treated with eCF506 or 
dasatinib for 6 hours prior to cell lysis and co-immunoprecipitation using SRC (rabbit or mouse 
as specified) antibody overnight. Bound proteins were eluted and analysed using Western blot 
with total cell lysates as control. No SRC control in top right blot as strong background at 
similar molecular weight as SRC. Representative Western blots of one biological replicate. All 
concentrations given in µM. 
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Appendix A.11. Subcellular fractionation of different cell lines (chapter 4.3.1 and 
5.2.2.1). Subcellular fractionation of MetBo2, SCC, MCF-7, T-47D and ZR-75.1 cells treated 
with eCF506 or dasatinib (both 0.1 µM) for 6 hours prior to subcellular fractionation and 
analysis by Western blot. Representative Western blot of three (MetBo2, SCC, MCF-7) or one 
(T-47D, ZR75.1) biological repeats. (L.E.) = longer exposure. All concentrations given in µM. 
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Figure continued from previous page 
 
















































































































































Appendix A.12. Dose-response curves of SCC cell lines treated with eCF506 or 
dasatinib (chapter 4.3.1). SCC, SCC FAK WT, SCC FAK -/- and SCC FAK NLS cells were 
treated with eCF506 or dasatinib for 5 days. Effects on cell proliferation were measured using 
PrestoBlueTM reagent and curves were fitted using GraphPad Prism 7. Cell viability on the day 
of treatment was subtracted from final readings and normalised to DMSO treated control. All 













Appendix A.13. Pharmacokinetic data of eCF506 in Sprague-Dawley rats (chapter 
5.1.2.1). Mean concentrations in ng/mL or µM from three animals per time point with standard 
deviation. BLQ = below limit of quantification (<10 ng/mL) in at least two of the three animals 
measured. Grey indicates no measurements taken at this time point. 
 
 IV 1 mg/kg PO 10 mg/kg PO 200 mg/kg 






























































































Appendix A.14. Detailed results of metabolite study (chapter 5.1.2.2). a) LC-MS 
chromatograms of the Q-Tof UPLC-MS/MS platform showing combined metabolite peaks after 
incubation of human hepatocytes with eCF506 for 0 minutes, 60 minutes or 120 minutes. (b) 
LC-MS chromatograms of the Q-Tof UPLC-MS/MS platform showing detailed metabolite 
peaks of m/z 527.3090 after incubation of human hepatocytes with eCF506 for 120 minutes. 
 




































Appendix A.15. Dose-response curve of Met1 cells (chapter 5.2.2.1). Met1 cells were 
treated with five different SRC and/or ABL kinase inhibitors for 5 days. Effects on cell 
proliferation were measured using PrestoBlueTM reagent and curves were fitted using 
GraphPad Prism 7. Cell viability on the day of treatment was subtracted from final readings 
and normalised to DMSO treated control. All dose-response curves represent the average of 




Appendix A.16. IHC of MetBo2 mammary fat pad tumours of FVB mice stained with Ki67 
antibody (chapter 5.2.2.4). Immunohistochemical analysis of MetBo2 tumours in FVB mice 
stained with Ki67 antibody. Images show a necrotic core (white) and proliferative patches on 
the edge of the tumours (brown). Two representative images are shown per group. Scale bar 
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